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Abstract 
The epidermal growth factor receptor (EGFR, also known as ErbB1) is a prototypical 
receptor tyrosine kinase (RTK) that activates multi-kinase phosphorylation cascades to regulate 
diverse cellular processes, including proliferation, migration and differentiation.  ErbB1 hetero-
oligomerizes with three close homologues: ErbB2, ErbB3 and ErbB4.  ErbB1-3 receptors are 
frequently mutated, overexpressed or activated by autocrine or paracrine ligand production in solid 
tumors and have been the target of extensive drug discovery efforts.  Multiple small molecule kinase 
inhibitors and therapeutic antibodies against ErbB receptors are in clinical use or development.  
Despite their importance as RTKs, oncogenes and drug targets, regulation of ErbB receptors by the 
interplay of conformational change, phosphorylation, phosphatases and receptor trafficking remains 
poorly understood, and the impact of these dynamics on physiological activity and cellular responses 
to anti-ErbB drugs is largely unknown.   
This thesis investigates the dynamic opposition of kinases and phosphatases within the ErbB 
pathway.  By standard biochemical analysis, ErbB receptors and downstream proteins appear to 
become phosphorylated and then dephosphorylated in approximately 30 minutes.  However, pulse-
chase experiments where cells are exposed to ligand and then to small molecule kinase inhibitors 
reveal that individual proteins must in fact cycle rapidly between being phosphorylated and 
dephosphorylated in seconds.  We construct a succession of differential equation-based models of 
varying biochemical resolution, each model appropriate for analyzing a different aspect of ErbB 
regulation, to help interpret the data and gain quantitative insight into receptor and drug biology. 
Rapid phosphorylation and dephosphorylation of receptors has important implications for the 
assembly dynamics of signalosomes.  We find that signals are rapidly propagated through some 
downstream pathways but slowly through others, resulting in prolonged activation in the absence of 
upstream signal.  We show that fast phosphorylation/dephosphorylation may provide cells with the 
flexibility necessary to rapidly detect and respond to changes in their extracellular environment.  
These fast dynamics also play a crucial role in determining the response to ErbB1-targeting cancer 
therapies, which we find to vary significantly between drugs with different mechanisms of action.  
We show that treatment with one class of these drugs results in sustained signaling, instead of 
inhibition, and thus may actually promote tumor proliferation or invasion.  Our work may help 
explain why certain drugs have been more effective in patients than others and suggests new 
approaches for evaluating biochemical signaling networks and targeted therapeutics. 
 
 
Thesis Supervisor: Peter K. Sorger, Ph.D. 
Title:  Professor of Systems Biology, Harvard Medical School and Professor of Biological Engineering, 
Massachusetts Institute of Technology  
 
 
 
- 4 - 
Thesis Supervisor: Douglas A. Lauffenburger, Ph.D. 
Title: Ford Professor of Biological Engineering, Chemical Engineering, and Biology, Massachusetts 
Institute of Technology 
 - 5 - 
Thesis Committee 
 
Forest M. White 
Associate Professor of Biological Engineering (Massachusetts Institute of Technology) 
Thesis Committee Chair 
 
 
 
Peter K. Sorger 
Professor of Biological Engineering (Massachusetts Institute of Technology) 
Professor of Systems Biology (Harvard Medical School) 
Thesis Supervisor 
 
 
 
Douglas A. Lauffenburger 
Ford Professor of Biological Engineering, Chemical Engineering, and Biology (Massachusetts 
Institute of Technology) 
Thesis Supervisor 
 
 
 
Tyler Jacks 
David H. Koch Professor of Biology (Massachusetts Institute of Technology) 
Thesis Committee Member 
 
 
 
Dennis Vitkup 
Assistant Professor of Biomedical Informatics (Columbia University) 
Thesis Committee Member 
 - 6 - 
Table of Contents 
Abstract ..................................................................................................................... 3 
Figures and Tables ................................................................................................... 9 
Acknowledgements ................................................................................................ 11 
CHAPTER 1: Introduction ...................................................................................... 13 
Protein phosphorylation regulates signal transduction and physiological processes .... 14 
Net phosphorylation levels are determined by kinases and phosphatases ............................14 
Receptor tyrosine kinases (RTKs) sense the extracellular environment and initiate 
phosphorylation cascades .....................................................................................................15 
General goals of this work .....................................................................................................15 
The ErbB receptor family ............................................................................................... 17 
Mechanisms regulating activation of the ErbB receptors and downstream signaling pathways
..............................................................................................................................................17 
Mechanisms leading to downregulation of ErbB signaling .....................................................18 
Protein tyrosine phosphatases (PTPs) .......................................................................... 20 
Identification and characterization of PTPs and their substrates ............................................22 
Evidence for ErbB1 PTPs......................................................................................................22 
Hyperactivation of the ErbB pathway in cancer ............................................................. 28 
Drugs targeting the ErbB receptors .......................................................................................28 
Inhibitors elucidate the dynamic opposition of phosphorylation and dephosphorylation 33 
Specific goals of this thesis and key findings ................................................................ 36 
CHAPTER 2: Results .............................................................................................. 37 
ErbB1 receptors rapidly dephosphorylated were actively signaling ............................... 42 
Estimating rates of phospho-ErbB1 turnover using a kinetic model .............................. 45 
ErbB1 dephosphorylation dynamics in response to different drugs ............................... 52 
 - 7 - 
Development of a more detailed computational scheme to understand different inhibitor 
effects ............................................................................................................................ 54 
Investigating the role of ErbB1 phosphatases ............................................................... 58 
Low dosing with gefitinib results in sustained ErbB1 phosphorylation ........................... 61 
Physiological consequences of fast phosphorylation cycling ........................................ 65 
Stochastic simulation illustrates switching times between phosphorylation states ........ 67 
Supplementary Data...................................................................................................... 70 
Effects of gefitinib on levels of cell surface ErbB1 .................................................................70 
Dose-response behavior of the irreversible ErbB1 inhibitor canertinib ...................................71 
ErbB3 is dephosphorylated slowly after heregulin stimulation ...............................................73 
Development of a more complete mathematical model that describes ErbB receptor 
trafficking ..............................................................................................................................74 
The role of degradation and phosphatases in regulating the lower steady state ErbB1 pY 
levels after EGF pulses of different durations followed by gefitinib ........................................75 
The ErbB1 dephosphorylation rate does not influence receptor dynamics after EGF alone but 
plays an important role in the presence of gefitinib ................................................................78 
Exploring mechanisms for sustained ErbB1 signaling following treatment with low doses of 
gefitinib .................................................................................................................................80 
CHAPTER 3: Discussion and Future Directions .................................................. 83 
Summary of approach and key results .......................................................................... 84 
Rapid ErbB1 dephosphorylation following sequential ligand and gefitinib treatment ..... 85 
Previous evidence indicating an important role for phosphatases .........................................86 
Computational models of ErbB1 regulation ................................................................... 86 
Phosphatase activity regulating ErbB1 .......................................................................... 87 
ErbB1 is rapidly dephosphorylated regardless of subcellular localization ..............................87 
Identification of PTPs responsible for rapid ErbB1 dephosphorylation ...................................88 
Transient phosphorylation and binding events are likely general regulatory mechanisms
 ...................................................................................................................................... 90 
Prior indications that other proteins may also undergo rapid phosphorylation cycling ............90 
 - 8 - 
All proteins measured in the ErbB network undergo fast phosphorylation cycling .................91 
Phosphatase regulation of ErbB2 and ErbB3 ................................................................ 94 
Examining whether phosphatases are activated following ligand stimulation to promote 
overall phospho-ErbB downregulation ...................................................................................95 
Stimulation of ErbB3 by EGF and HRG .................................................................................96 
ErbB3 relevance in cancer ....................................................................................................97 
Physiological consequences of rapid phosphorylation cycling ...................................... 97 
Future studies to relate receptor activity to membrane protrusion dynamics .........................99 
Investigating the striking differences in the responses to ErbB1-targeting drugs .......... 99 
Pulse-chase experiments reveal transient drug effects .........................................................99 
Differences between drugs with various mechanisms of action ........................................... 100 
ErbB1 phosphorylation cycling in the presence of constitutive receptor activation ............... 106 
Conclusions ................................................................................................................. 106 
CHAPTER 4: Methods .......................................................................................... 108 
Detailed experimental materials and methods ............................................................ 109 
Computational models of ErbB1 phosphorylation dynamics ....................................... 118 
Overview ............................................................................................................................. 118 
Exponential decay model for half life estimates ................................................................... 119 
Small model describing ErbB1 phosphorylation and dephosphorylation .............................. 122 
Stochastic model describing the intervals between switching events .................................. 127 
Model describing different ErbB1 conformations and drug responses ................................. 130 
Model incorporating mechanisms for kinase activation and receptor trafficking ................... 141 
CHAPTER 5: References ...................................................................................... 156 
  
 - 9 - 
Figures and Tables  
Figure 1.1 - Protein phosphorylation on tyrosine residues is regulated by the dynamic opposition 
of PTKs and PTPs. ............................................................................................................16 
Figure 1.2 - Simplified illustration of immediate-early ErbB pathway activation initiated by 
binding of EGF to ErbB1. ...................................................................................................20 
Figure 1.3 - The diverse family of classical protein tyrosine phosphatases (PTPs) includes both 
receptor-like and non-transmembrane PTPs. ....................................................................27 
Figure 1.4 – Structures of ATP-competitive small molecule kinase inhibitors targeting the ErbB 
receptors. ..........................................................................................................................31 
Figure 1.5 - Ratiometric imaging of COS7 cells after EGF stimulation and kinase inhibition. .....35 
Figure 2.1 – ErbB1 is rapidly dephosphorylated in the presence of 10µM gefitinib. ...................40 
Figure 2.2 – Rapid ErbB1 dephosphorylation regardless of intracellular localization. ................41 
Figure 2.3 – Rapid dephosphorylation of ErbB2, ErbB3 and Shc after ErbB1 inhibition. ............44 
Figure 2.4 – Dephosphorylation dynamics of the Akt and ERK pathways. .................................45 
Figure 2.5 – Simple biochemical scheme describing ErbB1 phosphorylation dynamics and 
estimation of kinetic rate constants. ...................................................................................51 
Figure 2.6 – ErbB1 dephosphorylation dynamics after competing away ligand or addition of 
ErbB1 small molecule kinase inhibitors with different mechanisms of action. ....................53 
Figure 2.7 – More detailed model describing gefitinib and lapatinib binding to ErbB1................57 
Figure 2.8 – Pervanadate treatment but not PTP1B knockdown blocks gefitinib-induced ErbB1 
dephosphorylation. ............................................................................................................60 
Figure 2.9 - Low gefitinib dosing converts a transient response to ligand into a sustained signal 
by altering receptor trafficking. ...........................................................................................63 
Figure 2.10 - Pretreatment with low concentrations of gefitinib also leads to sustained signaling.
 ..........................................................................................................................................64 
Figure 2.11 – Lamellipodia retract almost immediately after ErbB1 is dephosphorylated following 
gefitinib treatment. .............................................................................................................66 
Figure 2.12 – Stochastic model illustrates fluctuations of individual ErbB1 receptors between 
being phosphorylated and unphosphorylated. ...................................................................69 
Figure 2.13 – Effects of gefitinib on levels of cell surface ErbB1. ..............................................70 
Figure 2.14 – Dose-response behavior of canertinib, an irreversible ErbB1 tyrosine kinase 
inhibitor. ............................................................................................................................72 
 - 10 - 
Figure 2.15 – ErbB3 is dephosphorylated slowly after HRG stimulation alone as well as after 
additional gefitinib treatment. .............................................................................................74 
Figure 2.16 – ErbB1 phosphorylation after EGF pulses of different durations followed by addition 
of 1µM gefitinib. .................................................................................................................77 
Figure 2.17 – Increasing or decreasing the rate of ErbB1 Y1173 dephosphorylation in the model 
does not strongly influence dynamics after EGF only, but significantly alters the response 
to gefitinib. .........................................................................................................................79 
Figure 2.18 – Model prediction that sustained phosphorylation of ErbB1 Y1173 after low doses 
of gefitinib results from a faster dephosphorylation rate of the Cbl-binding site. .................82 
Figure 4.1 - An illustration of the combinatorial complexity of binding events described in the 46 
ODE model. ..................................................................................................................... 136 
Figure 4.2 – Simple example of how the model reduction approach was applied by separation 
into modules. ................................................................................................................... 149 
 
Table 1.1 – Dissociation constants, mechanisms of action and FDA approval status of ErbB-
targeting kinase inhibitors. .................................................................................................32 
Table 4.1 – Summary of decay rates and half lives. ................................................................ 121 
Table 4.2 – Species and initial protein concentrations in the 46 ODE model. .......................... 137 
Table 4.3 – Reaction rules describing the 46 ODE model. ...................................................... 138 
Table 4.4 – Description of parameters in the 46 ODE model and their fitted values. ............... 139 
Table 4.5 – Macrospecies in the 203 ODE model. .................................................................. 150 
Table 4.6 – Macrospecies in the 203 ODE model (continued). ................................................ 151 
Table 4.7 – Parameters in the 203 ODE model and their fitted values. ................................... 152 
 - 11 - 
Acknowledgements 
 
Many people have contributed to making this thesis possible, and I am unable to 
recognize everyone individually.  Nevertheless, there are several people who played a 
particularly important role in my graduate career and I would like to take this opportunity to 
acknowledge their contributions.   
I must begin by thanking my primary advisor, Peter Sorger.  Peter gave me the time and 
freedom to explore projects and learn how to become an independent scientist.  He encouraged 
me to form effective collaborations, and provided valuable guidance throughout my thesis 
project.  His enthusiasm for science is infectious and working in his lab has been an enjoyable 
experience. 
Nor would this thesis have been possible without the constant support, encouragement 
and guidance provided by my co-advisor, Doug Lauffenburger.  The rest of my thesis 
committee, Forest White, Tyler Jacks and Dennis Vitkup, also played a key role in developing 
this thesis.   
 
I feel very privileged to have been in the first class of students in the Computational and 
Systems Biology Ph.D. program at MIT.  I will be forever thankful to all of those at MIT who 
made it possible for me to have this amazing opportunity.  I hope that I am able to honor the 
faith they placed in me throughout my scientific career.   
In 2006, Peter’s lab moved to the Department of Systems Biology at Harvard Medical 
School (HMS), and I was fortunate to become a member of that community, as well.  The HMS 
Systems Biology Department provides a wonderful, jovial learning and research environment 
that stimulates cross-disciplinary collaborations through which I cultivated special friendships. 
I could not have made it through graduate school without my friends in Peter’s lab and at 
HMS, all of whom were bottomless wells of friendship, support and lively scientific 
conversations.  In particular, I would like to thank Julio Saez-Rodriguez, Thomas Maiwald, Floris 
Foijer, Debbie Flusberg, Will Chen, Holger Conzelmann, Yangqing Xu, Sudhakaran 
Prabakaran, Jenny Gallop, Leo Alexopoulos and Carlos Lopez.  Sabrina Spencer, my “partner-
in-crime” throughout graduate school, deserves special recognition.  Sabrina and I 
serendipitously met before we even applied to MIT and we wound up experiencing almost every 
aspect of our graduate careers at MIT and HMS together – it would not have been the same 
without her. 
 
I would also like to thank John Albeck, Suzanne Gaudet and Keara Lane for taking me 
under their wings when I was just a first-year graduate student rotating through their labs, and 
for helping me ease into experimental biology.  Their guidance and encouragement helped me 
persevere through a sometimes overwhelming first year. 
The work detailed in this thesis would not have been possible without my collaborators.  
Holger Conzelmann and Thomas Maiwald each made invaluable contributions to this project 
and, just as importantly, they taught me how effective collaborations can make science so much 
more fun and rewarding.  Will Chen originally encouraged me to work on this project and was 
always there to brainstorm ideas, talk me through setbacks and celebrate exciting results. 
 - 12 - 
 
Words cannot adequately express my gratitude for the love and unwavering support of 
my family.  I have been very lucky to have much of my family nearby for the last several years.  
While I moved up to Boston alone in 2004, my brother, husband, parents and then sister-in-law 
were soon to follow! 
Dad, thank you for introducing me to the field of systems biology before most people 
even knew that it existed.  I am extremely grateful to have inherited your passion for science, 
learning and critical thinking. 
Mom, thank you for your love and support through the years and for still doing “mom 
things” for me, even though I am sure I am too old for that. 
To my brother, David, and my sister-in-law, Violeta, your friendship and support means 
so much to me; it has been fantastic having you both with me here at MIT.   
To my in-laws, Michael and Frayda, thank you for welcoming me into your family from 
the start, for encouraging me to be strong in the face of challenges, and for reminding me to 
always focus on the important things in life. 
And, most importantly, to Matt, my husband and my best friend, who has patiently 
listened to endless stories of the highs and lows of graduate school, who has celebrated my 
successes and comforted me when I have been down, you are my rock and I would not have 
made it through this journey without you.  Thank you for always reminding me that there is more 
to life than science.   
 
 
 - 13 - 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: Introduction 
 
 - 14 - 
Protein phosphorylation regulates signal transduction and 
physiological processes 
Cellular signal transduction is regulated by various forms of post-translational 
modification, and phosphorylation of cellular proteins is arguably the most common and 
important type of reversible post-translational modification.  Protein phosphorylation networks in 
cells are an integral part of almost all physiologic processes, including the immune response, 
cardiovascular system and endocrine action (Tarrant and Cole, 2009).  The first direct evidence 
for the enzymatic phosphorylation of a protein substrate was obtained by Eugene Kennedy in 
1954 (Burnett and Kennedy, 1954).  In 1955, Fischer et al. showed that the metabolic enzyme 
phosphorylase, which is responsible for the conversion of glycogen to glucose-1-phosphate, can 
be converted from an inactive to active state by a protein kinase that catalyzes the attachment 
of a phosphate group to phosphorylase (Fischer and Krebs, 1955).  It is now thought that 
approximately 30% of all proteins are phosphorylated at any given time (Cohen, 2000).  
Phosphorylation of an enzyme can be activating (e.g. by energizing an enzyme to participate in 
subsequent reactions) or inhibitory (e.g. through a conformational change that masks its kinase 
domain), and can alter protein-protein interactions.  Some proteins have multiple 
phosphorylation sites, with phosphorylation of certain sites being activating and others 
inhibitory.  This thesis focuses on activating phosphorylation events. 
 
Net phosphorylation levels are determined by kinases and phosphatases 
Protein phosphorylation levels are determined by the balanced action of protein kinases 
and phosphatases (Fig. 1.1).  Kinases catalyze the incorporation of covalently bound phosphate 
groups to their substrates, usually on serine, threonine or tyrosine residues, by using ATP.  Five 
hundred different protein kinases have been identified in mammals (approximately 2% of all 
human genes (Manning et al., 2002)).  Protein kinases are highly regulated by their 
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phosphorylation, binding of activating or inhibitory proteins or small molecules, and their 
subcellular localization with respect to substrates.  Phosphatases act in opposition to kinases to 
catalyze the removal of phosphate groups from their substrates by hydrolysis.  Much less is 
known about the factors and cellular components that regulate protein dephosphorylation than 
phosphorylation. 
 
Receptor tyrosine kinases (RTKs) sense the extracellular environment and initiate 
phosphorylation cascades 
Tyrosine-specific protein kinases play an important role in signal transduction by acting 
as growth factor receptors and as cytoplasmic proteins that regulate downstream signaling from 
growth factors.  There are 90 protein tyrosine kinases (PTKs) in humans (Manning et al., 2002), 
of which more than 50 are receptor tyrosine kinases (RTKs) (Robinson et al., 2000) such as the 
epidermal growth factor receptor (ErbB1), platelet-derived growth factor receptor (PDGFR) and 
insulin receptor (IR).  RTKs are composed of an extracellular N-terminal domain that serves as 
the ligand-binding part of the molecule, a transmembrane-spanning domain, and a cytoplasmic 
C-terminal domain that includes the catalytic subunit responsible for their kinase activity.  RTKs 
and other cell surface receptors help cells sense and respond to their surroundings by binding 
ligands in the extracellular environment.  Once an RTK is activated by ligand, it can bind to and 
phosphorylate specific target proteins via its intracellular domain and trigger a cascade of 
protein phosphorylation events that relay the extracellular signal to downstream pathways that 
modulate phenotypic responses to the environmental stimulus.   
 
General goals of this work 
Signal transduction by kinases is thought to depend on the extent and duration of 
substrate phosphorylation.  Since phosphorylation plays an essential role in complex signaling 
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networks, it is crucial to understand how phosphorylation events are regulated and how they 
influence signal propagation in order to understand how cellular fate decisions are controlled.  
This thesis investigates the dynamic interplay between kinases and phosphatases.  The 
following general questions are addressed: (1) how frequently individual proteins are 
phosphorylated and dephosphorylated and (2) what the consequences are of these time scales.  
Since ErbB1 is well studied and relevant in disease processes, this thesis focuses on analyzing 
the phosphorylation dynamics of the ErbB receptor family and its downstream pathways 
following activation by growth factors.  Nevertheless, the results may be generalizable to other 
RTKs and signaling pathways. 
 
 
 
 
Figure 1.1 - Protein phosphorylation on tyrosine residues is regulated by the dynamic 
opposition of PTKs and PTPs.   
Tyrosine phosphorylation leads to activation of downstream signaling pathways through binding of SH2- 
or PTB-domain containing proteins.  SH2 = Src homology 2; PTB = phosphotyrosine binding.  Figure 
adapted from Pincus, D., Letunic, I., Bork, P., and Lim, W.A. (2008). “Evolution of the phospho-tyrosine 
signaling machinery in premetazoan lineages.” Proc Natl Acad Sci U S A 105, 9680-9684. 
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The ErbB receptor family 
ErbB1 is a prototypical RTK that activates multi-kinase phosphorylation cascades to 
regulate diverse cellular processes including proliferation, migration and differentiation (Citri and 
Yarden, 2006; Fry et al., 2009; Yarden and Sliwkowski, 2001).  ErbB1 (also known as EGFR or 
Her1) hetero-oligomerizes with three close homologues: ErbB2 (Her2 or Neu2), ErbB3 (Her3 or 
Neu3) and ErbB4 (Her4).  Deficiencies in ErbB signaling are associated with the development of 
neurodegenerative diseases in humans, and the importance of these receptors during 
development and in normal adult physiology has become apparent from analyses of genetically 
modified mice (Bublil and Yarden, 2007; Hynes and Lane, 2005).  Excessive ErbB signaling, on 
the other hand, is associated with many types of cancers (Holbro and Hynes, 2004; Hynes and 
Lane, 2005). 
 
Mechanisms regulating activation of the ErbB receptors and downstream 
signaling pathways 
The 11 known extracellular ligands for the ErbB receptors exhibit differential binding to 
ErbB1, ErbB3 and ErbB4 (Linggi and Carpenter, 2006).  For example, EGF and TGFα bind to 
only ErbB1 and neuregulins bind to ErbB3 and ErbB4.  ErbB2 has no known high-affinity ligand 
and instead functions by associating with other ErbB receptors (Klapper et al., 1999) or, in 
tumors that overexpress ErbB2, by forming active ErbB2 homodimers independent of ligand 
(Yarden and Sliwkowski, 2001).  Ligand-independent activation is possible because ErbB2 
constitutively exists in a quasi-active conformation that resembles the ligand-bound state of 
ErbB1, ErbB3 and ErbB4 (Garrett et al., 2003).   
Ligand binding promotes homo- and heterodimerization of ErbB receptors, as well as 
higher-order oligomers (Clayton et al., 2008), and a conformational change that positions the 
cytoplasmic C-terminal tail of one receptor near the activation loop of the other, thereby 
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facilitating receptor phosphorylation in trans (Fig. 1.2).  Phosphorylation of RTKs within their 
activation loop normally stabilizes activity (Huse and Kuriyan, 2002); however, this form of 
regulation has not been found for ErbB1.  Receptor homo- and heterodimers may also form in 
the absence of ligand, but under most circumstances these receptors are inactive, switching to 
an active conformation only upon ligand binding (Tao and Maruyama, 2008).   
Activated ErbB receptors phosphorylate each other in trans on 4-12 tyrosine residues 
that serve as docking sites for the recruitment of diverse Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domain containing intracellular adaptor proteins (Jones et al., 
2006; Kaushansky et al., 2008; Schulze et al., 2005).  These adaptor proteins, and the proteins 
that bind to them, are often themselves targets for phosphorylation by ErbB receptors or by 
cytoplasmic kinases.  ErbB3 lacks key residues present in other ErbB kinase domains and is 
therefore catalytically inactive, but ErbB3 is biologically active as part of heterodimers containing 
ErbB1, ErbB2 or ErbB4 (Jura et al., 2009).  Receptor phosphorylation and binding of multiple 
SH2/PTB proteins leads to assembly of large multi-protein “signalosomes” that transmit signals 
to downstream targets that include Ras, the mitogen activated protein kinase/extracellular 
signal-regulated kinase (MAPK/ERK) and phosphoinositide 3-kinase (PI3K)-Akt cascades 
(Yarden and Sliwkowski, 2001) and the Cdc42-regulated actin cytoskeleton (Hirsch et al., 2006).  
 
Mechanisms leading to downregulation of ErbB signaling 
A fundamental question in the study of ErbB signaling is what determines the magnitude 
and duration of receptor activation.  In cells exposed to a pulse of exogenous ligand, particularly 
following serum starvation, receptors and adaptor proteins become phosphorylated in a 
response that peaks ~10 minutes later and then declines to the pre-stimulus level within ~1-2 
hours (the immediate-early response; (Chen et al., 2009)).  Activated ErbB1 receptors are 
endocytosed and then either degraded in the lysosome or recycled to the plasma membrane 
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where they are once again able to bind ligand (Sorkin and Goh, 2009).  Internalized receptors 
are also capable of signaling to some, but not all, downstream pathways.   
In cells stimulated with low concentrations of EGF, ErbB1 is internalized through clathrin 
coated pits and is not ubiquitinated (Sigismund et al., 2005).  In contrast, at higher EGF 
concentrations, ErbB1 becomes ubiquitinated and endocytosed through caveolae via a clathrin-
independent pathway.  Ubiquitin is required for early endosomal cargoes to be sent to the 
lysosome for degradation.  The E3 ubiquitin ligase Cbl is recruited to ErbB1 after ligand 
stimulation (Levkowitz et al., 1998), binds directly to ErbB1 on phosphorylated tyrosine 1045 
(pY1045) or indirectly through Grb2 (Waterman et al., 2002), and mediates ubiquitination and 
degradation of the receptor.  During the period between receptor uptake and subsequent 
recycling to the membrane, but before receptor resynthesis, ErbB1-mediated responses are 
significantly downregulated.  The mechanisms responsible for downregulation of other ErbB 
receptors are less well understood, but internalization is not thought to play a major role 
(Baulida et al., 1996). 
ErbB1 degradation is a potential mechanism to terminate receptor signaling following 
ligand stimulation.  In addition, negative feedback regulators of ErbB1 such as MIG6 and 
Sprouty2 have been found to be activated after ~1-2 hours (Amit et al., 2007; Wong et al., 2001; 
Zhang et al., 2007).  It is unclear whether these proteins play a role in downregulation of 
activated ErbB1 or only prevent subsequent ligand-induced activation.  Furthermore, ERK-
dependent phosphorylation of ErbB1 on a threonine residue in the receptor juxtamembrane 
cytoplasmic domain has been shown to contribute to ErbB1 downregulation (Li et al., 2008), 
possibly by inducing an inactivating conformational change in the receptor (Yang et al., 2009).  
Extensive evidence also points to an important role for phosphatases in ErbB1 
dephosphorylation. 
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Figure 1.2 - Simplified illustration of immediate-early ErbB pathway activation initiated by 
binding of EGF to ErbB1.   
EGF binds to ErbB1 directly and induces formation and phosphorylation of ErbB1-containing homo- and 
heterodimers.  ErbB3 lacks catalytic activity so ErbB1 is not phosphorylated in an ErbB1-ErbB3 dimer.  
Binding of adaptor proteins such as Shc to the receptors leads to activation of many downstream proteins, 
including the canonical MAPK (Raf-MEK-ERK) and Akt kinase pathways.  Targets of several inhibitors 
of the pathway are indicated. 
 
Protein tyrosine phosphatases (PTPs) 
Phosphatases can be divided into the following groups based on their substrate 
specificity: tyrosine-specific phosphatases, serine/threonine-specific phosphatases, dual 
specificity phosphatases (tyrosine as well as serine/threonine-specific), histidine phosphatases 
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and lipid phosphatases.  Since activated ErbB1 becomes phosphorylated primarily on tyrosine 
residues following ligand stimulation (Olsen et al., 2006), phosphorylated ErbB1 is thought to be 
a target of various protein tyrosine phosphatases (PTPs).  PTPs are characterized by the active 
site signature motif HC(X)5R in the conserved catalytic domain.  The cysteine residue in this 
motif acts as a nucleophile to attack the phosphorus atom of the phosphotyrosine residue of the 
PTP substrate, whereas the arginine residue interacts with the phosphate moiety of the 
phosphotyrosine.  An invariant aspartic acid residue outside of the signature motif is also 
essential for catalytic activity and serves as the catalytic acid that protonates the phenolic 
oxygen of the tyrosyl leaving group (Zhang, 2002). 
Interestingly, there are roughly the same number of tyrosine-specific phosphatases as 
kinases (Alonso et al., 2004; Manning et al., 2002).  Approximately 100 members of the PTP 
family have been identified and can be divided into four classes based on the primary structure 
of their catalytic domains (Alonso et al., 2004).  Class I PTPs is the largest group and is divided 
into classical PTPs, defined by cysteine-based phosphotyrosine specificity, and VH-1-like or 
dual specificity phosphatases (DSPs), which includes the MAPK phosphatases (MPKs) and 
PTEN.  The classical PTPs can be further subdivided into transmembrane receptor PTPs 
(RPTPs) or non-transmembrane cytoplasmic PTPs (Fig. 1.3).  Through their extracellular 
domains, RPTPs can bind soluble ligands and mediate cell-cell and cell-matrix interactions.  
Substrate specificity of non-transmembrane PTPs is conferred by their noncatalytic regulatory 
domains, which can regulate their activity, subcellular localization and interaction with other 
proteins. DSPs are non-transmembrane PTPs with a shallower catalytic pocket conformation 
(compared to PTPs that can only act on phosphotyrosines) that allows them to also interact with 
phosphoserines and phosphothreonines (Yuvaniyama et al., 1996).  The other three classes of 
PTPs are very small: class II contains the low-molecular-weight phosphotyrosine phosphatase 
(LMPTP), class III contains CDC25A, B and C, and class IV contains Eya1-4.  Most cells 
express 30-60% of all PTPs, however, hematopoietic and neuronal cells express a higher 
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number of PTPs in comparison to other cell types (Alonso et al., 2004).  PTP signaling 
specificity is determined by their expression pattern, subcellular localization, post-translational 
modifications such as phosphorylation and oxidation that regulate PTP activity, and intrinsic 
structural differences within the PTP domain and noncatalytic domains. 
Identification and characterization of PTPs and their substrates 
PTPs have traditionally been identified and characterized using purified proteins, 
isolated membranes and permeabilized cells (Butler et al., 1989; Swarup et al., 1982).  PTP 
function has typically been studied using paranitrophenyl phosphate or synthetic 
phosphopeptides as substrates in vitro.  These reactions critically neglect what are now known 
to be important subcellular localization effects.  A more accurate view of PTP regulation requires 
in vivo measurements.  Various techniques have been used to identify physiological PTP 
substrates, such as dephosphorylation assays for substrates in vitro, modulating substrate 
tyrosine phosphorylation in cells (e.g. by increasing or decreasing expression of the PTP) and 
measuring the interaction of substrates with PTP substrate-trapping mutants.  Mutagenesis of 
the invariant catalytic aspartate residue to alanine converts an active PTP enzyme into a 
“substrate trap” (Flint et al., 1997).  These catalytically inactive PTPs form stable, 
phosphotyrosine-dependent associations with their substrates both in vitro and in cells. 
 
Evidence for ErbB1 PTPs 
The full spectrum of phosphatases acting on ErbB1 and their means of regulation are 
unknown, but many PTPs have been shown to interact with or have some specificity for ErbB1 
(Tiganis, 2002).  Much less is known about PTPs that act on the other ErbB receptors.  The best 
characterized ErbB1 PTPs are PTP1B, Shp-1 and Shp-2.  This section will describe in detail 
what is known about the regulation of ErbB1 by PTP1B, Shp-1 and Shp-2, and will then briefly 
discuss other potential ErbB1 PTPs. 
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PTP1B 
Although PTP1B-/- mice show no obvious evidence of increased ErbB1 signaling, 
primary and immortalized PTP1B-/- fibroblasts exhibit increased and sustained ErbB1 
phosphorylation following ligand stimulation (Frangioni et al., 1992).  Similarly, in HeLa cells 
knockdown of PTP1B prolongs ErbB1 phosphorylation after EGF stimulation (Eden et al., 2010).  
Substrate-trapping mutants of PTP1B form a stable, phosphotyrosine-dependent complex with 
ErbB1 (Flint et al., 1997) and PTP1B displays specificity for ErbB1 Y992 and Y1148 (Milarski et 
al., 1993).  The COOH-terminal extension of PTP1B contains a small hydrophobic stretch that is 
necessary and sufficient for targeting the enzyme to the cytoplasmic side of the endoplasmic 
reticulum (ER), where it resides (Frangioni et al., 1992).  PTP1B-mediated dephosphorylation of 
ErbB1 thus requires receptor endocytosis (Reynolds et al., 2003), and the two proteins interact 
through direct membrane contacts between the perimeter membrane of multivesicular bodies 
and the ER (Eden et al., 2010).  Following EGF stimulation and binding to ErbB1, PTP1B has 
been found to be tyrosine phosphorylated, and this phosphorylation correlates with a 3-fold 
increase in PTP catalytic activity (Liu and Chernoff, 1997). 
 
Shp-1 and Shp-2 
Shp-1 and Shp-2 contain two SH2 domains that face away from the active phosphatase 
domain and interact with phosphotyrosine containing peptides, and a C-terminal tail that can be 
phosphorylated by receptor-mediated kinase activity at two tyrosine sites.  These 
phosphorylated sites can bind the SH2 domains, relieving basal autoinhibition and activating the 
PTP catalytic domain (Hof et al., 1998; Lu et al., 2001; Zhang et al., 2003).  Phosphorylation of 
Shp-1 may also promote interactions with adaptor proteins such as Grb2 (Zhang et al., 2003), 
sequestering the PTP near its substrates (Neel et al., 2003).  In this way, PTPs may use 
receptor-associated phosphorylation to modulate their own phosphatase catalytic activities. 
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Shp-1 negatively regulates signaling primarily in hematopoietic cells by 
dephosphorylating signaling molecules that promote signaling (Zhang et al., 2000).  Shp-1 has 
been shown to bind ErbB1 at Y1173 through an SH2 domain (Keilhack et al., 1998), and both 
SH2 domains of Shp-1 appear to be important for binding to ErbB1 and receptor 
dephosphorylation.   
Shp-2 positively regulates growth factor-induced signaling pathways in a wide variety of 
cell types (Feng, 1999).  Shp-2 substrate-trapping mutants identified ErbB1 as an interactor and 
substrate (Agazie and Hayman, 2003a).  Autophosphorylation sites on ErbB1 were mutated 
such that they could not become phosphorylated, and only the Y992F mutant did not now bind 
to the substrate trapping mutant of Shp-2 (Agazie and Hayman, 2003b).  Furthermore, a 
dominant negative Shp-2 construct mutated in its phosphatase active site led to an increase in 
basal phosphorylation of ErbB1 Y992, and overexpression of wild-type Shp-2 decreased 
phosphorylation of this site (Sturla et al., 2005).  GTPase-activating proteins (GAPs) can 
stimulate the low intrinsic GTPase activity of Ras, thus accelerating Ras deactivation.  
Dephosphorylation of ErbB1 Y992 has been shown to prevent p120RasGAP from being 
recruited to a complex to inactivate Ras (Agazie and Hayman, 2003b), and Shp-2 can also 
directly dephosphorylate RasGAP (Kontaridis et al., 2004).  Thus, Shp-2 positively stimulates 
the Ras-MAPK pathway (Neel et al., 2003). 
 
Other potential ErbB1 PTPs 
A number of potential ErbB1 PTPs exist in addition to PTP1B, Shp-1 and Shp-2.  To 
identify PTPs specific for ErbB1, an siRNA screen was performed where expression of each 
PTP was knocked down and the effect on basal and ligand-stimulated ErbB1 phosphorylation 
was measured.  Knocking down DEP-1, a PTP that resides on the cell surface and does not 
internalize along with ErbB1, significantly increased basal ErbB1 phosphorylation (Tarcic et al., 
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2009).  EGF stimulation resulted in more ErbB1 receptors bound by substrate-trapping mutants 
of DEP-1, but no significant increase in receptors bound by wild-type DEP-1, suggesting that 
their interaction is transient. 
Co-expression of ErbB1 and various RPTPs in cells lacking ErbB1 receptors enabled 
identification of RPTPκ as an enzyme capable of reducing ErbB1 phosphorylation (Xu et al., 
2005).  ErbB1 phosphorylation was also reduced upon inducible expression of RPTPσ (Suarez 
Pestana et al., 1999).  Similarly, decreasing expression of the phosphatase LAR increased 
EGF-induced but not basal ErbB1 phosphorylation (Kulas et al., 1996).  TCPTP was identified 
as an ErbB1 phosphatase (Tiganis et al., 1998) and is activated at the plasma membrane by a 
collagen-binding integrin to negatively regulate ErbB1 (Mattila et al., 2005).  Although normally 
located in the nucleus, a substrate-trapping mutant of TC45 (a 45 kDa variant of TCPTP) co-
localized with phosphotyrosine ErbB1 at the cell periphery within minutes of EGF stimulation 
(Tiganis et al., 1999).   
The effects of modulating relative PTP/RTK expression levels were studied by transient 
co-overexpression of ErbB1 along with TCPTP, PTP1B or CD45 (Lammers et al., 1993).  ErbB1 
overexpression without PTPs led to a high level of basal ErbB1 phosphorylation with no 
significant increase after ligand stimulation.  With expression of each of the three PTPs, the 
basal level of ErbB1 phosphorylation was almost completely suppressed and the receptor was 
able to respond to ligand.  These experiments point to a high degree of redundancy in PTP 
regulation of ErbB1. 
 
Dynamic regulation of ErbB1 PTPs after ligand stimulation 
As described above, PTP activity can be dynamically regulated by various mechanisms 
following ligand-induced ErbB1 activation.  Activating mechanisms include PTP 
phosphorylation, co-localization with ErbB1 and allosteric activation by binding directly to 
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activated ErbB1 via SH2 domains.  Conversely, induction of hydrogen peroxide synthesis in 
EGF-treated cells transiently inhibits phosphatases such as PTP1B, thereby acting to increase 
net ErbB1 phosphorylation (Lee et al., 1998).   
 
Deregulation of PTPs 
While ErbB receptors are often overactive in cancer, potential ErbB1 phosphatases are 
also deregulated and play a role in promoting disease (reviewed in (Ostman et al., 2006)).   
DEP-1 is deleted or mutated in some cancers (Ruivenkamp et al., 2002) and decreased 
expression of DEP-1 leads to sustained ErbB1 signaling and hyperproliferation (Tarcic et al., 
2009).  Shp-1 is epigenetically silenced in leukemias and lymphomas (Oka et al., 2002).  On the 
other hand, gain of function Shp-2 mutations have been identified in various malignancies such 
as hereditary and sporadic leukemias and Noonan syndrome (Fragale et al., 2004; Tartaglia et 
al., 2001; Tartaglia et al., 2003).  PTP1B is upregulated in ErbB2-transformed cell lines (Zhai et 
al., 1993) and promotes tumorigenesis mediated by ErbB2.  The majority of human breast 
tumors overexpress PTP1B (Wiener et al., 1994). 
PTPs have been proposed to act as both tumor suppressors and oncogenes, and are 
being considered as drug targets.  For example, PTP1B inhibitors are under development as 
anti-diabetic compounds (reviewed in (Johnson et al., 2002)).  As discussed later in this thesis, 
developing selective phosphatase inhibitors is proving to be more challenging than targeting 
kinases. 
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Figure 1.3 - The diverse family of classical protein tyrosine phosphatases (PTPs) 
includes both receptor-like and non-transmembrane PTPs.   
BRO-1, BRO-1 homology; CAH, carbonic anhydrase-like; Cad, cadherin-like juxtamembrane sequence; 
FERM, FERM domain; FN, fibronectin type III-like domain; Gly, glycosylated; HD, histidine domain; 
Ig, immunoglobulin domain; KIM, kinase-interaction motif; MAM, mephrin/A5/µ domain; Pro, proline-
rich; RGDS, RGDS-adhesion recognition motif; SEC14, SEC14/cellular retinaldehyde-binding protein-
like; SH2, Src-homology 2.  Figure reproduced from Soulsby, M., and Bennett, A.M. (2009). 
“Physiological signaling specificity by protein tyrosine phosphatases.” Physiology 24, 281-289. 
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Hyperactivation of the ErbB pathway in cancer 
ErbB1-3 receptors are frequently mutated, overexpressed or activated by autocrine or 
paracrine ligand production in solid tumors (Holbro and Hynes, 2004; Hynes and Lane, 2005; 
Sharma and Settleman, 2009) and have been the target of extensive drug discovery efforts 
(Sebastian et al., 2006).  The ErbB pathway is further implicated in cancer through activating 
mutations in downstream signaling molecules (e.g. Cbl mutations in lung cancer (Tan et al., 
2010) and B-Raf mutations in melanoma (Tuveson et al., 2003)) and inactivation of tumor 
suppressors (e.g. PTEN (Parsons, 2004)).  Pharmaceutical companies are therefore 
aggressively targeting this pathway, and gaining a better understanding of how signals are 
propagated through this network and how alterations within the pathway deregulate signaling 
should help in this effort. 
 
Drugs targeting the ErbB receptors 
Multiple small molecule kinase inhibitors and therapeutic antibodies against ErbB 
receptors are in clinical use or development.  The ErbB2-targeting antibody trastuzumab 
(Herceptin®) is a front-line therapeutic for ErbB2-overexpressing breast cancers (Nahta and 
Esteva, 2007).  Cetuximab (Erbitux®; C225) is a chimeric monoclonal antibody that binds 
directly to the ligand-binding site on the extracellular domain of ErbB1 and is used to treat 
metastatic colorectal cancer and head and neck cancers (Gebbia et al., 2007; Maiello et al., 
2007).  Small molecule tyrosine kinase inhibitors compete with ATP for binding to the ErbB1 
intracellular tyrosine kinase domain and inhibit receptor catalytic activity. 
 
ErbB1-specific small molecule kinase inhibitors 
Various 4-anilinoquinazoline derivatives have been exploited as selective and effective 
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ErbB inhibitors (inhibitor structures and information relevant to this thesis are shown in Fig. 1.4 
and Table 1.1) (Johnson, 2009).  Gefitinib (Iressa®; ZD1839) and erlotinib (Tarceva®; OSI-774) 
are selective tyrosine kinase inhibitors that bind reversibly to ErbB1 with high affinity and likely 
bind to ErbB1 when in an active or inactive conformation (Jecklin et al., 2009).  Both drugs are 
used to treat non-small cell lung carcinoma and erlotinib is also approved to treat pancreatic 
cancer (Eck and Yun, 2009; Stamos et al., 2002; Yun et al., 2007).  These drugs have been 
found to be particularly effective in tumors expressing mutated forms of ErbB1 (Eck and Yun, 
2009). 
An alternative approach has been to target ErbB1 using kinase inhibitors with non-
canonical mechanisms of action, such as drugs that bind irreversibly or with a preference for the 
inactive conformation of the kinase (Liu and Gray, 2006).  Canertinib (CI-1033) acts through 
covalent modification of a conserved cysteine residue present in the ErbB1 ATP binding pocket 
and thus binds to the receptor irreversibly (Fry et al., 1998).  ErbB2 and ErbB4 contain the same 
active site cysteine and therefore are also inhibited by canertinib.  Lapatinib (Tykerb®; 
GW572016) is a selective and reversible ATP-competitive dual ErbB1/ErbB2 inhibitor approved 
to treat patients with advanced or metastatic breast cancer whose tumors overexpress ErbB2.  
While the ATP binding cleft of ErbB1 complexed with erlotinib or gefitinib is more open (active), 
lapatinib-bound ErbB1 is in a relatively closed (inactive) conformation (Wood et al., 2004; Yun et 
al., 2007).  A bulky aniline substituent off the quinazoline ring of lapatinib may make the 
compound unable to complex with the small back pocket found in the active-like conformation of 
ErbB1 (Wood et al., 2004).   
Lapatinib also differs dramatically from gefitinib and erlotinib in that it binds to ErbB1 with 
slow kinetics.  A very slow off rate for lapatinib dissociation from ErbB1 results in a long half life 
of ~220 minutes as opposed to a gefitinib half life of ~10 minutes (Gilmer et al., 2008; Wood et 
al., 2004).  ErbB1 is no longer inhibited 24 hours after washing away erlotinib, but 72 hours after 
washing away gefitinib, receptors are still 40% inhibited (Wood et al., 2004).  However, 96 hours 
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after washing away lapatinib, ErbB1 receptors are still 85% inhibited.  Since these three drugs 
have similar dissociation constants for ErbB1, lapatinib also binds with a much slower on rate.  
Slower kinetics may be explained by the considerable structural differences between active and 
inactive ErbB1 kinase conformations and the notion that to bind and/or release lapatinib may 
require a conformational change in the receptor.  Indeed, lapatinib is thought to stabilize the 
inactive-like ErbB1 conformation (Wood et al., 2004).   
 
Use of inhibitors as tools to study signaling pathways 
Deregulation of kinase activity is a common cause of various cancers, and kinases have 
thus been attractive drug targets.  Imatinib (Gleevec®), an inhibitor of the Abl tyrosine kinase, 
has been extremely successful in patients with chronic myelogenous leukemia (Capdeville et 
al., 2002).  Unfortunately, the search for other kinase inhibitors as successful as imatinib has 
proved to be very challenging and may be partially due to our still primitive understanding of the 
function and regulation of protein kinases, phosphatases, and their substrates and effectors.  
Beyond their use as therapeutics, kinase and phosphatase inhibitors are useful tools to probe 
signaling states and can potentially reveal rapid (short-term) kinetics, as opposed to genetic and 
conventional biochemical approaches such as RNAi that typically only elucidate the effects on 
steady state behavior.  In this thesis, we use potent kinase and phosphatase inhibitors to study 
the ErbB signaling network in cells and examine the time scales of phosphorylation events. 
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Figure 1.4 – Structures of ATP-competitive small molecule kinase inhibitors targeting the 
ErbB receptors. 
Figure adapted from Wood, E.R., Shewchuk, L.M., Ellis, B., Brignola, P., Brashear, R.L., Caferro, T.R., 
Dickerson, S.H., Dickson, H.D., Donaldson, K.H., Gaul, M., et al. (2008). “6-Ethynylthieno[3,2-d]- and 
6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases.” Proc Natl 
Acad Sci U S A 105, 2773-2778. © 2008 National Academy of Sciences, U.S.A. 
 
 - 32 - 
 
Table 1.1 – Dissociation constants, mechanisms of action and FDA approval status of 
ErbB-targeting kinase inhibitors.   
Lower binding results (Kd values) indicate higher affinity.  Since ErbB3 lacks catalytic activity it is not 
inhibited by these drugs.  Kd values were reproduced with permission from Macmillan Publishers Ltd: 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., 
Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). “A quantitative analysis of kinase inhibitor selectivity.” 
Nat Biotechnol 26, 127-132.  Erlotinib binding to ErbB2 was weak (Kd > 10µM) or not detected in a 
primary screen (10µM).  Slightly different values are reported in other sources (Wood et al., 2004).   
 
 
 ErbB1 (nM) ErbB2 (nM) ErbB4 (nM) Mechanism of 
binding to ErbB1 
US FDA-approved 
indication 
      
Gefitinib 1 3,500 410 Fast binding to active 
conformation 
Lung cancer 
Erlotinib 0.67 >10,000 230 Fast binding to active 
conformation 
Lung and pancreatic 
cancers 
Lapatinib 2.4 7 54 Slow binding to 
inactive conformation 
Breast cancer 
Canertinib 0.19 87 29 Irreversible binding Not approved 
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Inhibitors elucidate the dynamic opposition of phosphorylation and 
dephosphorylation 
Despite their importance as prototypical RTKs, oncogenes and drug targets, regulation 
of ErbB receptors through the interplay of conformational change, phosphorylation, 
phosphatases and receptor trafficking remains poorly understood, and the impact of these 
dynamics on physiological activity and cellular responses to anti-ErbB drugs is largely unknown.  
The rapid rise in ErbB1 tyrosine phosphorylation within the first 10 minutes of ligand stimulation 
is thought to reflect kinase activation, and the gradual fall from approximately 10 to 90 minutes 
the time required to internalize and degrade active signaling complexes.   
However, several experiments hint at a much more dynamic balance between activation 
and inactivation than assumed by the standard model.  The potent pan-specific tyrosine 
phosphatase inhibitor pervanadate (the combination of vanadate and hydrogen peroxide) is 
commonly used to study PTP activity in cells due to a lack of good inhibitors of specific PTPs 
(Gordon, 1991; Huyer et al., 1997; Zhao et al., 1996).  The activity of PTPs is tightly regulated in 
vivo by oxidation and reduction reactions involving the invariant cysteine in the PTP catalytic 
domain.  Pervanadate irreversibly inhibits PTPs such as PTP1B by oxidizing their catalytic 
cysteine (Huyer et al., 1997).  Treatment of cells with pervanadate causes an immediate and 
large increase in phosphorylation of ErbB1 (and many other proteins) in the absence of added 
ligand (e.g. (Reynolds et al., 2003)), implying auto-activation that is continuously opposed by 
phosphatases. 
Similarly, sequential exposure of cells to ligand and small molecule kinase inhibitors 
causes phosphorylation to fall rapidly (Bohmer et al., 1995; Offterdinger et al., 2004; Yudushkin 
et al., 2007).  These dynamics have primarily been measured by live-cell imaging techniques 
with the purpose of showing reversibility of probes for ErbB1 phosphorylation.  In an elegant 
study, a sensor for ErbB1 tyrosine phosphorylation was constructed by fusing a YFP-tagged 
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PTB domain of the adaptor protein Shc to CFP-tagged ErbB1 (Fig. 1.5A) (Offterdinger et al., 
2004).  Intramolecular binding of the PTB domain to specific phosphotyrosine residues on 
ErbB1 provides a readout of the phosphorylation state of ErbB1 and was monitored by forester 
(fluorescence) resonance energy transfer (FRET) in cells expressing this construct.  After two 
minutes of EGF stimulation, an ErbB1-specific tyrosine kinase inhibitor was added and led to 
reversion of the YFP/CFP fluorescence emission ratio changes (Fig. 1.5B & C).  These 
experiments hint at rapid dephosphorylation of drug-bound ErbB1 even in the continued 
presence of ligand. 
While useful for tracking real-time dynamics and subcellular localization within a single 
cell, live-cell imaging approaches have some limitations that may influence the interpretation of 
these measurements.  Typically, artificial constructs are overexpressed in cells lacking the 
target protein, and overexpression may misrepresent the dynamics of endogenous kinases.  
Activation of substrates of the target protein is often measured in live-cell microscopy and these 
measurements are therefore indirect with a time delay between phosphorylation of the target 
protein and the readout.  Furthermore, the activity of only one protein is normally monitored in 
live-cell microscopy, yet it is important to understand how that protein functions within a 
signaling network.  Nonetheless, the ErbB1 dephosphorylation kinetics described above seem 
to have profound implications for the dynamic regulation of ErbB1 activity by PTPs and the time 
scale of ErbB1 phosphorylation cycling.  A mechanistic study of these dynamics and their 
functional consequences is thus warranted. 
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Figure 1.5 - Ratiometric imaging of COS7 cells after EGF stimulation and kinase 
inhibition.  
(A) Fusion construct of ErbB1 (EGFR) and the PTB domain of Shc (“FLAME”).  ECFP, enhanced cyan 
fluorescent protein; EYFP, enhanced yellow fluorescent protein; Y, tyrosine residues on ErbB1.  Potential 
PTB domain binding sites are highlighted in red and light red.  (B) COS7 cells expressing FLAME were 
stimulated with 100 ng/ml EGF. EYFP/ECFP ratios are presented.  AG1478 (100 nM), an ErbB1-specific 
tyrosine kinase inhibitor, was added after 2 minutes of EGF stimulation.  (C) Quantitation was performed 
in four regions of interest (white circles) or on the whole image for FLAME_F5 (a construct where all 
major autophosphorylation sites were knocked out by replacing tyrosine residues with phenylalanine 
residues). Region of interest 1, X; region of interest 2, ○; region of interest 3, ▵; region of interest 4, ⋄; 
cells expressing FLAME_F5, -.  This research was originally published in Journal of Biological 
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Chemistry. Offterdinger, M., Georget, V., Girod, A., and Bastiaens, P. (2004). “Imaging phosphorylation 
dynamics of the epidermal growth factor receptor”. Journal of Biological Chemistry 279, 36972-36981. © 
The American Society for Biochemistry and Molecular Biology. 
 
Specific goals of this thesis and key findings 
This thesis examines ErbB receptor phosphorylation dynamics following stimulation of 
cells with exogenous ligand.  The experiments involve the exposure of cells to EGF or other 
ligands followed by a kinase or phosphatase inhibitor (“pulse-chase” experiments) and 
biochemical assays that measure receptor modification.  Relative to earlier studies, our 
experiments benefit from potent and selective kinase inhibitors, many of which are therapeutic 
drugs, and phospho-specific antibodies.  More importantly, we analyze pulse-chase data using 
a series of computational models of receptor enzymology that help us interpret the experimental 
data and make it possible to derive quantitative information on receptor dynamics.  Although 
multiple models of ErbB signaling have previously been developed, we find it necessary to build 
new models to accurately describe regulation of ErbB1 phosphorylation, and no one model was 
sufficient to address all aspects of ErbB regulation by phosphatases and drugs. 
We arrive at lower bounds for the rate of phospho-ErbB1 turnover showing receptors to 
cycle rapidly between being phosphorylated and dephosphorylated on the time scale of 
seconds, in stark contrast to the 30 minutes or so suggested by standard biochemical analysis.  
Rapid phosphorylation and dephosphorylation of receptors has important implications for the 
assembly dynamics of signalosomes and results in strikingly different dose-response behaviors 
for different ErbB1-targeting drugs.  Our revised view of receptor dynamics may also help 
explain why some anti-ErbB1 drugs are more effective in the clinic than others.   
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CHAPTER 2: Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The material in this thesis is an extended version of a manuscript to be submitted for publication: 
 
Coupled fast and slow dynamics regulate ErbB1 signaling  
Laura B. Kleiman, Holger Conzelmann, Thomas Maiwald, Douglas A. Lauffenburger and Peter 
K. Sorger 
 
 
(All experiments were performed by Laura Kleiman.  Mathematical modeling was done by Laura 
Kleiman in collaboration with Holger Conzelmann and Thomas Maiwald.) 
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The dynamics of ErbB receptor activation and inactivation were analyzed in the well-
characterized H1666 human non-small cell lung carcinoma (NSCLC) cell line that expresses 
only wild-type ErbB1 receptors (Paez et al., 2004).  Receptor expression levels are lower and 
presumably more physiological in H1666 cells (~105 molecules per cell, see Chapter 4) than in 
lines such as A431 commonly used to study ErbB1 (~106 molecules per cell (Kwok and 
Sutherland, 1991)).  Moreover, NSCLC is an important target of anti-ErbB1 therapy and the 
H1666 line is often considered to be representative of NSCLC lines lacking drug-sensitizing 
ErbB1 mutations (e.g. (Mukohara et al., 2005)).  Following serum starvation to lower the level of 
basal phosphorylation, H1666 cells were treated with epidermal growth factor (EGF), an ErbB1 
ligand, at 100ng/ml (t=0) and levels of total ErbB1 and phosphorylated ErbB1 on tyrosine 1173 
(pY1173) were measured using a variety of methods, including immunofluorescence, ELISA 
assays and Western blotting.  Y1173 is a physiologically important site on the ErbB1 tail to 
which the adaptor protein Shc binds.  Levels of pY1173 increased after EGF addition, peaking 
at ~4.5-fold over unstimulated levels at t=10 min, declining slowly thereafter and returning to 
pre-stimulus levels by t~2 hours; over this period total receptor levels also declined (Fig. 2.1A).  
If we assume simple exponential decay from peak total or phosphorylated receptor levels (see 
Chapter 4), the estimated half lives (t1/2) of total and phosphorylated receptor are ~30 minutes.   
Next we performed a pulse-chase experiment by treating cells with 100ng/ml EGF (the 
pulse) and subsequently with the ATP-competitive ErbB1 kinase inhibitor gefitinib (the chase) at 
10µM.  Gefitinib (Iressa®) is a potent ErbB1 inhibitor approved for the treatment of NSCLC (Eck 
and Yun, 2009) whose selectivity has been established using a variety of kinome profiling 
methods (Karaman et al., 2008).  Measurable pY1173-ErbB1 levels fell rapidly (t1/2 ~6 sec; see 
Chapter 4 for details) in the presence of gefitinib (Fig. 2.1B; ~4-fold decrease in signal within the 
first minute).  Western blotting revealed no detectable decrease in total ErbB1 levels over the 
short time period (30 seconds) during which gefitinib promoted loss of the pY1173-ErbB1 signal 
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(Fig. 2.1C).  Thus, ErbB1 appeared to be dephosphorylated rather than degraded following 
gefitinib addition.  Similarly rapid ErbB1 dephosphorylation was observed by ELISA assays at 
six other tyrosine phosphorylation sites for which selective antibodies are available (Fig. 2.1D) 
and for ErbB1 agonists other than EGF (e.g. amphiregulin; not shown).  Rapid 
dephosphorylation of pY1173-ErbB1 was also observed in gefitinib-treated non-transformed 
MCF-10A mammary epithelial cells (Fig. 2.1E) and in several other tumor cell lines (A549, 
H3255 and PC9 cells; not shown).  Thus, addition of gefitinib after an EGF pulse causes rapid 
receptor dephosphorylation, resulting in a half life for active receptor of ~6 seconds in contrast 
to ~30 minutes in cells treated with EGF alone.  In the former case receptors must cycle rapidly 
between phosphorylated and unphosphorylated states in a kinase-dependent manner, a point 
we examine in much greater detail below. 
The best characterized protein tyrosine phosphatase (PTP) for ErbB1, PTP1B, resides in 
the endoplasmic reticulum (ER) (Frangioni et al., 1992; Reynolds et al., 2003) and we therefore 
wondered whether these proteins have to be co-localized for ErbB1 dephosphorylation.  PTP1B 
is thought to interact with ErbB1 in perinuclear regions of the cell ~30 minutes after EGF 
stimulation (Haj et al., 2002).  Immunofluorescence of ErbB1 in EGF-stimulated cells showed 
receptor to be present largely on the plasma membrane at t=2 min but by t=10 min receptor was 
substantially internalized and in early endosomes, and by t=30 min presumably in late 
endosomes (Fig. 2.2A; (Oksvold et al., 2000)).  However, when gefitinib was added at t=10 min 
and receptor localization then examined one minute later (at which point pErbB1 levels had 
fallen to background levels) no change in receptor localization was observed (Fig. 2.2A).  
Moreover, when gefitinib was added at different times after exposure of cells to EGF (t=2 to 30 
min), pY1173-ErbB1 had a similarly short half life despite the fact that the bulk of the receptor 
was transiting from the cell surface to internal compartments (Fig. 2.2B).  We therefore conclude 
that ErbB1 is rapidly dephosphorylated regardless of its localization in the cell, implying that the 
receptor is continuously accessible to PTPs. 
 - 40 - 
 
 
Figure 2.1 – ErbB1 is rapidly dephosphorylated in the presence of 10µM gefitinib.   
High-throughput fluorescence microscopy (HTM) measurements of total (cell surface and internal) or 
phosphorylated (Y1173) ErbB1 dynamics after stimulation of H1666 cells with 100ng/ml EGF followed 
by addition of 10µM gefitinib after 10 minutes (unless otherwise noted).  The average and standard 
deviation of triplicate measurements is plotted.  (A) Receptor dynamics for EGF stimulation only.  The 
two time courses were normalized separately and the intensity values are not comparable.  (B) ErbB1 
dephosphorylation dynamics in the presence of gefitinib.  (C) ErbB1 dephosphorylation with gefitinib as 
measured by Western blotting.  (D) Dephosphorylation of ErbB1 on six different phospho-sites by 
ELISA.  These data are from the non-targeting (NT) siRNA controls in Fig. 2.8D.  (E) Effects of gefitinib 
in MCF-10A non-transformed mammary epithelial cells. 
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Figure 2.2 – Rapid ErbB1 dephosphorylation regardless of intracellular localization. 
High-throughput fluorescence microscopy (HTM) measurements of total (cell surface and internal) or 
phosphorylated (Y1173) ErbB1 dynamics after stimulation of H1666 cells with 100ng/ml EGF followed 
by addition of 10µM gefitinib.  (A) H1666 cells treated with 100ng/ml EGF.  In the indicated well 
gefitinib was added after 10 minutes of EGF.  Green = total ErbB1, Red = ErbB1 pY1173, Blue = 
Hoechst and protein dye.  (B) Gefitinib addition after 2, 10 or 30 minutes of EGF and ErbB1 
phosphorylation was measured. 
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ErbB1 receptors rapidly dephosphorylated were actively signaling 
Is the pool of pErbB1 receptors that is rapidly dephosphorylated following gefitinib 
treatment the pool that is active in signaling to downstream pathways?  To answer this question 
we assayed activating phosphorylation levels on several direct and indirect ErbB1 targets 
including co-receptors, adaptor proteins, and components of the ERK and Akt kinase cascades.  
We reasoned that by showing these downstream proteins to be phosphorylated and 
dephosphorylated with similar kinetics to ErbB1 following EGF pulse/gefitinib chase we could 
establish functional consequences for rapid pErbB1 turnover.  ErbB2 and ErbB3 are known to 
be phosphorylated following EGF stimulation of cells (Wolf-Yadlin et al., 2006), presumably by 
ErbB1 since EGF binds with high affinity only to ErbB1 (Linggi and Carpenter, 2006).  In H1666 
cells both ErbB2 Y1221/1222 (a Shc-binding site) and ErbB3 Y1289 (a PI3K-binding site) 
(Schulze et al., 2005) were rapidly phosphorylated following EGF addition and were then rapidly 
dephosphorylated upon subsequent addition of gefitinib at t=10 min (t1/2 ~15 sec and 32 sec, 
respectively; Fig. 2.3A).  The SH2- and PTB-containing adaptor protein Shc was also 
phosphorylated rapidly upon EGF addition, concomitant with binding to ErbB1, as assayed by 
co-immunoprecipitation (Fig. 2.3B).  Upon subsequent addition of gefitinib, pShc was rapidly 
dephosphorylated (t1/2 ~26 sec) and it then dissociated from receptor complexes (Fig. 2.3A & B).  
SH2 and PTB domains are thought to protect phosphotyrosine residues from the action of 
phosphatases (Brunati et al., 1998; Lammers et al., 1993; Rotin et al., 1992) but our data 
suggest that the Shc-pErbB1 interaction is too transient to significantly protect modified 
receptors.  This is consistent with fast association and dissociation rates reported for 
interactions of various SH2 and PTB domains with tyrosine phosphorylated proteins (Felder et 
al., 1993; Zhou et al., 1995).  
The PI3K-Akt and MAPK (Raf-MEK-ERK) kinase cascades are two of the canonical 
signaling pathways downstream of ErbB1 and both are activated in H1666 and MCF-10A cells 
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following growth factor stimulation.  Upon EGF addition, levels of active pS473-Akt increased in 
both cell lines and then fell rapidly upon subsequent exposure to gefitinib at t=10 min (t1/2 ~80 
sec; Fig. 2.4).  The same was true of pT202/Y204-ERK1/2 in MCF-10A cells, although ERK was 
dephosphorylated slightly slower than Akt (t1/2 ~211 sec; Fig. 2.4).  In H1666 cells however, the 
rate of ERK dephosphorylation was significantly slower (t1/2 >10 min), implying either that ERK 
phosphatases are not as active as in MCF-10A cells or that the activating signal is longer lived.  
Treatment of EGF-stimulated H1666 cells with the small molecule MEK kinase inhibitor 
PD0325901 at t=10 min resulted in rapid ERK dephosphorylation (t1/2 ~43 sec; Fig. 2.4) 
however, arguing against the former hypothesis.  We speculate that the mutant Raf found in 
H1666 cells (Pratilas et al., 2008) may be involved in extending the duration of signaling.  For 
the current discussion the important point is that EGF-induced Akt phosphorylation in H1666 
and MCF-10A cells and ERK phosphorylation in MCF-10A cells are subject to negative 
regulation following gefitinib addition with similar fast kinetics as pErbB1.  We therefore 
conclude that the pool of ErbB1 receptors subject to rapid dephosphorylation represents the 
pool of receptors active in signal transduction.  We turn to a kinetic analysis of receptor 
biochemistry to further interpret these dynamics. 
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Figure 2.3 – Rapid dephosphorylation of ErbB2, ErbB3 and Shc after ErbB1 inhibition. 
Stimulation of H1666 cells with 100ng/ml EGF followed by addition of 10µM gefitinib after 10 minutes.  
(A) Rapid dephosphorylation of ErbB2, ErbB3 and Shc.  Phosphorylation of ErbB2 and ErbB3 were 
measured by ELISA and Shc phosphorylation was measured by HTM.  (B) Co-immunoprecipitation of 
ErbB1 and Shc (left).  Quantification (right) was done by background correction and normalizing to the 
total amount of ErbB1 immunoprecipitated for each sample.  The three Shc bands are different Shc 
isoforms.   
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Figure 2.4 – Dephosphorylation dynamics of the Akt and ERK pathways. 
Measurements of Akt (left) or ERK (right) phosphorylation by high-throughput fluorescence microscopy 
(HTM) after stimulation of H1666 or MCF-10A cells with 100ng/ml EGF followed by addition of 10µM 
gefitinib or 1µM PD0325901 (an allosteric MEK inhibitor) added after 10 minutes. 
 
Estimating rates of phospho-ErbB1 turnover using a kinetic model 
Mass-action models based on sets of coupled differential equations represent the 
simplest means to encapsulate different kinetic schemes of receptor regulation.  By 
incorporating data from previous studies and by calibrating models against time course data 
collected from EGF and drug-treated cells, we can estimate the values of rate constants that 
appear in the models as free parameters.  In formulating models we have a choice: with the 
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simplest models, available data can uniquely specify parameter values (that is, uncertainty 
arises only from experimental error), but the models are not particularly realistic.  Complex 
models incorporate more of the known or suspected biochemistry of ErbB regulation, but 
parameter values cannot be fully constrained (the models are non-identifiable given the data).  
For some parameters, calibration is expected to yield a narrow range of estimated values, but 
for other parameters values can assume a much wider range without altering model output.  In 
an attempt to balance competing demands of biological realism and model identifiability, we 
constructed a series of models of increasing complexity.  In each case, we performed additional 
experiments to improve parameter estimation or to test specific model predictions.  Both simple 
and complex models are most consistent with the view that ErbB phosphorylation is 
antagonized by potent phosphatases. However, many results can only be explained using 
relatively complex models, thereby justifying the complexity and adding additional insight to our 
analysis. 
We estimate rate constants for both ErbB1 dephosphorylation and degradation in the 
presence of EGF only to be ~0.02/min by fitting a simple exponential decay ODE model to the 
experimental data.  However, in the presence of gefitinib we estimate an ErbB1 
dephosphorylation rate constant of ~7/min.  If we assume that 40% of receptors are 
phosphorylated after 10 minutes of EGF stimulation (40,000 molecules per cell; see Chapter 4), 
these rate constants correspond to ~5,000 receptors per cell dephosphorylated within the first 
second after drug addition, compared to ~10 receptors in the presence of EGF only.  This 
suggests that individual receptors are constantly undergoing cycles of phosphorylation and 
dephosphorylation and that these cycles are masked in measurements of population-level 
phosphorylation dynamics after treatment with ligand alone. 
The exponential decay model is the simplest model to describe ErbB1 
dephosphorylation dynamics and does not allow for any mechanistic insight or for estimates of 
the receptor phosphorylation rate.  To deduce the frequency with which individual receptors 
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cycle between being phosphorylated and dephosphorylated, we developed a slightly more 
detailed biochemical scheme that describes how the concentration of phosphorylated receptors 
changes over time in the presence and absence of gefitinib (Fig. 2.5A). From this scheme we 
built a simple computational model and then attempted to infer the rate constants.  To calibrate 
the model and constrain it as much as possible, we measured the effects of 1, 10 and 20µM 
gefitinib, added at t =10 min after EGF stimulation, on pY1173-ErbB1 dephosphorylation with 
dense temporal sampling (including 10, 20 and 30 seconds after drug addition) (Fig. 2.5B).  
Surprisingly, 1µM gefitinib resulted in very rapid dephosphorylation with no further decrease 
after the initial ~50% drop.  We aimed to characterize this fast dephosphorylation of ErbB1 
immediately following gefitinib addition, and therefore, in this scheme we only considered 
reactions we believed to be important from t=10-20 min after EGF stimulation of H1666 cells.   
During this time, maximum ErbB1 phosphorylation has been reached and the average 
level of phosphorylation stays approximately constant; slow processes such as ligand binding, 
dimerization and degradation are likely not changing significantly so we do not describe these 
processes.  Moreover, we consider only ErbB1 receptors in this model since H1666 cells 
express considerably more of these receptors than other ErbB receptors (see Chapter 4), and 
thus, after cells are stimulated with EGF we expect ErbB1 homodimers to be the predominant 
oligomer.  ErbB1 species in the model describe individual receptors that are in a homodimeric 
state.  Because the six ErbB1 phosphotyrosine sites we examined have similar dynamics (Fig. 
2.1D) we use easily measured pY1173-ErbB1 dynamics as a proxy for all sites.  We assume 
that all receptors are phosphatase-bound and that adaptor proteins do not bind to 
phosphotyrosine sites to protect them from dephosphorylation (Brunati et al., 1998; Lammers et 
al., 1993; Rotin et al., 1992), which is reasonable due to the observed fast dynamics. 
To extract kinetic data from this scheme, we assume that the ErbB1 phosphorylation 
rate effectively decreases with increasing concentrations of gefitinib, and that gefitinib binding 
and phosphorylation are independent.  We are able to estimate a phosphorylation rate constant 
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that is independent of the gefitinib concentration by calculating the fraction of receptors bound 
by gefitinib and therefore unable to become phosphorylated ( Gf ), assuming that gefitinib 
binding is in pseudo-equilibrium, a reasonable assumption since gefitinib binding is likely 
diffusion limited (Northrup and Erickson, 1992).  We can calculate Gf  because we have 
experimental measurements for the effects of modulating the gefitinib concentration.  In this 
scheme, ATP is implicitly bound to ErbB1 due to high cellular ATP concentrations (Lehninger et 
al., 2000), but gefitinib is allowed to bind and once bound the receptor is immediately 
catalytically inactive (i.e. gefitinib displaces ATP).  We define the ordinary differential equation 
(ODE) describing the change in the fraction of phosphorylated receptors ( px ) with respect to 
time as: 
1 1(1 )(1 )p G p px k f x k x
•
−= − − −    (1) 
where 1k  = phosphorylation rate constant, 1k−  = dephosphorylation rate constant, the term 
1 px− represents the fraction of all ErbB1 receptors that are unphosphorylated, and 
1 Gf− represents the fraction of receptors that are not gefitinib-bound.  At steady state, the 
association constant for gefitinib binding to ErbB1 ( eqGK ) is: 
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where G  = gefitinib concentration.  By solving for Gf  and substituting it into (1), it follows that:  
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                              (3) 
We assume that 40% of the receptors are phosphorylated at steady state (corresponding to 10 
minutes after EGF addition) and 0.5% after 20µM gefitinib treatment (see Chapter 4). 
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We performed Monte Carlo simulations to obtain probabilistic estimates of the three 
parameters ( 1k , 1k−  and eqGK ) from the variance in the experimental data.  To do this, we 
generated 1,000 artificial time courses by choosing random values from a log-normal 
distribution with the same mean and standard deviation as the experimental measurements in 
Figure 2.5B for each time point and concentration of gefitinib.  For each artificial time course the 
parameters were fitted (see Chapter 4 for details) and we obtained good fits to the experimental 
data (Fig. 2.5B).  We simulated the gefitinib dose-response behavior based on fitting to only the 
experiments of 1 and 10µM gefitinib and asked how well the model could predict the response 
of cells to additional concentrations of drug; we found that the model could indeed predict new 
experimental results (Fig. 2.5C).   
We estimated parameter values of 1k ~4.5/min, 1k−  ~8/min and eqGK ~1.3/µM (Fig. 2.5D).  
The ErbB1 phosphorylation and dephosphorylation rate constants ( 1k and 1k− , respectively) are 
consistent with those used in previously published models of ErbB signaling.  These values fall 
within a large range and if estimated from fitting to experimental data they are usually obtained 
from fitting to data of cells treated with EGF only (Blinov et al., 2006; Chen et al., 2009; 
Kholodenko et al., 1999).  In vitro kinase measurements of wild-type ErbB1 estimate 
catk ~1.5/min (Yun et al., 2008).  We provide reasonable estimates for ErbB1 phosphorylation 
and dephosphorylation rate constants based on experimental data of dense temporal sampling 
following inhibitor perturbations.  The estimated value for eqGK  (equivalent to a dissociation 
constant of ~1µM) seems high but reflects competition with ATP, which we do not describe 
explicitly in the model and is therefore incorporated into the estimated value.  The underlying 
microscopic dissociation constant for gefitinib can be calculated using the Cheng-Prusoff 
equation based on our data showing an IC50 of 1µM: using an ATP concentration of 2mM 
(Lehninger et al., 2000) and a Km for ATP of 5µM (Yun et al., 2008) we calculate a drug affinity 
 - 50 - 
of 2.5nM, which is similar to measured values (Karaman et al., 2008). 
The solution to the ODE in (3) can be calculated analytically, and we can prove that by 
measuring the level of receptor phosphorylation all parameters are identifiable (i.e. exact values 
of the parameters could be obtained if the measurements were exact; see Chapter 4 for details).  
Therefore, the distributions of parameter values obtained from fitting experiments using the 
experimental data comprise biological variation and error in the data, and not any non-
identifiabilities.  These distributions represent confidence intervals for the parameters; in other 
words, we can conclude that with a certain level of confidence the real parameter values fall in a 
given interval, assuming an accurate model and that all replicate experiments fall within the 
standard deviation measured and used here.   
In this scheme receptors are phosphorylated and dephosphorylated based only on the 
catalytic phosphorylation and dephosphorylation rates and whether gefitinib is bound, assuming 
that gefitinib binding is in pseudo-equilibrium.  In reality, ATP and gefitinib compete for binding 
to a single site on each ErbB1 molecule to regulate receptor catalytic activity, and whether a 
receptor can become dephosphorylated depends on whether a phosphatase and adaptor 
protein are bound at that time.  Thus, only a fraction of the receptors that we consider can 
actually become phosphorylated or dephosphorylated, with this fraction changing over time.  
Calculating this fraction and fitting the model to the experimental data (as we did above) would 
lead to higher estimates for the phosphorylation and dephosphorylation rate constants.  The 
estimates we obtained therefore represent lower bounds for the true rates.  To obtain more 
accurate estimates we need to take into account the dynamics of other relevant binding 
processes that regulate the level of ErbB1 phosphorylation (see extended model below).  
However, these more realistic schemes are difficult to analyze computationally, and even a 
slightly extended model with 5 ODEs and 6 parameters where we describe the dynamics of 
gefitinib and adaptor protein binding is no longer identifiable given our measurements. 
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Figure 2.5 – Simple biochemical scheme describing ErbB1 phosphorylation dynamics 
and estimation of kinetic rate constants.   
(A) Illustration of simple scheme describing ErbB1 phosphorylation.  (B) Effects of various gefitinib 
concentrations on ErbB1 Y1173 phosphorylation in H1666 cells by HTM with 100ng/ml EGF stimulation 
followed by dense temporal sampling immediately after drug addition (including after 10, 20 and 30 
seconds).  Mean and standard deviations of experimental data points are shown along with simulation 
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results using the median parameter values obtained.  (C) Simulation of predicted gefitinib dose-response 
behavior based on fitting to only the 1 and 10µM gefitinib experimental data shown in (B) (red).  Also 
shown are some of the data points used for model training (orange) and experiments with additional 
concentrations of drug (purple).  (D) Histograms of estimates for parameters based on fitting to all data in 
(B). 
 
 
ErbB1 dephosphorylation dynamics in response to different drugs 
To establish that rapid ErbB1 dephosphorylation is not a peculiarity of gefitinib inhibitor 
treatment, we performed the straightforward experiment of treating cells with EGF and then 
washing it away (replacing the media) after 10 minutes.  This treatment resulted in ErbB1 Y1173 
dephosphorylation with faster kinetics than in the presence of continued exposure to ligand 
(data not shown).  Furthermore, we obtained similar results by stimulating cells with EGF and 
then adding saturating concentrations of the anti-ErbB1 monoclonal antibody 225 after 10 
minutes, which competes with EGF for binding to ErbB1 (t1/2 ~7 min; Fig. 2.6A).  The ErbB1 
dephosphorylation rate in these experiments likely reflects the rate at which EGF dissociates 
from ErbB1.  Measuring the effects of blocking receptor catalytic activity directly eliminates 
these potentially slower time scales from the analysis and allows us to better constrain the rates 
of ErbB1 phosphorylation and dephosphorylation.   
We asked whether ErbB1 is also rapidly dephosphorylated after treatment with ErbB-
targeted kinase inhibitors other than gefitinib.  Gefitinib and erlotinib (Tarceva®) bind with fast 
kinetics to ErbB1 when the receptor is in an active conformation (Stamos et al., 2002; Yun et al., 
2007), whereas lapatinib (Tykerb®) binds with slow kinetics to ErbB1 when in an inactive 
conformation (Wood et al., 2004).  Canertinib (CI-1033) covalently binds ErbB1 to act as an 
irreversible inhibitor (Fry et al., 1998).  Cells were stimulated with 100ng/ml EGF and these 
inhibitors were subsequently added (t=10 min) at 10µM.  Erlotinib (not shown) and canertinib 
result in rapid ErbB1 dephosphorylation, whereas lapatinib causes slow dephosphorylation (t1/2 
~8 min) in both H1666 (Fig. 2.6B) and MCF-10A cells (Fig. 2.6C).  We turned to a more detailed 
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computational model to better understand the different dephosphorylation dynamics induced by 
the various drugs. 
 
 
 
Figure 2.6 – ErbB1 dephosphorylation dynamics after competing away ligand or addition 
of ErbB1 small molecule kinase inhibitors with different mechanisms of action.   
High-throughput fluorescence microscopy (HTM) measurements of ErbB1 Y1173 phosphorylation 
dynamics after stimulation of H1666 cells with 100ng/ml EGF followed by addition of drugs after 10 
minutes (unless otherwise noted).  (A) Effects of competing away EGF with 10µg/ml anti-ErbB1 
monoclonal antibody 225 in H1666 cells.  (B) ErbB1 dephosphorylation dynamics after treatment with 
10µM gefitinib (as shown in Fig. 2.1B), canertinib or lapatinib.  (C) Effects of 10µM gefitinib (as shown 
in Fig. 2.1D) or lapatinib in MCF-10A cells.   
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Development of a more detailed computational scheme to understand 
different inhibitor effects  
We aimed to understand properties of ErbB1 receptors and drugs that give rise to the 
striking differences in ErbB1 dephosphorylation dynamics, specifically between gefitinib and 
lapatinib.  The utility of the previously discussed model is clearly limited because it does not 
account for the dynamics of many important events regulating receptor phosphorylation.  We 
therefore constructed an extended model consisting of 46 ODEs and 24 parameters (see 
Chapter 4 for model details).  While the parameters in this larger model are not identifiable, the 
model nevertheless allows us to perform qualitative analyses.  It describes the binding of ATP or 
drug (and competition between the two), phosphatases and adaptor proteins, and includes 
similar assumptions as for the previously described model, e.g. ErbB1 species are individual 
receptors in a homodimeric state and the model steady state is representative of EGF treatment 
only (Fig. 2.7A).  We model Shc binding to the receptor since we measure phosphorylation of 
tyrosine 1173 on ErbB1, which is a high affinity binding site for Shc; however, this could also be 
interpreted as the family of adaptor proteins that bind to this site.  We assume that 
phosphatases directly bind ErbB1 before catalyzing receptor dephosphorylation and consider 
one pool of phosphatases with an average binding constant and activity.    
Although they have similar dissociation constants for ErbB1, gefitinib preferentially binds 
to ErbB1 when the receptor is in an active conformation, while lapatinib binds with slower on 
and off rates to an inactive receptor conformation (Johnson, 2009; Wood et al., 2004).  We 
incorporated this conformational distinction into the model and assume that in the presence of 
EGF the active ErbB1 conformation is dominant.  We assume that ATP and gefitinib bind much 
better to ErbB1 when in the active conformation but that they can still bind although with much 
lower affinity to the inactive conformation.  On the other hand, lapatinib is only allowed to bind to 
ErbB1 when it is in the inactive conformation, and once bound the receptor cannot switch 
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conformations.  However, when lapatinib dissociates ErbB1 is again allowed to switch 
conformations. 
We performed model fitting and parameter estimation in the MATLAB toolbox 
PottersWheel (Maiwald and Timmer, 2008), where we simultaneously fit the model to a large 
dataset consisting of ErbB1 phosphorylation dynamics following treatment with 100ng/ml EGF 
and then various gefitinib or lapatinib concentrations or the phosphatase inhibitor pervanadate.  
We used a trust-region optimization approach, minimizing χ2, the sum of weighted and squared 
residuals between the model trajectories and our measurements.  Since the model is non-
identifiable given our measurements, we consider a family of good fits of the model to data, and 
plot the fits along with a subset of the experimental training dataset (Fig. 2.7B).  The model 
includes binding events that can slow down receptor dephosphorylation (e.g. Shc binding), and 
therefore we obtain faster estimates for the intrinsic phosphorylation and dephosphorylation rate 
constants (Fig. 2.7C; both ~ 50/min) compared to those estimated in Figure 2.5D.  The model 
accurately predicts fast dissociation of Shc from ErbB1 following inhibition of receptor catalytic 
activity, and the Shc dissociation rate was estimated to be similar to the rates of receptor 
phosphorylation and dephosphorylation (not shown).   
We find that the dose-response behavior of gefitinib and lapatinib look very different: 
only high gefitinib doses completely block receptor phosphorylation and lower doses result in a 
very fast equilibrium of partial inhibition, whereas even low dosing with lapatinib results in 
complete receptor inhibition, although at a slower rate (Fig. 2.7B).  Gefitinib and lapatinib have 
similar Kd’s for ErbB1, but in the model a preference for the inactive receptor conformation gives 
rise to more effective inhibition by lapatinib because lapatinib encounters less competition with 
ATP than gefitinib and leads to an increase in the number of inactive receptors.   
We decreased the rates of ErbB1 phosphorylation and dephosphorylation in the best fit 
model to reveal the dependency of the different trends of ErbB1 dephosphorylation by 10µM 
gefitinib or lapatinib on these rates (Fig. 2.7D).  We find that the different dynamics rely on the 
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fast kinetics; if the rates were slower we would not see a difference between treatments with the 
two drugs.  ErbB1 dephosphorylation in the presence of these drugs is therefore determined by 
the velocity and mechanism of drug binding, and is dependent on fast ErbB1 phosphorylation 
and dephosphorylation cycling.   
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Figure 2.7 – More detailed model describing gefitinib and lapatinib binding to ErbB1. 
High-throughput fluorescence microscopy (HTM) measurements of ErbB1 Y1173 phosphorylation 
dynamics after stimulation of H1666 cells with 100ng/ml EGF followed by addition of drugs after 10 
minutes (unless otherwise noted).  (A) Simplified illustration of a biochemical scheme describing ErbB1 
phosphorylation dynamics as determined by the dynamics of binding of ATP, lapatinib (“L”) or gefitinib 
(“G”), protein tyrosine phosphatase (“PTP”) and the adaptor protein Shc.  The ErbB1 species is a 
monomer that exists in a stable ErbB1 homodimer.  The model also distinguishes between active and 
inactive conformations of ErbB1, and the dashed arrow denotes the change in conformation (not a change 
in binding state).  Gefitinib preferentially binds to ErbB1 when it is in the active conformation, while 
lapatinib binds with slower on and off rates to the inactive receptor conformation (similar Kd’s).  EGF 
binding and receptor dimerization are not explicitly modeled here.  (B) The best 100 model fits out of 
2000 are shown along with a portion of the training dataset.  Each data point is an average of replicate 
measurements made on the same day, and the error bars were calculated from an error model.  The t=0 
data point is artificial and was used to force pre-equilibration of the model (t<10min).  (C) Histograms of 
phosphorylation and dephosphorylation rate constant estimates from ~400 separate fits.  (D) Effects of 
decreasing the rates of phosphorylation (from 209/min to 0.3/min) and dephosphorylation (from 38/min 
to 0.06/min) in the best fit model (black dotted curves) on ErbB1 inhibition by 10µM gefitinib or 
lapatinib.  Each curve is a decrease in the rates by a factor of ~1.5 where the ratio of the two rates is held 
constant.  The curves were first normalized to 40% at t<10min to be able to compare the trends. 
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Investigating the role of ErbB1 phosphatases 
Thus far we have assumed that phosphatases are responsible for the fast gefitinib-
induced dephosphorylation.  We wanted direct evidence of this and turned to phosphatase 
inhibitors, but unfortunately, the tools to study phosphatases are blunt and we are lacking good 
chemical inhibitors of specific phosphatases.  Therefore, we first evaluated the effects of the 
non-specific tyrosine phosphatase inhibitor pervanadate, which results in the irreversible 
oxidation of the catalytic cysteine of PTPs such as PTP1B (Huyer et al., 1997).  
As reported in other studies, inhibiting tyrosine phosphatases with pervanadate leads to 
significantly higher ErbB1 phosphorylation than saturating EGF (Fig. 2.8A), suggesting that 
phosphatases are constantly acting to suppress maximal receptor activation.  Addition of 
pervanadate after EGF stimulation still leads to a large increase in receptor phosphorylation 
(Fig. 2.8B), suggesting that only ~50% of ErbB1 receptors are phosphorylated after ligand 
stimulation.  This may be explained by pervanadate activating receptors located in all 
subcellular compartments (Offterdinger et al., 2004), whereas EGF activates only cell surface 
receptors.   
We turned to the computational model depicted in Figure 2.7A to better understand the 
counteracting dynamics of simultaneous inhibition of kinase and phosphatase activity.  The 
model predicts that treatment with 10µM gefitinib and 100µM pervanadate together would block 
the fast gefitinib-induced ErbB1 dephosphorylation, and we experimentally verified this 
prediction (Fig. 2.8B).  We find that gefitinib binds rapidly, but when it also unbinds rapidly it 
leads to an increase in phosphorylation due to inactive phosphatases.  The correspondence of 
the model and our data argues in favor of an accurate understanding of the biochemistry, and 
these results verify that ErbB1 dephosphorylation is dependent on active phosphatases.   
Next, we investigated whether PTP1B regulates the fast gefitinib-induced ErbB1 
dephosphorylation.  We knocked down PTP1B levels by 80% with siRNA (Fig. 2.8C).  This 
knockdown had no effect on basal phosphorylation or gefitinib-induced dephosphorylation of six 
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different phosphorylation sites on ErbB1 when gefitinib was added 10 minutes after EGF (Fig. 
2.8D).  Commercially available chemical inhibitors also had no effect (not shown).  These 
results are not very surprising since many factors could contribute to the difficulty in pinpointing 
the exact phosphatase(s) responsible for the fast phosphorylation cycling.   
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Figure 2.8 – Pervanadate treatment but not PTP1B knockdown blocks gefitinib-induced 
ErbB1 dephosphorylation. 
(A) ErbB1 Y1173 phosphorylation as measured by high-throughput microscopy (HTM) after stimulation 
of H1666 cells with 300ng/ml EGF or pervanadate (the combination of sodium orthovanadate and 
hydrogen peroxide).  (B) Model prediction (cyan curves) and experimental validation (dark black cyan-
filled squares) of simultaneous treatment with gefitinib and pervanadate (best 100 fits out of 2000).  
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Pervanadate and/or gefitinib were added after 10 minutes of 100ng/ml EGF in H1666 cells and ErbB1 
pY1173 was measured by HTM.  Each data point (square) is an average of replicate measurements made 
on the same day, and the error bars were calculated from an error model (see Chapter 4).  The t=0 data 
point is artificial and was used to force pre-equilibration of the model (t<10min).  Long term treatments 
with 100µM pervanadate resulted in loss of cells from the plate, presumably due to effects on adhesion 
molecules, and for this reason it was not possible to obtain data for time points after ~30 min.  Sodium 
orthovanadate and hydrogen peroxide alone each had no effect on ErbB1 phosphorylation when added 
after EGF in H1666 cells.  (C)-(D) Effect of siRNA knockdown of PTP1B or a non-targeting control 
(NT) on ErbB1 Y1173 phosphorylation by Western blotting (C) or six different ErbB1 phosphotyrosine 
sites by ELISA (D) in H1666 cells.  10µM Gefitinib (“G”) or a DMSO control (“D”) was added after 10 
minutes of 100ng/ml EGF stimulation.   
 
Low dosing with gefitinib results in sustained ErbB1 phosphorylation 
Whereas even low dosing with lapatinib eventually results in complete receptor inhibition 
(Fig. 2.9A), our modeling suggests that at some point low gefitinib dosing after EGF addition 
may result in more receptor activity than with EGF alone, which is eventually shut off.  Indeed, 
we find that adding low concentrations of gefitinib (0.5 or 1µM) after a few minutes of EGF 
stimulation (t=1 or 2 min) results in a surprisingly stable level of receptor phosphorylation for 
many hours, crossing over the EGF only treatment curve (Fig. 2.9B for MCF-10A cells; H1666 
cells not shown).  Total ErbB1 levels (consisting of cell surface plus internal receptors) under 
these treatment conditions show that even low gefitinib concentrations prevent receptor 
degradation (Fig. 2.9B).  Microscopy images illustrate altered ErbB1 trafficking in the presence 
of gefitinib such that only a fraction of receptors are located in endocytic compartments by 20 
minutes, with no change in ErbB1 localization detected by 4 hours (Fig. 2.9C; 4 hour time point 
not shown). 
It is unclear how frequently ErbB1 is exposed to growth factors, and therefore how active 
the receptor is, in vivo.  We asked whether exposure of cells to low doses of gefitinib prior to 
ligand stimulation could turn a future transient response to ligand into a sustained signal.  Cells 
were pretreated with various concentrations of gefitinib for one hour followed by stimulation with 
EGF for 4 hours.  In control cells with no drug, the typical response to long-term ligand 
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stimulation was observed where ErbB1 phosphorylation returned to basal levels and receptors 
were degraded (Fig. 2.10).  Pretreatment with gefitinib had a similar effect as addition after 
ligand stimulation: ErbB1 degradation was inhibited but receptor phosphorylation sustained in 
the presence of 0.5 and 1µM gefitinib (Fig. 2.10). 
Only a fraction of receptors are gefitinib-bound at any given time, and while gefitinib is 
not bound the receptors can rapidly become phosphorylated again.  This can result in rapid 
shuffling of individual receptors between being bound by drug and being phosphorylated and 
dephosphorylated, with a higher fraction of receptors not bound and therefore phosphorylated in 
the presence of low gefitinib concentrations.  We propose that when low concentrations of 
gefitinib are added while ErbB1 is still at the cell surface, each ErbB1 molecule may not be 
phosphorylated long enough for activation and recruitment of a ubiquitin ligase complex (i.e. 
Cbl-Grb2), which may allow these receptors to evade internalization and degradation and lead 
to sustained signaling.  Interestingly, according to pharmacokinetic data obtained in phase I 
clinical studies, the mean steady state plasma concentration of gefitinib at the FDA-approved 
dosing is approximately 1µM (Baselga et al., 2002), which is the “low” gefitinib concentration 
used here. 
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Figure 2.9 - Low gefitinib dosing converts a transient response to ligand into a sustained 
signal by altering receptor trafficking.   
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(A) Treatment of H1666 cells with various concentrations of lapatinib after 10 minutes of 100ng/ml EGF 
stimulation as measured by HTM.  (B) Various gefitinib concentrations were added after one minute of 
EGF stimulation of MCF-10A cells, and ErbB1 pY1173 and total ErbB1were measured by HTM.  (C) 
Higher magnification images of selected time points in (B).  Blue = Hoechst and protein dye, Green = 
total ErbB1.   
 
 
 
 
Figure 2.10 - Pretreatment with low concentrations of gefitinib also leads to sustained 
signaling. 
H1666 cells were pretreated with various gefitinib concentrations or a DMSO control for one hour 
followed by stimulation of cells with 100ng/ml EGF for 4 hours, and ErbB1 pY1173 and total ErbB1 
were measured by HTM. 
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Physiological consequences of fast phosphorylation cycling 
We wondered whether there could be a functional consequence of rapid and continual 
protein phosphorylation, as opposed to becoming phosphorylated and staying phosphorylated 
for a longer duration.  We hypothesized that these fast dynamics may allow cells to rapidly 
sense and respond to changes in their environment.  EGF is a well-known initiator of cell 
migration (Jorissen et al., 2003) and protrusion of lamellipodia is a rapid and early event in the 
process of cell migration, beginning almost immediately after EGF stimulation of MCF-10A cells 
(Fig. 2.11A).  Extension and retraction of these protrusions are normally complete after 20 
minutes, although additional protrusions are common in the continued presence of ligand, but 
the timing is more variable between cells (not shown).  We quantified protrusion dynamics using 
kymograph analysis (see Chapter 4).   
Cells were treated with EGF and 10µM gefitinib was added 40 seconds later.  ErbB1 
receptors were dephosphorylated within 15 seconds (data not shown) and further lamellipodia 
extensions stopped in 40 seconds (Fig. 2.11B & C), followed by retraction of the lamellipodia 
with similar kinetics to EGF only (Fig. 2.11B).  Similar retraction dynamics may be attributed to 
fixed dynamics of actin depolymerization.  The difference between the time it takes for the 
receptor to be shut off and protrusions to halt is likely due to how long it takes for intermediates 
(e.g. ERK and Akt) to be inhibited under these conditions.  Our results show that lamellipod 
extension is a reversible process that depends on continual receptor phosphorylation. 
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Figure 2.11 – Lamellipodia retract almost immediately after ErbB1 is dephosphorylated 
following gefitinib treatment. 
(A) DIC images of MCF-10A cells stimulated with 300ng/ml EGF (pink arrows point to example 
membrane protrusions).  (B) Results of kymograph analysis showing the effects of adding 10µM gefitinib 
or DMSO after 40 seconds of 100ng/ml EGF stimulation on protrusion dynamics in MCF-10A cells.  For 
each treatment condition the average and standard error of the mean for 5-10 cells is plotted.  (C) 
Derivatives of average data points in (B) immediately after addition of gefitinib.    
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Stochastic simulation illustrates switching times between 
phosphorylation states 
To illustrate the cycling times of individual ErbB1 molecules between being 
phosphorylated and dephosphorylated in the presence or absence of gefitinib, we developed a 
stochastic simulation with a similar structure as the scheme depicted in Figure 2.5A.  We used 
the parameters estimated for H1666 cells with that simple ODE model (Fig. 2.12A).  The 
addition of gefitinib is mimicked by decreasing the phosphorylation rate after 10 minutes based 
on the equation 1
1 eqG
k
K G+
as derived in equations (2) and (3) above.  Time courses of individual 
ErbB1 receptors before (t < 10min) and after (t > 10min) 10µM gefitinib treatment demonstrate 
the frequency of phosphorylation events (Fig. 2.12B).   
While individual molecules are being phosphorylated and dephosphorylated at different 
times after EGF stimulation, the average level of phosphorylation stays constant at steady state.  
Shortly after gefitinib is added (i.e. the phosphorylation rate changes), a new average level of 
phosphorylation for the population is reached.  We estimate that on average, receptors that are 
phosphorylated become dephosphorylated in ~8 seconds.  In the presence of EGF only, 
unphosphorylated receptors become phosphorylated within ~14 seconds, and in the presence 
of 10µM gefitinib this increases to ~190 seconds.  Therefore, ErbB1 can still become 
phosphorylated even in the presence of saturating gefitinib concentrations, but each receptor 
spends more time being unphosphorylated.  This reasoning can help explain our results in 
Figure 2.8B where we added 10µM gefitinib and pervanadate simultaneously, and ErbB1 was 
rapidly dephosphorylated and then slowly re-phosphorylated.  These infrequent re-
phosphorylation events in the presence of 10µM gefitinib accumulate due to inactive 
phosphatases. 
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Overall, our results suggest that ErbB1 is regulated by processes that occur at both slow 
and fast time scales.   Slow dynamics of ligand binding and dimerization result in increased 
receptor kinase activity and phosphorylation, and presumably slow degradation leads to signal 
attenuation.   These slow time scales are coupled with constant fast cycling of individual 
receptors between being phosphorylated and dephosphorylated in the presence of ligand. 
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Figure 2.12 – Stochastic model illustrates fluctuations of individual ErbB1 receptors 
between being phosphorylated and unphosphorylated. 
(A) The average ErbB1 phosphorylation over 1000 individual molecules from the stochastic simulation 
(blue) is overlaid with the ODE formalism (green).  10µM gefitinib is added after 10 minutes.  (B) Time 
courses of two ErbB1 molecules before (t < 10 min) and after (t > 10 min) 10µM gefitinib addition. 
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Supplementary Data 
Effects of gefitinib on levels of cell surface ErbB1 
ErbB1 receptors in H1666 cells were internalized approximately 2 to 10 minutes after 
EGF addition, as detected by immunofluorescence using a total ErbB1 antibody that recognizes 
the extracellular domain of the receptor and by not permeabilizing the cell membrane (Fig. 
2.13).  This is also evident from the images shown in Figure 2.2A, where the cell membrane 
was permeabilized to allow for total (cell surface plus intracellular) ErbB1 staining.  The addition 
of 10µM gefitinib after 2 minutes of EGF stimulation appears to have inhibited normal receptor 
internalization following EGF, whereas the addition of 10µM gefitinib after 10 minutes of EGF 
stimulation led to a slow rise in the number of cell surface receptors (Fig. 2.13).  This increase in 
cell surface receptors could be due to inhibited internalization of newly synthesized receptors at 
the plasma membrane or recycling of drug-bound receptors already internalized. 
 
 
Figure 2.13 – Effects of gefitinib on levels of cell surface ErbB1. 
H1666 cells were stimulated with 100ng/ml EGF and 10µM gefitinib was added to certain wells after 2 or 
10 minutes, and cell surface ErbB1 receptors were measured by immunofluorescence.  The cell 
membrane was not permeabilized and we used an antibody to total ErbB1 that recognizes the extracellular 
domain of the receptor. 
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Dose-response behavior of the irreversible ErbB1 inhibitor canertinib  
The irreversible ErbB1 tyrosine kinase inhibitor canertinib has a dose-response behavior 
that looks different from gefitinib, erlotinib and lapatinib.  In cells stimulated with EGF followed 
by high concentrations of canertinib after 10 minutes, ErbB1 is dephosphorylated very rapidly.  
However, at low concentrations of canertinib, ErbB1 dephosphorylation is slow but complete 
inhibition is reached (Fig. 2.14, top).  Thus, canertinib seems to have a dose-response behavior 
that is intermediate between gefitinib/erlotinib and lapatinib, which could be explained by a fast 
on rate and a very slow off rate due to formation of a covalent bond with ErbB1 (Fry et al., 
1998).  The delay in ERK dephosphorylation that was measured following gefitinib treatment 
can also be seen after canertinib treatment (Fig. 2.14, bottom).   
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Figure 2.14 – Dose-response behavior of canertinib, an irreversible ErbB1 tyrosine kinase 
inhibitor. 
H1666 cells were stimulated with 100ng/ml EGF followed by canertinib after 10 minutes, and phospho-
ErbB1 Y1173 (top) or phospho-ERK1/2 (bottom) was measured using HTM. 
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ErbB3 is dephosphorylated slowly after heregulin stimulation 
After EGF stimulation only, ErbB3 phosphorylation increased and decreased more 
rapidly than ErbB1 and ErbB2 (compare Fig. 2.1A and 2.3A).  The phosphotyrosine site on 
ErbB3 that we measured is Y1289, a PI3K binding site (Schulze et al., 2005).  ErbB3 is known 
to potently activate Akt via multiple binding sites for PI3K on its C-terminal tail (Schulze et al., 
2005), and we found that Akt phosphorylation followed similar dynamics to ErbB3 after EGF 
stimulation (Fig. 2.4).  When 10µM gefitinib was added after 10 minutes of exposure to EGF, 
both ErbB3 and Akt were quickly dephosphorylated (Fig. 2.3 and 2.4), again with very similar 
dynamics.  These results imply potent downregulation mechanisms for ErbB3.   
We wondered whether a ligand that binds directly to ErbB3 would induce similar 
transient dynamics.  We therefore treated cells with 100ng/ml heregulin (HRG) and measured a 
time course of ErbB3 phosphorylation (Fig. 2.15).  ErbB3 phosphorylation was sustained under 
these conditions, suggesting that ErbB3 may be downregulated by different mechanisms 
following exposure to the two different growth factors.  Since ErbB3 was dephosphorylated 
rapidly after treatment with EGF and then gefitinib, we then tested the effects of gefitinib in the 
presence of HRG.  After treating cells with 100ng/ml HRG followed by 10µM gefitinib, ErbB3 
was dephosphorylated slowly.  Possible explanations for the differences between ErbB3 
regulation after EGF and HRG stimulation are discussed in detail in Chapter 3. 
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Figure 2.15 – ErbB3 is dephosphorylated slowly after HRG stimulation alone as well as 
after additional gefitinib treatment. 
H1666 cells were stimulated with 100ng/ml HRG and after 10 minutes gefitinib was added at 10µM.  
ErbB3 phosphorylation at Y1289 was measured by ELISA.  
 
 
 
Development of a more complete mathematical model that describes ErbB 
receptor trafficking 
The computational models described so far have made the simplifying assumptions that 
EGF is bound and ErbB1 receptors are in stable homodimers, and since receptor 
downregulation was also not described in the models, they only allowed us to analyze receptor 
dynamics in a relatively short time frame from ~10-30 minutes after EGF stimulation.  To study 
ErbB1 dephosphorylation dynamics in a larger context and the effects of gefitinib in the 
presence of normal receptor trafficking, we constructed a more complete mathematical model 
that describes the processes of ligand binding to the ErbB1-3 receptors (we considered EGF, 
HRG and amphiregulin), ErbB dimerization and phosphorylation, adaptor protein and 
phosphatase binding, and receptor ubiquitination, internalization and degradation.  A complete 
mechanistic description of all the mentioned processes would result in a model composed of 
more than 100,000 ordinary differential equations (ODEs).  Using the model reduction 
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techniques of Conzelmann et al. (Conzelmann et al., 2008) and Koschorreck et al. (Koschorreck 
et al., 2007), which had to be partly extended, we reduced the model to 648 ODEs.  By focusing 
on the interplay of EGF and gefitinib, it was possible to further reduce the model to 203 ODEs.  
Development and reduction of this model was a substantial undertaking and both are described 
in detail in Chapter 4.   
These two models (the 203 and 648 ODE versions) qualitatively produce remarkably 
similar receptor dynamics under various conditions compared to our experiments, even without 
systematic model calibration to estimate parameter values.  For example, ErbB1-3 are rapidly 
dephosphorylated in the model following EGF stimulation and gefitinib inhibition (see Fig. 2.3A), 
while ErbB1 is slowly dephosphorylated under conditions of EGF stimulation and then addition 
of a competitor of EGF binding (see Fig.2.6A) (simulations not shown).  Here we focus on a few 
of the biological insights we have gained from this model. 
 
The role of degradation and phosphatases in regulating the lower steady state 
ErbB1 pY levels after EGF pulses of different durations followed by gefitinib 
This thesis focuses on analyzing the rapid ErbB1 phosphorylation turnover that occurs 
throughout receptor trafficking and not on the mechanisms regulating the slow 
dephosphorylation of bulk ErbB1 following ligand stimulation, which we have assumed is from 
ErbB1 degradation or dephosphorylation of ErbB1 by PTPs immediately preceding degradation.  
Experiments using the protein synthesis inhibitor cycloheximide suggest that transcriptional 
upregulation of phosphatases or other negative regulators is likely not playing a role in the 
downregulation of ErbB1 phosphorylation following growth factor stimulation (Amit et al., 2007).  
However, as discussed in Chapter 1, other mechanisms can dynamically increase the activity of 
ErbB1 PTPs, such as phosphorylation of the PTP or co-localization of the PTP and ErbB1. 
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We tried to address whether ErbB1 phosphatase activity changes over time by 
monitoring ErbB1 dephosphorylation after EGF pulses of different durations followed by addition 
of subsaturating concentrations of gefitinib, which rapidly reduces ErbB1 phosphorylation levels 
by ~50% and results in a new steady state level.  We hypothesized that the new steady state 
reached after gefitinib treatment would be representative of the ratio of kinases and 
phosphatases that can act on the receptors at that time.  Following treatment of H1666 cells 
with 1µM gefitinib after different durations of EGF stimulation, we found that slightly lower 
steady state levels of ErbB1 Y1173 phosphorylation were reached when gefitinib was added at 
later times (Fig. 2.16A).  Furthermore, the “steady state” level itself slowly decreased over time 
when gefitinib was added after ErbB1 internalization (~2-10 min after EGF addition; Fig. 2.13), 
perhaps due to some receptors already being on the path for degradation. 
Without implementing a mechanism for PTP activity to increase after ligand stimulation 
in the 648 ODE model, we asked whether ErbB1 degradation alone could explain the different 
steady states reached.  The model qualitatively captured the phosphorylation dynamics of 
ErbB1 Y1173 in H1666 cells even without systematic calibration of the model (Fig. 2.16B, left).  
We next asked whether these steady states are a result of ErbB1 degradation by normalizing 
the phosphorylation dynamics by total receptor levels, which then resulted in the same steady 
state (Fig. 2.16B, right).  Therefore, the steady state differences when adding subsaturating 
concentrations of gefitinib after various durations of ligand stimulation can be attributed to 
receptor degradation alone and does not require an increase in phosphatase activity.  These 
results suggest that there may not be a significant increase in overall phosphatase activity 
during a time course of ligand stimulation in vivo. 
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Figure 2.16 – ErbB1 phosphorylation after EGF pulses of different durations followed by 
addition of 1µM gefitinib. 
(A) Treatment with 1µM gefitinib at different times after adding 100ng/ml EGF in H1666 cells where 
ErbB1 pY1173 was measured by high-throughput microscopy.  (B) Model simulations of ErbB1 Y1173 
phosphorylation (left) or ErbB1 Y1173 phosphorylation normalized by the total number of ErbB1 
receptors (right) after addition of 1µM gefitinib at different times after adding 100ng/ml EGF.  The values 
on the left are normalized between 0 and 1 to be able to easily compare the trends.  
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The ErbB1 dephosphorylation rate does not influence receptor dynamics after 
EGF alone but plays an important role in the presence of gefitinib 
We performed systematic model calibration with the 203 ODE model to estimate and 
constrain the parameter values based on our experimental data shown in Fig. 2.9B, where 
MCF-10A cells were stimulated with EGF for one minute and then gefitinib was added at various 
concentrations, and ErbB1 Y1173 phosphorylation and total receptor levels were measured 
(see Chapter 4 for details of the fitting procedure).  The data show that following treatment with 
low concentrations of gefitinib, ErbB1 Y1173 phosphorylation became sustained and the 
receptor was not degraded, suggesting that low concentrations of gefitinib can turn a transient 
ErbB1 response to ligand into a sustained receptor signal, a point we examined in more detail 
using this model. 
To understand how the model parameters influence the transient-to-sustained ErbB1 
behavior, we performed a sensitivity analysis to investigate relative changes of the derived 
system quantities as a result of relative changes in the parameter values (see Chapter 4 for 
details).  We found that the only sensitive parameter with respect to the sustained 
phosphorylation of Y1173 after 20 and 240 minutes of 1µM gefitinib treatment was the 
parameter describing dephosphorylation of that ErbB1 phosphotyrosine site when phosphatase 
is bound to the receptor (“k2Poff”).  Interestingly, this parameter was not sensitive with respect 
to the EGF only treatment curve.  To illustrate this point, we plotted the fitted dynamics of ErbB1 
Y1173 phosphorylation, as well as the predicted effects of modulating the rate (Fig. 2.17).  
Higher values for this dephosphorylation rate resulted in complete dephosphorylation of Y1173 
following 1µM gefitinib treatment, while a lower rate surprisingly led to even higher levels of 
sustained phosphorylation, even after addition of saturating concentrations of gefitinib.  There 
was basically no effect of changing this parameter on the EGF only treatment curve, suggesting 
that the rate of ErbB1 phosphorylation cycling does not control the overall levels of receptor 
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phosphorylation after exposure to growth factors and that this is instead regulated by the 
presumably slower processes of ligand binding, receptor dimerization and degradation.  We are 
currently unable to modulate the receptor dephosphorylation rate experimentally, but these 
model simulations illustrate the importance of using perturbations to uncover underlying 
biochemistry and suggest that the rate of ErbB1 phosphorylation cycling is very important to 
determining the response to ErbB1-targeting drugs. 
 
 
Figure 2.17 – Increasing or decreasing the rate of ErbB1 Y1173 dephosphorylation in the 
model does not strongly influence dynamics after EGF only, but significantly alters the 
response to gefitinib. 
Experimental data of ErbB1 phosphorylation at Y1173 from Fig. 2.9B and used for fitting are shown here 
as solid curves, along with error bars derived from an error model (see Chapter 4 for details).  Decreasing 
the parameter describing dephosphorylation of that site when ErbB1 is phosphatase-bound (“k2Poff”) by 
100-fold leads to the higher dashed curves, and increasing the rate by 100-fold leads to the lower dashed 
curves. 
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Exploring mechanisms for sustained ErbB1 signaling following treatment with 
low doses of gefitinib 
Even when the dephosphorylation rate of ErbB1 Y1173 was decreased in the model, 
which led to very high levels of sustained phosphorylation after simulated gefitinib treatment, 
ErbB1 was still not degraded (not shown).  It is generally thought that the degree of ErbB1 
phosphorylation (including phosphorylation on specific phosphotyrosine sites such as Y1173) 
correlates with the degree of receptor degradation (Roepstorff et al., 2009).  We explored 
potential mechanisms for this discrepancy between receptor phosphorylation and degradation in 
the model. 
The E3 ubiquitin ligase Cbl is known to be recruited to phosphorylated Y1045 on ErbB1 
(or indirectly through Grb2) after ligand stimulation (Levkowitz et al., 1998), and promote 
ubiquitination and degradation of the receptor.  Therefore, our model describes two 
phosphotyrosine sites on ErbB1 that are regulated separately, one that represents Y1173 to 
which the adaptor protein Shc binds and transmits signals to downstream pathways, and 
another that represents Y1045 where Cbl binds and promotes downregulation of the receptor 
(see Chapter 4 for details).  We hypothesized that the sustained phosphorylation on Y1173 is a 
result of altered receptor trafficking and inhibited degradation due to a difference in the ErbB1-
Cbl-ubiquitination pathway. 
Phosphorylation of ErbB1 at the Shc and Cbl-binding sites exhibit identical dynamics 
following stimulation with EGF alone in the model (Fig. 2.18, top, blue curves).  However, 
phosphorylation of ErbB1 on the Cbl-binding site was inhibited after even 0.5µM gefitinib due to 
a larger (faster) fitted value for the dephosphorylation rate of this site (“k5Poff”) compared to the 
dephosphorylation rate of Y1173 (73/min versus 2.5/min, respectively).  Indeed, decreasing this 
rate to be equivalent to the dephosphorylation rate of Y1173 led to higher levels of Y1045 
phosphorylation following gefitinib treatment, Cbl binding to ErbB1, trafficking and degradation 
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of the receptor, and therefore downregulation of Y1173 phosphorylation (Fig. 2.18, bottom). 
However, faster dephosphorylation of the Cbl-binding site on ErbB1 compared to the 
Shc-binding site is only one way to explain our experimental data.  If we force these two rates to 
be equivalent in the model, parameter values can still be found through fitting that match our 
experimental data of Y1173 phosphorylation and receptor degradation (not shown).  This clearly 
highlights the issue of model non-identifiability, since other parameter sets and therefore model 
behaviors can also reproduce the observable data.  Additional explanations for the sustained 
signaling on Y1173 without degradation could be other mechanisms regulating receptor 
trafficking, such as parameters controlling Cbl binding, ErbB1 internalization or receptor 
ubiquitination.  Nonetheless, these modeling results emphasize decoupling between the 
pathways promoting downstream signal propagation and receptor downregulation, and again 
illustrate the importance of pulse-chase experiments to detect this decoupling. 
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Figure 2.18 – Model prediction that sustained phosphorylation of ErbB1 Y1173 after low 
doses of gefitinib results from a faster dephosphorylation rate of the Cbl-binding site. 
Top left: same as the solid curves and data shown in Figure 2.17.  Top right: Predicted dynamics of ErbB1 
at the Cbl-binding site based on the fitted parameter values.  Even low doses of gefitinib lead to 
dephosphorylation.  Bottom: Effects of decreasing the dephosphorylation rate of the Cbl-binding site 
(“k5Poff”) to be equivalent to the Shc-binding site.  Now Y1173 is dephosphorylated after low doses of 
gefitinib. 
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CHAPTER 3: Discussion and Future Directions 
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Summary of approach and key results 
Protein phosphorylation networks play an essential role in the control of almost all 
physiologic processes, including cell growth, differentiation, migration and oncogenesis.  The 
ErbB pathway, a prototypical signaling network regulated by phosphorylation cascades, is 
frequently hyperactive in cancer and is being aggressively targeted in the clinic with various 
therapeutic antibodies and small molecule kinase inhibitors.  However, fundamental questions 
about the regulation of this pathway and the effects of the drugs remain unaddressed.  This 
thesis describes experimental and computational methods that were developed to examine how 
ErbB1 kinases and phosphatases work in concert to control the dynamics of receptor 
phosphorylation and downstream signaling and to understand how ErbB1-targeting drugs alter 
this regulation. 
We discovered that individual proteins undergo extremely rapid phosphorylation cycling 
and that these fast dynamics play a crucial role in determining the response to ErbB1-targeting 
cancer therapies, which we found to vary significantly between drugs with different mechanisms 
of action.  We showed that treatment with some of these drugs results in sustained signaling, 
instead of inhibition, and thus may actually promote tumor proliferation or invasion.  Beyond 
therapeutics, we elucidated the importance of teasing out the time scales of different events 
regulating cell signaling.  We found that signals are rapidly propagated through some pathways 
but slowly through others, leading to prolonged activation in the absence of upstream signal, 
and that fast phosphorylation and dephosphorylation may provide cells with the flexibility 
necessary to rapidly detect and respond to changes in their extracellular environment.  
Importantly, we formulate a general strategy for analyzing biochemical signaling networks that 
integrates pulse-chase experiments where one node within a pathway is very rapidly inhibited, 
with a hierarchy of computational models that each allow different biochemical aspects to be 
addressed. 
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Rapid ErbB1 dephosphorylation following sequential ligand and 
gefitinib treatment 
Once activated by ligand, cell surface receptors could theoretically remain active for a 
long time and continue to transduce signals to downstream pathways, or they could quickly turn 
off and require detection of upstream signal for further activation.  Based on population-level 
measurements, ErbB1 receptors appear to remain phosphorylated for many minutes or hours 
after exogenous growth factor stimulation.  Signal downregulation is primarily thought to result 
from dephosphorylation by phosphatases that are brought into close proximity after receptor 
endocytosis, ligand removal from endosomes (Burke et al., 2001), or ErbB1 degradation.  We 
investigated the frequency with which proteins in the ErbB1 signaling pathway are 
phosphorylated in response to growth factors to address whether these dynamics are 
representative of the phosphorylation and dephosphorylation rates of individual proteins.  Since 
it is not feasible to directly measure phosphorylation of a single protein over time, we deduced 
these individual molecule dynamics from population measurements.   
To this end, we performed the simple experiment of inactivating receptor catalytic activity 
after ligand addition with a panel of ATP-competitive ErbB1 kinase inhibitors (pulse-chase 
experiments) and measured receptor dephosphorylation kinetics.  If receptors become 
phosphorylated and then remain phosphorylated until degradation (~30-120 min), addition of 
kinase inhibitors after receptor phosphorylation should not significantly alter the degree of 
phosphorylation.  However, the results were striking: we found that drugs such as gefitinib result 
in dephosphorylation of nearly all ErbB1 receptors within 10 seconds after addition to cells, 
suggesting that individual receptors undergo multiple rounds of phosphorylation and 
dephosphorylation each minute, even though the overall level of phosphorylation changes very 
slowly.  Yet our explanation of the data was complicated by the fact that drugs with different 
mechanisms of action result in remarkably different dephosphorylation kinetics and dose-
response behaviors. 
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Previous evidence indicating an important role for phosphatases 
Over the past few decades, the field has begun to appreciate the importance of 
phosphatases in regulating the activity of signaling pathways.  Heinrich and colleagues 
(Heinrich et al., 2002) developed a simple mathematical model of the kinetics of protein kinase 
signaling pathways and computationally analyzed the effects of kinases and phosphatases on 
signaling rate, duration and amplitude.  The authors found that signaling rate and duration are 
primarily controlled by phosphatases (less so by kinases), and they considered the balance 
between the two opposing entities.  Yet their analysis did not include any experimental 
verification of their model predictions.   
Early indications of the role of phosphatases in regulating ErbB1 activity came from 
experimental observations that after receptor phosphorylation by ligand stimulation, the addition 
of inhibitors of the catalytic activity of ErbB1 led to faster ErbB1 dephosphorylation than in the 
presence of ligand alone (Bohmer et al., 1995; Offterdinger et al., 2004).  However, a detailed 
study of the dynamics and the seemingly profound implications of these findings had not been 
performed until now.  Here we integrated computation with experiments to improve our 
understanding of the underlying biochemistry. 
 
Computational models of ErbB1 regulation 
Models previously developed to study the ErbB system were inadequate for our 
purposes.  Some models do not accurately describe competition of kinase inhibitors with ATP 
for binding to ErbB1 and are only useful to simulate pre-incubation with inhibitors (e.g. (Chen et 
al., 2009)), and others assume that ErbB phosphatases do not play an important role in receptor 
and downstream regulation so therefore do not consider them (e.g. (Orton et al., 2009)).  
Furthermore, we found it necessary to develop a succession of mathematical models of varying 
biochemical resolution to help guide our interpretations of the data, each one useful for a 
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different question we wanted to address.  These models ranged from simple (one ordinary 
differential equation (ODE)) to quite elaborate and realistic (hundreds of ODEs).   
We estimated lower bounds for phospho-ErbB1 turnover using a small model describing 
receptor phosphorylation and dephosphorylation (the only one of these models with identifiable 
parameters) by fitting to phosphorylation measurements of dense temporal sampling following 
inhibitor addition.  While parameters of the larger models were not identifiable, the 
phosphorylation and dephosphorylation rate constants estimated with these models by 
considering many different fits of the model to data were only slightly higher.  These more 
detailed models were used to analyze properties of ErbB1 receptors and drugs that give rise to 
the different drug responses and to understand the somewhat non-intuitive effects of the drugs 
in the presence of decreased phosphatase activity.  The models fit the data well and we could 
accurately predict the results of new experiments, suggesting that our assumptions and those in 
the literature are consistent and reasonable and that we have a good biochemical 
understanding of how the receptors and drugs function.   
 
Phosphatase activity regulating ErbB1 
ErbB1 is rapidly dephosphorylated regardless of subcellular localization 
We found fast phosphorylation/dephosphorylation cycling regardless of ErbB1 
subcellular localization.  Our results challenge the classical notion that ErbB1 is phosphorylated 
at the plasma membrane after ligand binding and then remains phosphorylated until receptor 
degradation or dephosphorylation when the receptor co-localizes with PTP1B near the ER.  
Evidence of long-term EGF treatment resulting in accumulation of dephosphorylated receptor in 
the perinuclear region (Offterdinger et al., 2004) suggests that phosphatases may be more 
active at intracellular sites and play a significant role in overall ErbB1 signal attenuation.  
However, a recent paper showed that the phosphatase DEP-1 acts on ErbB1 only at the cell 
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surface and does not internalize along with ErbB1 (Tarcic et al., 2009).  After EGF stimulation, 
more receptors were bound by substrate-trapping mutants of DEP-1 than wild-type DEP-1, 
suggesting that phosphatases may bind in a reversible manner to dephosphorylate ErbB1.  We 
conclude that ErbB1 phosphatases are always localized near the receptors and are continually 
acting on them, although different phosphatases are likely to be important over a time course of 
ErbB1 stimulation and trafficking. 
 
 Identification of PTPs responsible for rapid ErbB1 dephosphorylation 
We do not know the full spectrum of phosphatases acting on ErbB1 or which tyrosine 
residues on the receptor are targets of specific PTPs.  It is also unclear if and when PTPs 
directly bind to the receptor and how that regulates their activity, and if different phosphatases 
can act on one receptor and if they can do so simultaneously.  We asked whether the best 
studied ErbB1 phosphatase, PTP1B, plays a role in rapid gefitinib-induced ErbB1 
dephosphorylation and found that knocking down PTP1B had no effect in H1666 cells when 
gefitinib was added after 10 minutes of EGF treatment.  It is possible that at this time ErbB1 and 
PTP1B are unable to interact due to their subcellular localizations and that their interaction only 
occurs at later times during receptor trafficking.  However, we could not find any evidence in the 
literature for PTPs that might act on ErbB1 while the receptor is being internalized and shuttled 
to early endosomes.   
Either way, our PTP1B knockdown results are not very surprising since, depending on 
the local concentration of kinases and phosphatases, basically all phosphatases capable of 
contributing to the fast dephosphorylation may have to be depleted to see any effect.  There are 
many potential candidates for the relevant PTP(s) (there are more than 100 different PTPs in 
the mammalian genome (Alonso et al., 2004)), and it is possible that chronic depletion of one 
could result in compensation by others.  Furthermore, phosphatase activity may be dynamically 
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regulated following ligand stimulation.  For all of these reasons, it will be very challenging, if not 
impossible, to identify the specific phosphatase(s) that contribute to rapid ErbB1 
phosphorylation cycling, and doing so is beyond the scope of this thesis.  Nonetheless, the pan-
specific tyrosine phosphatase inhibitor pervanadate blocked the gefitinib-induced ErbB1 
dephosphorylation, demonstrating that phosphatases are indeed responsible for this behavior. 
 
Chemical inhibitors of ErbB1 phosphatases 
Potent and selective phosphatase inhibitors could facilitate the search for PTPs that 
regulate fast phosphorylation cycling, as well as help identify PTPs that regulate specific ErbB1 
phosphotyrosine sites and ErbB1 in different subcellular localizations.  Unfortunately, 
commercially available inhibitors seem to be of poor quality.  A key challenge in developing PTP 
inhibitors is the issue of selectivity due to the highly conserved PTP active site (the 
phosphotyrosine binding site).  To address this problem, bidentate PTP inhibitors that 
simultaneously bind both the active site and a unique adjacent site for enhanced affinity and 
specificity are under development (Zhang, 2002).   
However, there may be fewer incentives to develop PTP inhibitors than PTK inhibitors 
since it is unclear whether these represent good targets for therapeutic drugs.  Intuitively, 
decreasing the activity of a PTP should lead to increased phosphorylation of the PTP substrate 
and hyperactivation of its downstream signaling pathway.  In this case, a potential method to 
curb overactive ErbB1 signaling could include activating or recruiting PTPs that 
dephosphorylate and inactivate the receptor.  Yet the effects of modulating phosphatase activity 
can be complex for multiple reasons: phosphatases can be positive (e.g. Shp-2) or negative 
(e.g. Shp-1) effectors of RTK signaling, phosphatases can dephosphorylate inhibitory sites, and 
each PTP can have multiple substrates and might regulate the activity of the various substrates 
in different ways.   The functions of PTPs in cell signaling are still being unraveled and will likely 
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influence the decision of whether to try to modulate their activity therapeutically. 
 
Future study: PTP siRNA screen 
Attempts could be made to identify PTPs that regulate the rapid phosphorylation cycling 
of ErbB1 using an RNAi screen of the potential phosphatases.  Following knockdown, similar 
experiments to the ones described in this thesis could be performed, where cells are stimulated 
with ligand and then ErbB1 catalytic activity inhibited with gefitinib.  ErbB1 phosphorylation 
measurements would then elucidate whether the knockdown blocked ErbB1 dephosphorylation.  
These measurements could be done for different ErbB1 phosphotyrosine sites and at different 
times during receptor trafficking.  In one recently published siRNA screen, the authors knocked 
down all PTPs and then measured the effect on ErbB1 phosphorylation (Tarcic et al., 2009).  
Another group screened the effects of knocking down 244 phosphatases (tyrosine-, serine- and 
threonine-specific phosphatases) on ERK and Akt phosphorylation (Omerovic et al., 2010).  
These two studies monitored the steady state effects of decreasing phosphatase activity, while 
the experiments proposed here would instead ask how important each phosphatase is under 
the particular pulse-chase conditions. 
 
Transient phosphorylation and binding events are likely general 
regulatory mechanisms 
Prior indications that other proteins may also undergo rapid phosphorylation 
cycling 
Fast cycling has been observed for the aggregation and phosphorylation of high affinity 
IgE receptors on rat basophilic leukemia cells (Mao and Metzger, 1997).  IgE receptors normally 
mediate inflammatory reactions such as allergic responses.  In this study, cells were stimulated 
with multivalent antigen (antigen-activated cells) followed by disaggregation with monomeric 
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hapten.  The receptors, which do not have intrinsic kinase activity and are phosphorylated by 
other cytosolic proteins, were rapidly dephosphorylated, suggesting that fast phosphorylation 
cycling may not be specific for ErbB1. 
It is also possible that the same PTPs that regulate phospho-ErbB1 cycling also regulate 
other proteins using similar mechanisms.  Each PTP can have multiple substrates and ErbB1 
PTPs have been shown to dephosphorylate other receptors.  For example, DEP-1 suppresses 
signaling emanating from other RTKs, such as PDGF β-receptors and HGF/Met receptors 
(Kovalenko et al., 2000; Palka et al., 2003).  Indeed, after sequential ligand and drug treatment 
specific for PDGF receptors, these receptors were dephosphorylated more rapidly than in the 
presence of ligand alone (Bohmer et al., 1995). 
 
All proteins measured in the ErbB network undergo fast phosphorylation cycling 
We measured activation of the canonical ErbB1 immediate-early downstream pathways 
after sequential exposure of cells to ligand and gefitinib, and reasoned that the rapid shut-off of 
other proteins would imply that the proteins also undergo fast phosphorylation cycling.  This 
approach of activating the ErbB1 network with ligand and then instantly turning off the receptor 
with gefitinib is analogous to applying a step function and allowed us to investigate how these 
rapid receptor dynamics propagate downstream.  We found that a fast dissociation rate of the 
adaptor protein Shc for binding to ErbB1 leads to a dynamic equilibrium with low stability of the 
ErbB1-Shc complex such that phosphatases can rapidly dephosphorylate ErbB1 sites that are 
Shc-bound at the time of gefitinib addition.  These results corroborate in vitro measurements 
showing that interactions of SH2 domains with phosphotyrosines can occur with a half life 
around 6 seconds (Felder et al., 1993), similar to our estimates for the ErbB1 dephosphorylation 
rate. 
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Proteins within the ErbB3-PI3K-Akt pathway were immediately dephosphorylated once 
ErbB1 activity was terminated, suggesting that activation of these proteins is closely linked to 
continued upstream signal.  However, there was a delay in attenuation of the Shc-Ras-MAPK 
(Raf-MEK-ERK) pathway, where gefitinib led to fast Shc dephosphorylation but slow ERK 
phosphorylation, which we determined was not due to slow ERK phosphatase activity since a 
MEK inhibitor led to rapid ERK dephosphorylation.  This delay was variable between cell types 
and correlated with the presence of activating mutations within the pathway that may prolong 
signaling (H1666 cells harbor a B-Raf G466V low-activity mutation (Pratilas et al., 2008)).  
Slower dephosphorylation of the ERK pathway in general could be attributed to more steps in 
the cascade between ErbB1 and ERK versus ErbB1 and Akt, therefore taking more time, or to 
GAP-mediated inactivation of Ras, which may be slower than the dephosphorylation reactions.  
Additional measurements of pathway activity between Shc and ERK (e.g. measurements 
of Ras activity, Raf phosphorylation or MEK phosphorylation) and additional inhibitors (e.g. Raf 
inhibitors) could be helpful to narrow down the position(s) within the pathway where the delay 
arises.  All proteins we measured were rapidly shut off when either ErbB1 or MEK were 
inhibited, which implies that they are undergoing rapid phosphorylation cycling and require 
upstream activation to remain phosphorylated.  Very little is known about the regulation of these 
other proteins by phosphatases and this would be interesting to explore using similar methods 
as those described above for ErbB1 PTPs.  These studies confirmed the notion that 
phosphorylation cycling not a property limited to ErbB1.  Moreover, we provide in vivo evidence 
that a single cell line under the same culture conditions exhibits transient ligand binding, protein-
protein interactions and phosphorylation, making it somewhat surprising that signals can still be 
effectively propagated through this pathway. 
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Binding affinities of adaptor proteins for ErbB1 may be dynamically regulated 
Several studies have suggested that binding affinities for ErbB1 adaptor proteins 
decrease upon phosphorylation of the adaptor proteins, which in some cases is mediated 
directly by ErbB1 catalytic activity.  For example, using molecular dynamics simulations 
phosphorylation of Shc on Y317 was shown to decrease its affinity for ErbB1 (Suenaga et al., 
2009).  Shc Y317 is phosphorylated by ErbB1 and acts as a major site for binding the Grb2 
adaptor and the Grb2-SOS complex, which triggers Ras activation.  The effects of this decrease 
in affinity are unclear.  We have shown rapid phosphorylation and dephosphorylation cycling of 
this phospho-site on Shc, so presumably if phospho-Shc could no longer bind ErbB1 it would be 
rapidly dephosphorylated.  However, Shc was phosphorylated with almost identical dynamics to 
ErbB1 in our measurements, and through co-immunoprecipitation we showed the ErbB1-Shc 
association to persist for at least 30 minutes after ligand stimulation.  This diminished binding 
may play a role in terminating signals emanating from ErbB1 on longer time scales. 
 
Future study: Broad signaling analysis of deactivation kinetics 
We found different time scales of propagation through the two canonical ErbB 
downstream pathways, where signals were transmitted through the Akt pathway very rapidly, 
but there was a delay between ErbB1 and Shc dephosphorylation and ERK dephosphorylation.  
This study served as a proof of principle for stimulating a signaling pathway and then 
immediately inhibiting a node of the pathway to measure deactivation kinetics.  Interestingly, this 
approach is not limited to gefitinib-induced dephosphorylation but could potentially be applied 
with any fast binding drug.  For example, the MEK inhibitor PD0325901 used in Chapter 2 
resulted in very rapid ERK dephosphorylation.   
This approach could be used in a broad signaling study where cells are treated with 
different combinations of ligand and then drug, and time courses of deactivation kinetics are 
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measured throughout the pathway.  This study would benefit from high-throughput methods for 
measuring protein phosphorylation, such as Luminex (bead-based multiplexed ELISAs) (Du et 
al., 2009; Saez-Rodriguez et al., 2009), mass spectrometry (Wolf-Yadlin et al., 2006) or reverse-
phase protein lysate arrays (Gujral and MacBeath, 2009; Sevecka and MacBeath, 2006).  Many 
positive and negative feedback loops regulate signal transduction networks and insight could be 
gained by inhibiting downstream nodes and measuring the effects on upstream nodes.  The 
breadth of this study will widen as more potent and selective inhibitors become available. 
 
Rewiring of signaling networks 
A comparison of different cell types in a study of this nature could reveal how signaling 
pathways are rewired during disease (for example, if the cell types being compared are normal 
versus cancer tissue) or as an effect of a certain genetic mutation (if isogenic cells differing only 
in the expression of that mutation were used).  Sophisticated computational modeling methods 
have recently been developed to analyze and interpret large datasets of this kind and 
deconstruct differential pathway usage (Saez-Rodriguez et al., 2009).  In addition to increasing 
our understanding of signal transduction networks, this study would provide crucial information 
about the effects of drugs and could be a way to screen for and identify promising therapeutics.  
Short-term effects of drugs, which presumably influence and perhaps determine the long-term 
response, cannot be revealed using the typical method of pretreating cells with drugs prior to 
ligand stimulation. 
 
Phosphatase regulation of ErbB2 and ErbB3 
Since ErbB1 signaling can be shut off through internalization and degradation, it will be 
interesting to understand how receptors that are not internalized are regulated by 
phosphatases, as it is possible that phosphatases play a more pertinent role in overall signal 
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attenuation from these receptors.  Downregulation of ErbB2 and ErbB3 following growth factor 
stimulation is not thought to be mediated by endocytosis (Baulida et al., 1996).  In Chapter 2 we 
showed that ErbB2 and ErbB3 are phosphorylated after EGF stimulation, and then rapidly 
dephosphorylated after addition of gefitinib with similar half lives as ErbB1.  These results 
suggest that ErbB2 and ErbB3 are also subject to rapid phosphorylation and dephosphorylation 
cycling, although very little is known about phosphatases for these receptors. 
 
Examining whether phosphatases are activated following ligand stimulation to 
promote overall phospho-ErbB downregulation 
We tried to address whether ErbB1 phosphatase activity changes over time by 
monitoring ErbB1 dephosphorylation after EGF pulses of different durations followed by addition 
of 1µM gefitinib.  This treatment immediately reduces ErbB1 phosphorylation levels by ~50% 
and results in a new steady state level.  We hypothesized that the new steady state reached 
after gefitinib would be representative of the ratio of kinases and phosphatases that can act on 
the receptor at that time, and if we could assume that the kinase activity remains constant it 
would provide clues to the phosphatase activity.  Of course, the concentration of active kinases 
for ErbB1 is expected to change over a time course of ligand stimulation, first increased due to 
receptor dimerization and then decreased due to receptor degradation.  Indeed, the steady state 
level decreased slightly as gefitinib was added at later times once the receptor was internalized, 
and our mathematical modeling suggested that this decrease could be attributed to receptor 
degradation alone and did not require an increase in phosphatase activity.  This experiment of 
adding 1µM gefitinib after different durations of EGF stimulation could be repeated and 
phospho-ErbB2 and ErbB3 measured.  These receptors are likely not degraded during this time 
and our measurements show ErbB3 becoming phosphorylated and then dephosphorylated 
within minutes of EGF stimulation.  Adding pervanadate at different times after EGF exposure 
and measuring phosphorylation of these two receptors could also be informative. 
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Stimulation of ErbB3 by EGF and HRG 
We wondered whether ErbB3 was also only transiently activated after stimulation with 
the growth factor heregulin (HRG), which binds to ErbB3 directly.  In contrast to stimulation with 
the ErbB1-ligand EGF, we found that ErbB3 phosphorylation was sustained following exposure 
to HRG.  Moreover, when gefitinib was added to cells after 10 minutes of HRG stimulation, 
ErbB3 was dephosphorylated slowly in comparison to when gefitinib was added after EGF.  
These intriguing results can be explained by a number of possibilities. 
The differences may indicate more potent phosphatase activity following EGF 
stimulation, perhaps triggered by different dimers that form and contribute to the level of ErbB3 
phosphorylation after exposure to the growth factors (likely ErbB1-ErbB3 dimers after EGF and 
ErbB2-ErbB3 dimers after HRG).  It is conceivable that different phosphatases are recruited to 
different dimers and that potent ErbB1 phosphatases recruited to ErbB1-ErbB3 dimers are more 
likely to act on ErbB3 as well due to close proximity.  Assuming that dimerization is a transient 
and continuous process, an alternative explanation for the different dynamics of ErbB3 
phosphorylation following EGF and HRG stimulation is that ErbB1 is internalized and therefore 
depleted from the pool of receptors available to bind ErbB3 at the cell surface after EGF 
stimulation.  This may lead to a decrease in the number of ErbB1-ErbB3 heterodimers and 
therefore a decrease in the number of phosphorylated ErbB3 receptors. 
If ErbB2-ErbB3 dimers are indeed dominant after HRG stimulation, the slow 
dephosphorylation of ErbB3 following HRG and then gefitinib addition could be a function of 
gefitinib binding to ErbB2.  Since gefitinib binds with lower affinity (higher Kd) to ErbB2, the slow 
dephosphorylation of ErbB3 could be due to the time it takes for gefitinib to inhibit ErbB2 
catalytic activity.  One way to address this could be to use a fast binding and specific small 
molecule kinase inhibitor of ErbB2 instead of gefitinib, which was not possible here since we are 
currently unaware of the existence of such an inhibitor.  HRG stimulation and gefitinib addition 
have been shown to promote the dissociation of ErbB2-ErbB3 dimers and formation of inactive, 
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gefitinib-bound ErbB1-ErbB2 and ErbB1-ErbB3 dimers (Anido et al., 2003).  This process could 
also contribute to the slow dephosphorylation of ErbB3 that we measured. 
 
ErbB3 relevance in cancer 
ErbB3 plays an important role in resistance to ErbB1- and ErbB2-targeting drugs.  
Resistance to gefitinib and erlotinib in lung cancer has been attributed to MET amplification-
driven activation of ErbB3 (Engelman et al., 2007).  In addition, ErbB3 has been found to be 
transcriptionally upregulated in breast cancer after lapatinib treatment (Amin et al., 2010).  
Prolonged gefitinib treatment of breast cancer cells was shown to cause resistance to ErbB3 
dephosphorylation following an additional pulse of gefitinib.  This resistance was explained by 
an increase in cell surface ErbB3 receptors and a decrease in ErbB3 phosphatase activity 
resulting from production of cellular reactive oxygen species, which are known to inhibit PTPs 
(Sergina et al., 2007).  Accordingly, attempts to target ErbB3 by blocking ligand binding are 
underway and the first therapeutic anti-ErbB3 antibody is in clinical development (Schoeberl et 
al., 2009).  The phospho-ErbB ELISA assays developed in this thesis and discussed in Chapter 
4 will be useful for future studies to dissect the regulation of ErbB2 and ErbB3 by phosphatases, 
since they are more specific, sensitive and quantitative than the typical methods used to 
measure receptor phosphorylation. 
 
Physiological consequences of rapid phosphorylation cycling 
It is typically assumed that the specific kinetics of phosphorylation reactions play a role 
in controlling the physiological behavior of cells, but this connection had not been fully 
established.  We discovered that fast phosphorylation cycling and signal propagation allows for 
rapid responses at the phenotypic level.  ErbB1 phosphorylation dynamics were intimately 
linked to protrusion of lamellipodia, an early event in the process of cell migration, such that 
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lamellipodia stopped protruding and began to retract almost immediately after shutting off the 
receptors with 10µM gefitinib, following an initial EGF pulse.  The short time difference between 
receptor dephosphorylation and lamellipodia retraction is likely attributed to how long it takes for 
intermediates (e.g. ERK and Akt) to be inhibited under these conditions.   
Interestingly, we found that adding 1µM gefitinib shortly after EGF blocks the typical 
EGF-induced increase in receptor phosphorylation and instead results in lower but sustained 
phosphorylation; however, short-term protrusion dynamics were unaffected.  Continued 
extension of lamellipodia therefore requires continued, but not necessarily increasing, receptor 
phosphorylation.  We conclude that fast phosphorylation and dephosphorylation may provide 
cells with the flexibility necessary to rapidly detect and respond to changes in their extracellular 
environment.  To our knowledge, this is the first study showing the dependency of short-term 
receptor signaling on lamellipodia extension and retraction following ligand stimulation.   
To more accurately determine whether rapid phosphorylation cycling allows ErbB1 to act 
as an immediate sensor, it is important to understand the effects of a decrease in the actual 
ligand concentration as opposed to a decrease in receptor catalytic activity.  Following EGF 
stimulation, removal of EGF by either washing away ligand or using the monoclonal antibody 
225 to compete with ligand binding led to slow receptor dephosphorylation (although faster than 
in the continued presence of ligand).   This dephosphorylation rate when removing ligand likely 
depends on the additional rates of ligand dissociation and the dissociation of ErbB1 oligomers.  
By measuring the effects of blocking phosphorylation directly with drugs like gefitinib, we 
eliminated these potentially slower time scales from the analysis (e.g. EGF is known to have a 
slow dissociation rate).  Many different ligands can bind to ErbB1, and ligands with faster off 
rates such as growth factor receptor ligands immobilized in the extracellular matrix (Iyer et al., 
2007; Tran et al., 2004) may have similar effects as gefitinib on ErbB1 dephosphorylation and 
retraction of membrane protrusions.  We therefore speculate that the rate of response to a 
decrease in ligand concentration is dominated by the specific ligand dissociation rate. 
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Future studies to relate receptor activity to membrane protrusion dynamics 
Ligands with faster dissociation rates could be used to test the relationship between a 
decrease in the extracellular growth factor concentration and the protrusion of lamellipodia.  For 
example, amphiregulin is a physiologically relevant ErbB1 ligand with low affinity for the receptor 
and is thought to have a fast off rate (Neelam et al., 1998; Roepstorff et al., 2009).  Thus, the 
fraction of ErbB1 receptors bound by amphiregulin after exposure to the ligand and then 
washing it away should diminish quickly, and a faster decrease in ErbB1 phosphorylation may 
be detected compared to our results with EGF.  If this is the case, experiments using a 
microfluidics device could explore the kinetics of and relationship between amphiregulin 
washout and retraction of lamellipodia. 
To more precisely determine the role of fast ErbB1 phosphorylation and 
dephosphorylation in regulating protrusion dynamics, modulation of these rates is necessary.  If 
specific PTPs responsible for the fast ErbB1 phosphorylation cycling are later identified, it would 
be interesting to inhibit (e.g. by knock down or chemical inhibition) or activate (e.g. by PTP 
overexpression) the PTP activity and correlate membrane protrusion dynamics with varying 
dephosphorylation rates.  
 
Investigating the striking differences in the responses to ErbB1-
targeting drugs 
Pulse-chase experiments reveal transient drug effects 
The search for effective drugs targeting the ErbB receptors has exploded over the past 
10 years (Knight et al., 2010).  Although some drugs are already being used to treat patients, 
several basic properties of the drugs and their cellular targets are still only poorly understood.  
The typical method used to determine drug efficacy in cell culture is to measure whether 
signaling is inhibited after treating cells with a drug for many hours or days, or pretreating with 
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the drug before challenging cells with exogenous ligand.  These experiments report on the 
steady state effects of drug treatment and may be useful for understanding the potential long-
term effects of drugs in vivo.  However, steady state signaling levels in vivo following drug 
treatment may also be modulated by factors that are not applicable in cell culture, so the 
relevancy of measuring steady state drug effects in cell culture is unclear.   
We find that there is a large amount of information contained in the early drug response.  
Here we illustrate the importance of understanding the transient (short-term) response to drugs 
and show that this approach can elucidate drug mechanism of action and immediate effects of 
inhibition.  We activated the ErbB signaling pathway with exogenous ligand before drug 
treatment (“pulse-chase” experiments) to be able to measure the dynamics of deactivation in the 
presence of various drugs.   
 
Differences between drugs with various mechanisms of action 
We evaluated the kinetics of ErbB1 dephosphorylation following EGF stimulation and 
then addition of gefitinib, erlotinib, lapatinib or canertinib and found very different dose-response 
behaviors.  We developed a computational model to quantitatively explore properties of the 
receptors and drugs that give rise to these striking differences, specifically between gefitinib and 
lapatinib.  We initially tried to explain these differences in the model by only taking into account 
their different binding velocities to ErbB1, but found that the model could not explain the 
experimental data without also accounting for the different conformations of ErbB1 to which the 
drugs bind, suggesting that this is important in determining their behavior.  Since it is unclear 
how to test this experimentally, using the model we showed that these distinct drug responses 
are caused by rapid ErbB1 phosphorylation cycling, and that slower phosphorylation and 
dephosphorylation rates generate similar ErbB1 dynamics in the presence of the two drugs. 
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For gefitinib or erlotinib, which bind reversibly to an active ErbB1 conformation with fast 
kinetics, dosing at the mean patient plasma concentration (~1µM (Baselga et al., 2002)) in 
pulse-chase experiments led to only partial receptor inhibition and surprisingly sustained 
signaling.  However, treatment at this concentration with lapatinib, which binds reversibly to an 
inactive ErbB1 conformation with slow kinetics, resulted in complete receptor inhibition.  
Interestingly, the irreversible inhibitor canertinib had an intermediate dose-response behavior 
where high doses resulted in rapid ErbB1 dephosphorylation and low doses resulted in slow but 
complete dephosphorylation. Lapatinib is currently only approved to treat breast cancers 
overexpressing ErbB2, but our results suggest that it may also be effective for other tumors. 
The time course dose-response behaviors shown in Chapter 2 for gefitinib, lapatinib and 
canertinib are very different and it would be difficult to make sense of these data if only the 
typically IC50 curves had been obtained, where one time point of receptor phosphorylation is 
measured for each concentration of drug.  These IC50 curves would vary based on the time 
point chosen, and the results would be especially uninformative if this time point was taken after 
~1 hour of drug treatment, when even low doses of lapatinib and canertinib result in complete 
receptor dephosphorylation.  IC50 curves after treatment with gefitinib should be relatively time-
independent since different doses result in a quite stable new steady state phosphorylation 
level.  IC50 curves generated after long durations of drug treatment (e.g. multiple days) may 
report on indirect effects of the drug binding to ErbB1, such as subsequent activation of drug 
resistance pathways or protein degradation.  Nonetheless, the variation measured here 
between these three drugs strongly advocates for dynamic measurements to be able to 
understand their direct effects. 
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Increased steady state inhibition of ErbB1 by lapatinib is likely due to its mode of binding to 
ErbB1 
In addition to binding to ErbB1, lapatinib has a high affinity for ErbB2 and a relatively 
high affinity for ErbB4.  ErbB1 phosphorylation following lapatinib treatment could be inhibited 
by lapatinib-bound ErbB2 or ErbB4 receptors that interact with ErbB1 in heterodimers and would 
normally phosphorylate ErbB1.  Therefore, at similar concentrations lapatinib could potentially 
lead to more steady state inhibition of ErbB1 than gefitinib, which only binds with high affinity to 
ErbB1 and thus should only inhibit ErbB1 homodimers.  However, we do not believe that binding 
of lapatinib to ErbB2 or ErbB4 is relevant to our results.  H1666 and MCF-10A cells express low 
or undetectable levels of ErbB receptors other than ErbB1, so ErbB1 homodimers are likely the 
predominant dimers formed following EGF stimulation.  Furthermore, our computational models 
could explain our experimental data without taking into account lapatinib binding to ErbB2 or 
ErbB4, and the lower steady states reached with lapatinib make sense based on its slow 
dissociation rate and ability to stabilize the inactive-like ErbB1 conformation (Wood et al., 2004).  
The irreversible inhibitor canertinib also eventually led to complete ErbB1 dephosphorylation at 
low doses and does not bind as strongly to ErbB2, suggesting that the effects of lapatinib can 
be explained based solely on mechanism of action of drug binding.  An additional possibility is 
that ErbB1 is efficiently degraded following lapatinib but not gefitinib treatment.  However, ErbB1 
was not found to be degraded after treatment with either of these drugs (Wood et al., 2004). 
 
Subsaturating doses of gefitinib turn a transient response to ligand into a sustained ErbB1 
signal 
We propose that gefitinib treatment leads to a rapid equilibrium of drug-bound receptors 
and phosphorylated receptors due to both fast drug binding and fast phosphorylation and 
dephosphorylation rates.  When gefitinib was added while ErbB1 was at the plasma membrane, 
normal receptor trafficking following EGF stimulation was altered such that internalization may 
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have been partially blocked and receptors were not degraded.  Receptors that were 
dephosphorylated due to gefitinib treatment would presumably be unable to recruit and bind the 
E3 ubiquitin ligase Cbl, which interacts with ErbB1 via phosphotyrosine residues to mediate its 
internalization and downregulation (Fry et al., 2009).  Indeed, gefitinib is known to inhibit ErbB1 
internalization and receptor trafficking (Nishimura et al., 2007). 
This straightforward explanation of the 10µM gefitinib data was brought into question by 
experiments where we treated cells with lower doses of gefitinib (0.5 or 1µM), which resulted in 
a fraction of receptors still phosphorylated on Y1173 but trafficking and degradation blocked.  
We examined this discrepancy using a very detailed mathematical model describing normal 
EGF-induced ErbB1 regulation, including activation by ligand binding and receptor dimerization, 
and downregulation by ErbB1 internalization, ubiquitination and degradation.  We found a 
disconnect between the pathways emanating from ErbB1 that lead to signal propagation (in our 
model, via binding of Shc to ErbB1) and receptor downregulation (via binding of Cbl to ErbB1) 
which was only detectable following subsaturating gefitinib treatments. 
After fitting the model to ErbB1 phospho-Y1173 and total ErbB1 data following treatment 
with different concentrations of gefitinib added after 1 minute of EGF stimulation, the model 
predicted that the sustained signaling after 1µM gefitinib was due to a faster dephosphorylation 
rate of the Cbl-binding site on ErbB1, compared to the Shc-binding site.  This results in Cbl 
being unable to bind to ErbB1 and promote its degradation, leading to sustained 
phosphorylation of the Shc-binding site since its normal downregulation by receptor degradation 
is now blocked.  However, the data could still be explained in the model by imposing the same 
dephosphorylation rates for the two phosphotyrosine sites on ErbB1, illustrating the basic non-
identifiability problem of these models (discussed in Chapters 2 and 4).  In Chapter 2 we 
measured dephosphorylation of multiple ErbB1 phospho-sites after sequential EGF and 10µM 
gefitinib treatment, including Y1045 where Cbl binds to ErbB1 directly.  We found that all sites 
were rapidly dephosphorylated and concluded that rapid phosphorylation cycling occurs at all 
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sites.  Nonetheless, it is still possible that there are different dephosphorylation rates for the 
sites that is undetectable under these conditions but may become apparent after treatment with 
various gefitinib doses. 
 
ErbB1vIII mutants are hypophosphorylated on the Y1045 Cbl-binding site  
ErbB1vIII (normally referred to as EGFRvIII, but for consistency we use the 
nomenclature ErbB1) is a truncation mutant of ErbB1 that is expressed in about 40-50% of 
human glioblastomas (Gan et al., 2009).  A portion of the extracellular domain is deleted in this 
mutant such that the receptor cannot bind ligand yet it is constitutively active.  ErbB1vIII is 
internalized at a much slower rate than wild-type ErbB1 and is inefficiently ubiquitinated and 
degraded (Grandal et al., 2007).  This seems to cause internalized ErbB1vIII in early 
endosomes to be recycled back to the plasma membrane instead of being delivered to 
lysosomes.  Direct binding of Cbl to phosphorylated Y1045 on ErbB1vIII has been found to be 
limited, and instead Cbl primarily binds to ErbB1vIII indirectly via Grb2.  Interestingly, this may 
be caused by negligible phosphorylation of Y1045 in comparison to other phosphotyrosine 
residues on ErbB1vIII such as Y1173 (Han et al., 2006; Pedersen et al., 2005), and thus Cbl 
would be unable to bind at that site.  This could promote sustained signaling from some 
phospho-sites while inhibiting downregulation, similar to what might occur in cells expressing 
wild-type ErbB1 after treatment with low doses of gefitinib.   
In fact, long-term exposure of ErbB1vIII-expressing cells to low concentrations of 
gefitinib has been found to result in sustained phosphorylation of ErbB1vIII Y1173 and ERK, 
and promote cell proliferation and anchorage-independent growth (Pedersen et al., 2005).  The 
phosphorylation sites Y992 and Y1173 required higher concentrations of gefitinib to be inhibited 
compared to other sites on the receptor.  While mechanisms leading to this sustained signaling 
have not yet been elucidated, the authors propose that the effect is due to an increase in 
ErbB1vIII dimerization and a slow decrease in the gefitinib concentration, such that at after a 
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while the receptors are able to trans-phosphorylate one another.   
It will be interesting to test for different dephosphorylation rates of Y1045 and Y1173 in 
the wild-type ErbB1 cells used in this thesis and cells expressing ErbB1vIII and see whether this 
can explain the sustained signaling.  Since 10µM gefitinib resulted in rapid dephosphorylation of 
both of these sites in H1666 cells as shown in Chapter 2, cells should be treated with various 
concentrations of gefitinib to better estimate the rates.  While an attractive possibility, a faster 
dephosphorylation rate of Y1045 is clearly not the only explanation of the data.  If true, though, it 
would hint at increased phosphatase activity directed at that site, and potentially provide for 
novel mechanisms to induce downregulation of ErbB1vIII as a therapeutic strategy. 
 
Future study: Effects of sustained receptor phosphorylation on downstream signaling  
Even though we found that phosphorylation of ErbB1 Y1173 remained constant for many 
hours following one or two minutes of EGF stimulation and then addition of low concentrations 
of gefitinib, ERK and Akt phosphorylation were still shut off over this time (data not shown).  
Therefore, receptors may become decoupled to their downstream kinases, which can still be 
efficiently turned off by their phosphatases to prevent aberrant signaling.  However, some of our 
preliminary data suggests that this might not always be the case, and that certain conditions 
such as adding drug after longer durations of ligand stimulation may lead to increased 
downstream signaling. 
A large-scale study to measure the phosphorylation states of many signaling proteins, 
for example, by mass spectrometry-based approaches, would be informative to better 
understand how signaling is altered by subsaturating concentrations of gefitinib and to 
determine whether activation of some downstream pathways could be prolonged by sustained 
receptor signaling.  The ability of ErbB1 to signal to certain pathways may be influenced by its 
localization, which may be relevant here if ErbB1 is stuck in a particular cellular compartment 
under these conditions.  Additional experiments to measure gene expression and physiological 
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changes such as proliferation and invasion would be revealing.  Finally, the drug effects could 
be tested in mice or in patients receiving gefitinib treatment if it were possible to obtain biopsy 
samples before and after treatment for signaling analysis. 
   
ErbB1 phosphorylation cycling in the presence of constitutive receptor activation 
Do ErbB1 dephosphorylation dynamics following pulse-chase experiments or after drug 
treatment alone look similar in the case of constitutive ErbB1 activation?  In this thesis, to lay 
the groundwork for this type of analysis we focused our studies on cell lines expressing wild-
type ErbB1 at moderate levels and stimulated cells with exogenous ligand to activate ErbB1.  
Since ErbB1 is often mutated or overexpressed in cancer, or activated by autocrine ligand 
stimulation, future studies should investigate the effects of these alterations on ErbB1 
phosphorylation/dephosphorylation cycling.  It will be important to measure the dose-response 
behavior to various drugs in these cellular contexts and address whether gefitinib and erlotinib 
result in sustained receptor signaling and, if so, at which concentrations.  We expect there to be 
a range of concentrations that give rise to sustained receptor signaling based on the results 
discussed above using ErbB1vIII-expressing cells (Pedersen et al., 2005).  ErbB1 mutations 
such as the L858R point mutation confer sensitivity to drugs such as gefitinib and erlotinib 
(Gazdar, 2009), and therefore, we may detect very similar dose-response behaviors just with 
the receptor being inhibited at lower concentrations of drug.  However, these mutations alter 
endocytosis (Shtiegman et al., 2007) and could potentially alter phosphatase activity, and it is 
therefore unclear what to expect. 
 
Conclusions 
This work has revealed the importance of teasing out the time scales of different events 
regulating cell signaling.  Whereas phosphorylation and dephosphorylation happen within 
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seconds, initial ErbB1 activation following exposure to growth factors can take a few minutes 
(primarily regulated by the kinetics of ligand binding and receptor dimerization) and 
desensitization by receptor endocytosis and degradation occurs on the order of minutes or 
hours.  Furthermore, oncogenesis induced by prolonged receptor activation may develop over 
months or years.  A key challenge in the future will be to better understand these relevant time 
scale separations. 
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CHAPTER 4: Methods 
 
 
 
 
 
 
 
 
The material in this thesis is an extended version of a manuscript to be submitted for publication: 
 
Coupled fast and slow dynamics regulate ErbB1 signaling  
Laura B. Kleiman, Holger Conzelmann, Thomas Maiwald, Douglas A. Lauffenburger and Peter 
K. Sorger 
 
 
(All experiments were performed by Laura Kleiman.  Mathematical modeling was done by Laura 
Kleiman in collaboration with Holger Conzelmann and Thomas Maiwald.) 
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Detailed experimental materials and methods 
Cell culture, reagents and general experimental protocols 
H1666 human lung carcinoma cells were maintained in ACL-4 media: RPMI 
supplemented with 0.5% BSA (2g/L), 10% fetal bovine serum, 100units/ml penicillin, 100µg/mL 
streptomycin, 4.5mM L-glutamine, 1x ITES, 50nM hydrocortisone, 0.1nM tri-iodothyronine, 
10µM phosphorylethanolamine, 10mM HEPES, 0.5mM sodium pyruvate and 1ng/ml epidermal 
growth factor (EGF).  Serum starvation medium consisted of RPMI with penicillin/streptomycin 
and glutamine.  MCF-10A human mammary epithelial cells were maintained in DMEM/F12 
supplemented with 5% horse serum, 20ng/ml EGF, 0.5mg/ml hydrocortisone, 100ng/ml cholera 
toxin, 10ug/ml insulin, and penicillin/streptomycin.  MCF-10A cells were cultured and passaged 
using standard protocols (Debnath et al., 2003).  Serum starvation medium consisted of 
DMEM/F12 with penicillin/streptomycin and L-glutamine. 
Recombinant human EGF and Heregulin-β1 (HRG) were purchased from PeproTech, 
recombinant human amphiregulin (AR) from R&D Systems, gefitinib, erlotinib and canertinib 
from WuXi PharmaTech, lapatinib from LC Laboratories, and PD0325901 from Selleck.  Ligands 
were dissolved in water and drugs in DMSO.  Mouse monoclonal antibody 225 was a gift from J. 
Spangler and D. Wittrup.  Pervanadate was prepared by mixing equal amounts of activated 
Na3VO4 (Sigma) and H2O2 (Sigma) in water 10 minutes before addition to cells. 
After seeding cells for an experiment in normal media, they were allowed to grow for one 
day and then switched to serum starvation medium for one additional day.  Cells were ~70-80% 
confluent at the time of treatment.  Ligands and inhibitors were diluted in serum starvation 
medium (10x the final concentration) and 10% of the final volume was added to cells to 
minimize changes to the cell culture medium that may alter short-term signaling.  For EGF 
washout experiments, EGF was added to cells and after 10 minutes was removed and replaced 
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with conditioned medium from another plate of identically growing cells that had not been 
exposed to EGF.  Data was typically normalized between 0 and 1 for visualization of the trends 
in signaling.   
 
High-throughput fluorescence microscopy  
Cells were seeded in Costar #3603 96-well optical plates (7,500 MCF-10A cells/well or 
9,000 H1666 cells/well) with 200µl of medium per well.  Edge wells were typically not used due 
to lower cell density at the time of the experiment.  At the end of the time course cells were fixed 
for 10 minutes with 2% paraformaldehyde, washed with PBS-T (0.1% Tween-20 in PBS) three 
times, permeabilized with 100% methanol for 10 minutes, washed with PBS-T, and blocked for 
1 hour with Odyssey Blocking Buffer (OBB; LI-COR Biosciences).  Primary antibodies, typically 
at 1:100 dilutions, were diluted in OBB and cells were incubated with the antibodies overnight at 
4°C.  The next day cells were washed again with PBS-T, incubated with secondary antibodies 
(Invitrogen Alexa Fluor 647 goat anti-rabbit IgG #A21245 or 488 donkey anti-mouse IgG 
#A21202 diluted 1:500 in OBB) for 1 hour in the dark at room temperature, washed with PBS-T 
and then with PBS.  To stain nuclei and cytoplasm, cells were then incubated with Hoeschst-
33342 (Molecular Probes #H1399 at 1:40,000 dilution in PBS) and Whole Cell Dye blue protein 
dye (Pierce Biotech at 1:1000 dilution in PBS) for 30 minutes in the dark at room temperature, 
washed with PBS and imaged with an Applied Precision cellWoRx scanner.  Images were 
analyzed using the custom segmentation software ImageRail (B. Millard and P.K. Sorger, 
Harvard Medical School) and intensity values were plotted as the mean ± standard deviation 
from triplicate wells.  Higher resolution images (all images shown in this thesis) were taken at 
20x magnification with a DeltaVision RT microscope (Applied Precision, Inc., Issaquah, WA, 
www.appliedprecision.com). 
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The following primary antibodies were used in these imaging experiments: ErbB1 
pY1173 (Epitomics #1124-1), ERK1 pT202/Y204 + ERK2 pT185/Y187 (Cell Signaling 
Technologies #4377), Akt pS473 (Cell Signaling Technologies #4058), Shc pY317 
(Upstate/Millipore #07-206) and total ErbB1 (Thermo Scientific Ab-12 #MS-400).  The 
permeabilization step was skipped for cell surface ErbB1 measurements and an ErbB1 antibody 
(Thermo Scientific Ab-3 #MS-311) that binds to the extracellular domain of the receptor was 
used. 
 
ELISA assays for ErbB receptor phosphorylation 
Rational for developing new assays  
There are a few issues with the typical methods for measuring phosphorylation of ErbB 
receptors.  The receptors are highly homologous and therefore antibodies sometimes cross-
react.  Since the receptors are all a similar size, detection by Western blotting is problematic.  
Furthermore, in many cell types ErbB receptors (especially ErbB3 and ErbB4) are expressed at 
very low levels, which may not be detectable by methods like Western blotting or microscopy.  
Sandwich enzyme-linked immunosorbent assays (ELISAs) have high sensitivity and specificity 
due to the use of two antibodies that recognize the same protein.  However, most commercial 
ELISAs for ErbB receptor phosphorylation use a pan-phosphotyrosine antibody for detection 
following capture with an antibody specific to one of the receptors.  We found that due to having 
to use a weak detergent in the lysis buffer, complexes are still present in the lysate prepared for 
these assays.  Thus, using a pan-phosphotyrosine antibody may actually detect phosphorylation 
of other proteins bound to the specific protein captured (e.g. other ErbB receptors present in 
heterodimers).  To get around these issues, we developed and optimized novel ELISA assays 
where one receptor is captured and a detection antibody recognizing a specific phosphorylation 
site on that same receptor is then used.  This approach also allows us to compare dynamics 
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between different phospho-sites on one receptor with increased sensitivity and specificity. 
ELISA Protocol 
Following treatment cells were quickly washed with cold PBS and lysed in 1% NP-40, 
20mM Tris, 137mM NaCl, 10% glycerol, 2mM EDTA and 1mM activated sodium orthovanadate 
supplemented with Halt Phosphatase Inhibitor Cocktail (1:100 dilution, Pierce/Thermo), 10ug/ml 
LPC (leupeptin, pepstatin A and chymostatin), 10ug/ml aprotinin and 1mM PMSF.  Lysates were 
incubated on ice rocking gently for 30 minutes followed by centrifugation, and the supernatant 
was stored at -80°C.  Total protein concentrations were determined using a Bicinchoninic Acid 
(BCA) protein assay kit (Pierce #23225). 
Capture antibodies were immobilized on 96-well plates (Costar #3601 purchased from 
Corning) overnight at room temperature.  The next day, plates were washed with PBS-T (0.05% 
Tween-20 in PBS), blocked for 1-2 hours with 1% BSA and 0.05% NaN3 in PBS, and then 
washed again.  Lysates were diluted in lysis buffer and incubated in the 96-well plates for 2 
hours at room temperature.  The amount of H1666 cell lysate that was used depended on the 
protein to be measured (100µl/well): pErbB1 = 2µg/well, pErbB2 = 40µg/well and pErbB3 = 
80µg/well.  After incubation with lysate the plates were washed again and detection antibodies 
were added in 20mM Tris, 137mM NaCl, 0.05% Tween-20 and 0.1% BSA and incubated 
overnight at 4°C.  The following day, plates were washed and incubated for 2 hours at room 
temperature in the dark with Peroxidase AffiniPure donkey anti-rabbit IgG (Jackson 
ImmunoResearch #711-035-152, 1:40,000 for pErbB1 and 1:5,000 for pErbB2 and pErbB3) 
diluted in 20mM Tris, 137mM NaCl, 0.05% Tween-20 and 0.1% BSA.  Plates were washed 
again and then incubated with substrate solution (1:1 Substrate Reagents A (H2O2) & B 
(Tetramethylbenzidine), R&D Systems #DY999) for ~20 minutes in the dark, followed by 
addition of stop solution (2N H2SO4, R&D Systems #DY994).  Optical density was determined at 
450nm and 560nm using a microplate reader, and readings at 560nm were subtracted from 
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450nm to correct for optical imperfections in the plate.  For each detection antibody, lysis buffer 
only controls were subtracted from measurements of wells with lysate. 
Capture antibodies that bind to the extracellular domains of the ErbB receptors were 
purchased from R&D Systems and used in 100µl/well: ErbB1 #AF231 goat IgG (used at 
0.4µg/ml), ErbB2 #MAB1129 mouse monoclonal IgG2B (used at 7µg/ml) and ErbB3 #MAB3481 
mouse monoclonal IgG1 (used at 2µg/ml).  The following rabbit detection antibodies were diluted 
1:200 and used in 100µl/well: ErbB1 pY845 (Cell Signaling Technologies (CST) #2231), pY992 
(Invitrogen #44-786G), pY1045 (CST #2237), pY1068 (Epitomics #1138-1), pY1148 (CST 
#4404), and pY1173 (Epitomics #1124-1), ErbB2 pY1221/1222 (CST #2243), and ErbB3 
pY1289 (CST #4791). 
 
ELISA assays for total ErbB expression 
The following human DuoSet IC ELISA kits were purchased from R&D Systems and 
used to measure total ErbB protein expression levels using the manufacturer’s protocols: ErbB1 
#DYC1854, ErbB2 #DYC1129, ErbB3 #DYC234 and ErbB4 #DYC1133.  To calculate the 
number of receptors per cell, we first estimated the concentration of the target protein in the 
whole cell lysate based on recombinant protein standards provided with the kits.  A replicate 
plate of cells was trypsinized and counted so that the total number of cells could be estimated, 
from which we then calculated the amount (picograms) of target protein per cell.  Using the 
molecular weight of the ErbB proteins, we obtained the following estimates for serum starved 
H1666 cells: ErbB1 ~60,000/cell, ErbB2 ~7,000/cell and ErbB3 ~1,000/cell (ErbB4 levels were 
not detectable).  In this thesis we assume that H1666 cells express ~100,000 ErbB1 molecules 
per cell. 
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Co-immunoprecipitation (co-IP) and Western blotting 
Following treatment cells were quickly washed with cold PBS and lysed in 50mM Tris, 
150mM NaCl, 2.5mM EDTA, 0.25% NP-40, and 1% Triton X-100 supplemented with Halt 
Phosphatase Inhibitor Cocktail (1:100, Pierce/Thermo), 10ug/ml LPC, 10ug/ml aprotinin and 
1mM PMSF.  Lysates were incubated on ice rocking gently for 30 minutes, and following 
centrifugation, the supernatant was retained for Western blotting (as whole cell lysate) or used 
for IP.  To IP ErbB1, cell lysates were incubated with an ErbB1 antibody-agarose bead 
conjugate (Santa Cruz #sc-120AC) overnight at 4°C with gentle mixing.  The next day the lysate 
and beads mixture was centrifuged and the pellet was washed gently with lysis buffer.  
Captured lysate proteins were eluted with 1% SDS at room temperature for 30 minutes.   
Lysates were diluted in 3x SDS sample buffer (187.5mM Tris-HCl, 6% w/v SDS, 30% 
glycerol, 150mM DTT, 0.03% w/v bromophenol blue) before boiling, separated by SDS-PAGE, 
and transferred to PVDF or nitrocellulose membranes.  Membranes were blocked with Odyssey 
Blocking Buffer (LI-COR Biosciences) and cut to enable proteins of different sizes to 
simultaneously be probed with different antibodies.  The following primary antibodies were used: 
total ErbB1 (Thermo Scientific Ab-12 #MS-400), ErbB1 pY1173 (Epitomics #1124-1), total Shc 
(Upstate #06-203) and GAPDH (Abcam #ab8245).  Membranes were then probed with IRDye 
800 conjugated anti-rabbit IgG (Rockland Immunochemicals) and/or Alexa Fluor 680 anti-mouse 
IgG (Invitrogen) at 1:5000, detected using an Odyssey Infrared Scanner (LI-COR Biosciences) 
and analyzed using Odyssey 2.1 software.  Integrated pixel intensities were calculated for 
uniformly-sized rectangular regions framing individual bands, and background correction was 
performed by subtracting the integrated pixel intensity for equally-sized regions within the same 
lane.  For Western blots with whole cell lysate, the background-corrected band intensity for the 
protein of interest was subsequently normalized by GAPDH from the same lane on the 
membrane.  For quantification of the ErbB1 and Shc co-IP, the Shc band was normalized by the 
ErbB1 band. 
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Live-cell microscopy for membrane protrusions 
MCF-10A cells were seeded in 96-well 0.17mm low glass bottom plates with square 
wells (Matrical #MGB096-1-2-LG) at 30,000 cells/well in 400µl/well, allowed to grow for one day 
and then switched to serum starvation medium for an additional day.  Before imaging, the 
medium was changed to phenol-red free CO2-independent medium (Invitrogen) supplemented 
with penicillin/streptomycin and L-glutamine, and ligands and inhibitors were prepared in the 
CO2-independent medium.  Cells were treated and imaged on a Nikon TE2000E with DIC optics 
and a 20x objective in a 37°C chamber.  Frames were taken every ~10 seconds, starting 5-20 
minutes before EGF was added.  Images were calibrated so that pixels were converted to 
distances (e.g. 1 pixel = X µm) based on the microscope and objective used.  To quantify short-
term membrane protrusion dynamics, kymographs were constructed in MetaMorph (Molecular 
Devices) and analyzed in MATLAB. Kymograph analysis tracks pixel intensity along an arbitrary 
line over time, say one that is drawn from the edge of a cell before treatment in the direction of a 
lamellipod extension, as a measure of protrusion distance.  Data are represented as the 
average ± standard error of the mean for 5-10 cells that began extending lamellipodia in 
response to EGF stimulation.   
Only a fraction of cells extended lamellipodia in response to EGF stimulation, typically 
those located at the edge of a cluster of cells and not those lacking cell-cell contact (this has 
been previously observed for MCF-10A cells; (Debnath et al., 2003)).  The data shown in this 
thesis focus on the first few minutes after EGF stimulation and lamellipodia normally retract by 
~15 minutes.  However, cells usually extend additional lamellipodia at later times in the 
continued presence of ligand; interestingly, these later protrusions exhibit more variability with 
respect to timing and protrusion distance. 
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siRNA for PTPs 
The following siRNA oligos were purchased from Dharmacon (Thermo Scientific): ON-
TARGETplus SMARTpool siRNA for PTPN1/PTP1B (#L-003529-00), PTPN6/Shp-1 (#L-
009778-00) and PTPN11/Shp-2 (#L-003947-00), ON-TARGETplus GAPDH siRNA Control Pool 
(Human) (#D-001830-10-05), and ON-TARGETplus Non-targeting Pool (#D-001810-10-05).  
siRNA treatment was performed in antibiotic-free complete medium that was replaced with 
normal growth medium the following day.  DharmaFECT #1, 2, 3 and 4 Transfection Reagents 
(Dharmacon #T-2005-01) were tested for H1666 cells based on GAPDH and PTP1B 
knockdown and all worked well except for #3.  PTP1B, Shp-1 and Shp-2 siRNAs at 
concentrations of 10, 50 or 100nM after treatment for 48 or 72 hours were optimized for 
maximal knockdown.  Maximal PTP1B knockdown was detected at 100nM after 72 hours, 
whereas all concentrations of Shp-2 siRNA produced good knockdowns after 72 hours.  The 
faint band thought to be Shp-1 did not diminish upon any siRNA treatment. 
To test the effects of PTP1B knockdown on fast gefitinib-induced dephosphorylation, 
DharmaFECT #4 was used at 3µl/well, and PTP1B and non-targeting control siRNAs were used 
at 100nM for 72 hours (including one day of serum starvation).  Samples were collected and 
analyzed following the ELISA and Western blotting protocols described above.  The following 
antibodies were used to analyze the effects of the knockdowns by Western blotting: PTP1B 
(Calbiochem Ab-1 #PH01), Shp-1 (Santa Cruz D-11 #sc-7289), Shp-2 (Epitomics #1590-1), 
GAPDH (Abcam #ab8245), total ErbB1 (Thermo Scientific Ab-12 #MS-400), ErbB1 pY1173 
(Epitomics #1124-1), and ERK1 pT202/Y204 + ERK2 pT185/Y187 (Cell Signaling Technologies 
#4377). 
 
Chemical inhibitors of PTPs 
The following chemical inhibitors of PTP1B, Shp-1 and/or Shp-2 were tested: NSC-
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87877 (Calbiochem #565851), CinnGel 2Me (Enzo #PR-115) and PTP1B inhibitor (Calbiochem 
#539741).  H1666 cells were unaffected by the inhibitors and we could not reproduce results 
reported in the literature with different cell lines.  For example, Shp-2 is thought to mediate EGF-
induced activation of ERK1/2, and therefore, Shp-2 inhibition could be detected indirectly by 
measuring ERK1/2.  H1666 cells were pretreated with 0-50µM NSC-87877 (supposedly a Shp-2 
inhibitor) for 3 hours and then stimulated with EGF for 10 minutes before fixation and 
immunofluorescence.  Although Chen et al. (Chen et al., 2006) showed that this drug inhibited 
ERK1/2 phosphorylation in a dose-dependent manner in HEK293 cells, pERK1/2 levels were 
not altered by this drug in H1666 cells under our conditions (data not shown).  However, a 
control treatment with a MEK inhibitor did lead to ERK1/2 dephosphorylation.  We were unable 
to find any better commercial PTP inhibitors or obtain more specific inhibitors synthesized by 
other academic laboratories. 
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Computational models of ErbB1 phosphorylation dynamics 
Overview 
In Chapter 2, various mathematical models were used to interpret the experimental data 
and explore ErbB1 phosphorylation/dephosphorylation cycling, and many details of the 
modeling were omitted.  In this chapter, we describe in detail the development and analysis of a 
succession of mathematical models that all focus on ErbB1 phosphorylation dynamics but 
incorporate varying degrees of biochemical resolution. 
General comments 
Mass action kinetics based on elementary reactions was used to construct all 
mathematical models.  No Michaelis-Menten approximations or other simplifications were made 
since their assumptions are often not appropriate for biochemical signaling networks in vivo.  
We assume compartments where proteins are located to be well mixed.  Protein concentrations 
were high (>1000 molecules per cell), so deterministic approaches were used.  Even though 
measurements of some kinetic parameters are available in the literature, they are usually from 
in vitro measurements and may not be relevant in the crowded environment of a cell (Schnell 
and Turner, 2004).  Therefore, instead of forcing these values that may be unreasonable, we 
typically allowed them to be fitted.  Equilibrium constants (keq) are always expressed as 
association equilibrium constants (kon/koff; therefore, higher values mean higher binding 
affinity), and on rates can be calculated directly as kon=keq x koff.  
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Exponential decay model for half life estimates 
We constructed the most simple ordinary differential equation (ODE) model to describe 
the decrease in the fraction of ErbB1 receptors that are phosphorylated ( px , which can also be 
thought of as the total number of receptors that can then be degraded) over time by assuming 
that the fraction of phosphorylated receptors decreases at a rate proportional to its value: 
1p px k x
•
−= − .  The solution to this equation is 1
k t
px e −
−=   (exponential decay) when 
( 0) 1px t = = , where 1k−  is the dephosphorylation or degradation rate constant.  To estimate half 
lives we scaled the experimental data (using the average of replicate data points) such that t=0 
was the maximum signal before starting to decline and had a value of 1, and the minimum 
signal was 0, and the model parameter 1k−  was fitted using the function NMinimize in 
Mathematica.  The half life (t1/2), or the time required for the decaying quantity to fall to one half 
of its initial value, was then calculated as 1ln 2 / k− . 
Since 1k tpx e −
−=   is equivalent to 1ln px k t−= − , a common way to estimate 1k−  and the 
half life is by plotting ln px  vs. t  and performing linear regression to calculate the slope ( 1k−− ).  
We obtain similar estimates using this method, but it is more accurate to fit the exponential 
decay directly instead of taking the logarithms of the data, so this is what we report on 
throughout the thesis.  Linear regression assumes normally distributed (Gaussian) noise, but 
since it is being used on a log scale it should really be log-normally distributed.  
If we consider the decline in ErbB1 phosphorylation after only EGF stimulation in Figure 
2.1A (starting at t=10 min after EGF is added), 1k− = 0.026/min and t1/2= 27 min.  The decline in 
total ErbB1 (receptor degradation) starts at t=30 min after EGF addition here, and fitting to this 
data results in 1k− = 0.022/min and t1/2= 31.5 min.  The decrease in ErbB1 phosphorylation after 
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EGF stimulation followed by addition of 10µM gefitinib was extremely fast with 1k− ~7/min.  
Assuming that 40% of the receptors are phosphorylated after 10 minutes of EGF stimulation 
(40,000 molecules per cell; see below), this corresponds to ~5,000 receptors per cell 
dephosphorylated within the first second after drug addition, compared to ~10 receptors in the 
presence of EGF only. 
ErbB1 dephosphorylation is nearly complete after stimulation of cells with EGF for 10 
minutes and then 10µM gefitinib for one minute, so the fitted dephosphorylation rate constant 
( 1k− ~2/min) is an underestimate when this is the first time point measured.  To better constrain 
this value we measured ErbB1 dephosphorylation after treatment with various concentrations of 
gefitinib where measurements were taken at 10, 20 and 30 seconds after drug addition (Fig. 
2.5B), and we obtained the following estimates: for 20µM gefitinib, 1k− ~8/min and t1/2 ~5 sec; for 
10µM, 1k− ~6.5/min and t1/2 ~6.5 sec; for 1µM, 1k− ~4.2/min and t1/2 ~10 sec.  
Following 20 minutes of 10µM gefitinib treatment of H1666 cells, ERK dephosphorylation 
still had not reached basal levels.  However, 15-20 minutes after addition of 10µM erlotinib or 
canertinib, ERK phosphorylation was down to the basal level and continued to decrease a little 
more over the next ~30 minutes (data not shown).  Assuming that after 20 minutes of 10µM 
gefitinib treatment ERK is completely dephosphorylated, we can estimate a lower bound for its 
half life (t1/2 > 9.4 min). 
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Table 4.1 – Summary of decay rates and half lives. 
*The first time point measured following addition of inhibitor (e.g. at t=10 min) was typically 1 minute 
(e.g. at t=11 min). 
 
 
Measurement Cell line Time after EGF that 
inhibitor is added* 
Inhibitor and 
concentration 
Decay rate 
 
t1/2 
 
Total ErbB1 H1666 – (EGF only) – 0.022/min 31.5 min 
pErbB1 
Y1173 
H1666 – (EGF only) – 0.026/min 27 min 
  10 min 
(first measurement 
after 10 sec) 
20µM Gefitinib 8/min 5 sec 
  10 min 
(first measurement 
after 10 sec) 
10µM Gefitinib 6.5/min 6.5 sec 
  10 min 
(first measurement 
after 10 sec) 
1µM Gefitinib 4.2/min 10 sec 
  10 min 
(first measurement 
after 1 min) 
10µM Gefitinib 2.04/min 20 sec 
  2 min 10µM Gefitinib 0.96/min 43 sec 
  30 min 10µM Gefitinib 2.21/min 19 sec 
  10 min 10µM  Canertinib 2.95/min 14 sec 
  10 min 10µM Lapatinib 0.09/min 7.7 min 
  10 min 10µg/ml mAb 225 0.093/min 7.5 min 
pErbB2  
Y1221/1222 
H1666 10 min 10µM Gefitinib 2.74/min 15 sec 
pErbB3  
Y1289 
H1666 10 min 10µM Gefitinib 1.32/min 32 sec 
ErbB1:Shc 
association 
H1666 10 min 10µM Gefitinib 2.92/min 14 sec 
pShc Y317 H1666 10 min 10µM Gefitinib 1.63/min 26 sec 
pERK1/2 H1666 10 min 10µM Gefitinib <  0.074/min > 9.4 min 
 H1666 10 min 1µM PD0325901 0.97/min 43 sec 
 MCF-10A 10 min 10µM Gefitinib 0.197/min 3.5 min 
pAkt S473 H1666 10 min 10µM Gefitinib 0.678/min 61 sec 
 MCF-10A 10 min 10µM Gefitinib 0.42/min 99 sec 
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Small model describing ErbB1 phosphorylation and dephosphorylation 
The exponential decay model does not take into account phosphorylation reactions.  
Since we wanted to understand how the phosphorylation reactions compete with 
dephosphorylation and to estimate the corresponding rate constants, we developed a slightly 
more detailed biochemical model that describes how the concentration of phosphorylated 
receptors changes over time in the presence and absence of gefitinib.  We aimed to 
characterize the fast dephosphorylation of ErbB1 immediately following gefitinib addition, and 
therefore, in this scheme we considered reactions we believed to be important for t=10-20 min 
after EGF stimulation of H1666 cells.  The ODE describing the change in the fraction of 
phosphorylated receptors (xp) with respect to time is given as described in the main text as: 
1
1(1 )1
p p p
eqG
kx x k x
K G
•
−= − −+
 
where 1k  is the phosphorylation rate constant, 1k−  is the dephosphorylation rate constant, the 
term 1 px− represents the fraction of all ErbB1 receptors that are not phosphorylated, eqGK  is 
association constant for gefitinib binding to ErbB1, and G  is the gefitinib concentration.   
The solution to the ODE was calculated analytically, resulting in an analytic solution for 
the concentration of phosphorylated receptors that depends on the three parameters (rates of 
ErbB1 phosphorylation and dephosphorylation and the association constant for gefitinib 
binding), the gefitinib concentration, and the initial concentration of phosphorylated species.  
The solution when 
2( 0)
5p
x t = =  (40% of ErbB1 receptors are phosphorylated at t=0; see below 
for details) is: 
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To test whether the parameters of the model are identifiable (i.e. exact values of the 
parameters can be obtained with exact data), we generated random values for the three 
parameters to obtain a fully parameterized model, from which we produced simulated exact 
data of time courses for two different concentrations of gefitinib.  We then numerically minimized 
the difference between these data points and the algebraic equations (without knowledge of the 
parameter values used to generate the data) and obtained the original parameter values.  
Alternatively, using three exact measurements (random parameter values and three different 
concentrations of gefitinib and time points) the algebraic equations could be solved uniquely and 
the original parameters exactly retrieved (direct calculation with no optimization).  Therefore, the 
model parameters are identifiable using three data points with no measurement error. 
We performed Monte Carlo simulations to obtain probabilistic estimates of the three 
parameters ( 1k , 1k−  and eqGK ) from the variance in the experimental data.  To do this, we 
generated 1,000 artificial time courses by choosing random values from log-normal distributions 
with the same mean and standard deviation as the experimental measurements (similar results 
were obtained using normal distributions, but using log-normal distributions avoided negative 
concentrations), for each time point and concentration of gefitinib.  For each artificial time 
course the parameters of the model were fit using the following procedure.  The time point and 
gefitinib concentration were substituted into the analytical solution to the ODE, resulting in an 
algebraic equation with three unknown parameter values, and optimization was then performed.  
To simultaneously minimize the objective function for all concentrations of gefitinib with different 
artificial data but the same parameters, we defined an objective function that calculated the 
difference between the algebraic equation and the artificial data, and then took the sum of the 
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squared values for each time point and the sum for each concentration of gefitinib (least 
squares method).  We minimized the objective function using NMinimize in Mathematica. 
For this model it was necessary to estimate the fraction of receptors that were 
phosphorylated at any given time.  Since this is difficult to measure experimentally, we tested 
different normalizations of the 1, 10 and 20µM gefitinib data (these drugs were added after 10 
minutes of EGF stimulation) to see which normalization fit the model best.  Pervanadate 
treatment inhibits phosphatase activity and results in an increase in ErbB1 phosphorylation to 
levels significantly above those reached after EGF stimulation, and we reasoned that after EGF 
treatment fewer than half of the receptors may become phosphorylated.  Therefore, we tested 
normalization for the fraction of receptors phosphorylated after 10 minutes of EGF treatment 
(the model steady state) between 25-50%, and normalization for the steady state after 20µM 
gefitinib treatment between 0.5-10%; these values define the range of receptor phosphorylation 
since 1 and 10µM gefitinib treatments result in intermediate levels.  We found that the model fit 
the experimental data best when the 20µM gefitinib data was normalized such that 0.5% of the 
receptors were phosphorylated after treatment.  However, normalization of the data for 10 
minutes of EGF treatment (the upper bound) was less sensitive and we got similar fits with the 
different normalizations; thus, we set the level of ErbB1 phosphorylation after 10 minutes of 
EGF to be 40%.  The data used for this model was therefore normalized to range between 0.5-
40% ErbB1 receptors phosphorylated under conditions of EGF stimulation and gefitinib 
treatment. 
Estimates for the values of the ErbB1 dephosphorylation rate and the association 
constant for gefitinib binding were similar for the different normalizations of the 10min EGF 
treatment (median values of 7.70-7.85/min and 0.91-1.55/µM, respectively).  Fitted values for 
the association constant for gefitinib binding differ from literature estimates due to the lack of 
ATP competition with drug for binding to ErbB1 in this model (discussed in Chapter 2).  Broader 
estimates were obtained for the ErbB1 phosphorylation rate based on the normalization of the 
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10min EGF treatment (median values of 2.15-6.57/min).  Median values were used instead of 
mean values because outliers sometimes resulted in enormous values for the average. 
In the main text we derived the following equation to describe the fraction of receptors 
gefitinib-bound at steady state: 
1
eqG
G
eqG
K G
f
K G
=
+
.  Therefore, since we estimated KeqG ~ 1.3/µM, 
after treatment with 1µM gefitinib ~56% of receptors are gefitinib-bound, and after treatment 
with 20µM gefitinib ~96% are gefitinib-bound.  
The phosphorylation and dephosphorylation rate constants that we estimated represent 
lower bounds for these parameters since in this model these reactions are basically only 
dependent on the catalytic rates.  This reasoning can be more easily understood with an 
example.  In this model we do not account for adaptor protein binding to ErbB1 phosphotyrosine 
sites, which would protect these adaptor-bound sites from dephosphorylation and decrease the 
overall fraction of receptors that are able to become dephosphorylated.  Consider a modified 
ODE where af  equals the fraction of receptors that are not adaptor bound and therefore able to 
become dephosphorylated:  
1
1(1 )1
p p a p
eqG
kx x k f x
K G
•
−= − −+
 
We can think of our estimate of the dephosphorylation rate constant ( 1k− ~8/min, as described in 
the main text) as 1 ak f− ~8/min where af  = 1.  If af  would now take on a value between 0 and 1, 
1k−  would be estimated to be greater than 8/min.  However, we cannot estimate af  because we 
do not have experimental data for the effects of modulating the adaptor protein concentration on 
receptor phosphorylation levels, like we have for gefitinib.  Other processes can also slow down 
receptor phosphorylation or dephosphorylation (thereby increasing our estimates of these rate 
constants), such as phosphatase binding and ATP and gefitinib competition for binding to 
ErbB1. 
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We asked whether the model could explain the lapatinib-induced dynamics where even 
low concentrations of drug result in complete ErbB1 dephosphorylation.  We tried to fit the 
model to data of ErbB1 phosphorylation levels following treatment with 0.5, 1 and 10µM 
lapatinib when the drug was added 10 minutes after EGF stimulation in H1666 cells.  We first 
tested different normalizations of the data, where the steady state phosphorylation level was 
taken to be 40% (10 min after addition of EGF) and the minimum level of phosphorylation 
reached with the drug was varied between 0.5-10%. The phosphorylation rate constant and 
association constant for lapatinib binding could not be identified unless this minimum 
phosphorylation level was set to be greater than ~6%, but the dephosphorylation rate constant 
was not dependent on this value.  However, all of these parameter sets produced dose-
response behavior that looked more like the response to gefitinib than lapatinib, and therefore 
produced very poor fits when compared to the experimental data.  Lower concentrations of drug 
still led to a lower steady state level of receptor phosphorylation (as for gefitinib), although it 
took much longer to reach this new steady state than with parameter values found from fitting to 
gefitinib data due to the much slower phosphorylation and dephosphorylation rate constants 
estimated here. 
From this fitting exercise we draw two conclusions.  First, if we only had the lapatinib 
data we would estimate a much slower rate of receptor phosphorylation cycling due to the slow 
phosphorylation and dephosphorylation rate constants.  Thus, very fast binding drugs are 
needed to get closer to the actual rates of phosphorylation cycling.  Second, this model is 
insufficient to explain the response to lapatinib.  This is an issue we explore with our extended 
models that incorporate more biochemical information about these receptors and drugs. 
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Stochastic model describing the intervals between switching events 
Instead of considering the average behavior of a large population of ErbB1 receptors 
that can be phosphorylated or dephosphorylated over time (for example using the small 
deterministic ODE model depicted in Figure 2.5) we considered individual molecules 
independently switching between phosphorylated and dephosphorylated states.  We were 
interested in calculating the waiting time between phosphorylation and dephosphorylation 
events and constructing time courses of state fluctuations for individual ErbB1 molecules.  
Similar to the ODE model, we considered these events to be a result of monomolecular 
reactions that are dependent on the catalytic rates of phosphorylation and dephosphorylation 
only (e.g. no explicit binding of gefitinib or adaptor proteins).  These events can be described as 
Poisson processes, stochastic processes in which events occur continuously and independently 
at a constant average rate (probability per unit time).  The time between events in a Poisson 
process is given by an exponential distribution.  We therefore took the probability that a certain 
ErbB1 molecule switches from being phosphorylated to dephosphorylated or vice versa (with 
each molecule having the same probability) to be described by an exponential distribution with a 
rate parameter equivalent to the dephosphorylation or phosphorylation rate constant, 
respectively.   
The relative likelihood of a switching event at a certain time is given by the probability 
density function ktke−  where k  is the rate parameter.  The probability that the switching time 
falls within the interval from 0 to t  is given by the integral of its density over the interval, also 
known as the cumulative distribution function (CDF), 1 kte−− .  Thus, the probability that the 
receptor is still in the same state at time t  is given by kte− .  Using the inverse of the CDF we 
can describe switching times in terms of these probabilities.  We generated exponential variates 
for switching times based on the inverse transform sampling method by choosing probabilities 
 - 128 - 
( p ) from a uniform distribution with an interval [0,1] and computing the inverse CDF (the 
quantile function), 
ln(1 )p
k
− −
.  We used the median values for the three parameters estimated 
with our small ODE model in Figure 2.5D (phosphorylation rate constant 1k = 4.4/min, 
dephosphorylation rate constant 1k− = 7.8/min, and association constant for gefitinib binding to 
ErbB1 eqGK = 1.3/µM) and calculated the phosphorylation rate in the presence of 10µM gefitinib 
using 1
1 eqG
k
K G+
, as derived in equations (2) and (3) in the main text.  The average switching 
times (times between events) calculated using this procedure are equivalent to 
1
k
, the mean or 
expected value of an exponentially distributed random variable with rate parameter k . 
Using the approach described above, we generated lists of the varying amounts of time 
it can take for ErbB1 receptors that are not phosphorylated to become phosphorylated (in the 
presence or absence of 10µM gefitinib), as well as for phosphorylated receptors to become 
dephosphorylated.  Time courses of phosphorylation and dephosphorylation cycling of individual 
ErbB1 molecules were constructed by combining these waiting times and setting the 
phosphorylated and unphosphorylated receptor state to 1 and 0, respectively.  The sum of all 
receptors phosphorylated over time was normalized by the total number of molecules simulated 
and plotted over time as an estimate of the average population behavior.  Only 1000 ErbB1 
molecules were simulated to illustrate noise in the stochastic simulation, which scales with 
1
# molecules
. 
Similar to the ODE formalism, this stochastic model does not account for the slow 
processes that normally regulate overall levels of ErbB1 phosphorylation after EGF stimulation 
(e.g. ligand binding, receptor dimerization and degradation) and therefore is most accurate ~10-
30 minutes after adding EGF.  
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To generate the green curve in Fig. 2.12A, the fraction of receptors phosphorylated over 
time as described in ODE formalism is defined as 1 1(1 )p p px k x k x
•
−= − −  and we assume that 
( 0) 0px t = = .  The analytical solution for px  was plotted with 1k  being the phosphorylation rate 
constant in the absence of gefitinib for the first 10 minutes of the simulation and in the presence 
of 10µM gefitinib afterward. 
An extension of this stochastic simulation to take into account bimolecular events such 
as ErbB1 phosphorylation/dephosphorylation as a function of whether the adaptor protein Shc is 
bound to the ErbB1 phosphotyrosine site is not as straightforward.  The probability that a 
receptor is dephosphorylated would depend on whether Shc is bound to that site, and the 
probability of the receptor binding Shc would be dependent on the absolute concentration of 
Shc.  Therefore, once one ErbB1 molecule bound Shc, the concentration of free Shc would 
change so that the probability of another ErbB1 molecule binding Shc would also change. 
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Model describing different ErbB1 conformations and drug responses 
We constructed a more detailed model of ErbB1 phosphorylation dynamics that also 
describes gefitinib and lapatinib binding to different receptor conformations.  This model 
describes how binding of the following molecules to ErbB1 affects ErbB1 phosphorylation 
dynamics: ATP or drug (and competition between the two), phosphatases and adaptor proteins.  
This model does not explicitly include the dynamics of ligand binding, dimerization, 
internalization or degradation, and we assume that EGF is bound and stays bound and that the 
receptor species represent monomers that exist in stable ErbB1 homodimers (similar 
assumptions as for the small ODE model).  ErbB1 can switch between active and inactive 
conformations.  The active conformation is likely dominant in the presence of high 
concentrations of EGF and is therefore the dominant conformation in our model at steady state.  
The ErbB1 phospho-site described in this model and measured in the corresponding 
experiments is Y1173, a high affinity binding site for the adaptor protein Shc.  When in the 
inactive conformation the receptor remains bound to EGF (implicitly), and can still be 
phosphorylated, Shc, ATP or gefitinib bound, although these are unlikely events.  We assume 
that phosphorylation is irreversible if ATP is bound because ATP is consumed in the process 
and is then no longer bound to the receptor, and that dephosphorylation is irreversible if a 
phosphatase is bound (no dephosphorylation is allowed if a phosphatase is not bound).  We 
assume that ATP and gefitinib bind much better to ErbB1 when in the active conformation but 
that they can still bind although with much lower affinity to the inactive conformation.  On the 
other hand, lapatinib is only allowed to bind to ErbB1 when it is in the inactive conformation (and 
binds with slower on and off rates than gefitinib), and once lapatinib-bound the receptor cannot 
switch conformations.  These assumptions are supported by structural data (Wood et al., 2004) 
and reduce the complexity of the model. 
 
 - 131 - 
The model consists of 46 dynamic variables/species that primarily represent different 
ErbB1 receptor states.  These are represented by the notation: 
“ac/in_0/ATP/G/L_0/Phos_0/P/Shc” and describe the following about a given ErbB1 receptor: 1) 
whether it is in an active (“ac”) or inactive (“in”) conformation, 2) not bound by ATP or drug (“0”), 
or bound by ATP (“ATP”), gefitinib (“G”) or lapatinib (“L”), 3) not bound by phosphatase (“0”) or 
bound by phosphatase (“Phos”), and 4) not phosphorylated (“0”), phosphorylated (“P”) or 
phosphorylated and Shc bound (just represented by being Shc bound) (“Shc”).  All 48 
combinatorial possibilities are allowed except that lapatinib cannot be bound to ErbB1 when it is 
in an active conformation (leaving a total of 42 receptor species).  In addition to the receptor 
species, we consider a family of free phosphatases that are available to bind to and 
dephosphorylate ErbB1 (“Phos”) as well as a family of free adaptor proteins that can bind to 
ErbB1 pY1173 (the only ErbB1 phospho-site modeled here), thought to primarily be comprised 
of Shc and is therefore termed “Shc”.  We consider the effects of pervanadate, a tyrosine 
phosphatase inhibitor, in this model.  To do so, we consider free pervanadate (“Van”) and 
pervanadate-bound phosphatases (“PhosVan”), which are unable to bind ErbB1 and are 
therefore inhibited.  We assume that only free phosphatases (not receptor-bound) can be 
inhibited by pervanadate.  An illustration of the combinatorial complexity of this model is shown 
in Figure 4.1, which is complementary to the model depiction in Figure 2.7A that details the 
different ErbB1 conformations to which the drugs can bind but not the combinatorial binding 
events.  A complete list of all species can be found in Table 4.2. 
We modeled pervanadate activity as a time dependent variable because literature 
results show that its activity decreases rapidly after addition to cells (Mikalsen and Kaalhus, 
1998), although making this assumption does not seem to significantly alter our results.  We 
consider pervanadate as an “injection” such that after adding it at a certain time its 
concentration value evolves within the differential equation as any other dynamical species.  
Two parameters describe the injection of pervanadate with exponential decay, one regulates the 
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decay/degradation time (‘koff2Van’; this value is fixed since we found it not to make much of a 
difference to our results) and another regulates the steady state level that is reached 
(‘keq2Van’; the receptor phosphorylation level goes down to ~20% after 7-10 minutes). 
We assign three non-zero initial species concentrations.  ErbB1 in the inactive 
conformation with no ATP or drug bound, no phosphatase bound and not phosphorylated 
(therefore also not Shc bound), “inR_0_0_0”, is 74nM.  ErbB1 phosphatases and Shc are both 
assumed to be in excess of ErbB1 and are assigned the concentration 740nM.  We assume that 
the ATP concentration within cells is very high and stays constant.  Therefore, we consider ATP 
to be a fixed parameter with a value 2.5mM (Lehninger et al., 2000). 
The model was implemented in a rule-based format in the MATLAB toolbox 
PottersWheel (Maiwald and Timmer, 2008) to account for the combinatorial complexity 
(Hlavacek et al., 2006).  Instead of manually enumerating ~100 reaction rates individually, the 
reactions are defined using only 17 rules.  As an example of one rule, consider the reaction rule 
describing lapatinib binding to ErbB1 when the receptor is in the inactive conformation and not 
bound by ATP or drug.  We assume that lapatinib binds similarly regardless of whether a 
phosphatase is bound or the receptor is phosphorylated or Shc bound.  The reactant (‘r1’) is 
'inR_O _<1:+>_<2:+>' and the product (‘p1’) is 'inR_Lap _<1>_<2>', where <1> and <2> are 
placeholders for phosphatase and Shc binding, which are irrelevant for lapatinib binding.  
Lapatinib is considered to be a modifier (‘m1’) of this reaction.  The rate signature is given by 
'k1*k2*m1*r1 - k2*p1' where the parameters are keqLap (‘k1’) and koffLap (‘k2’).  Since 
keqLap=konLap/koffLap, the aggregate reaction rate describing lapatinib binding to the inactive 
conformation of ErbB1 is equivalent to: 
 [ ] [ _ 0 _ _ ] [ _ _ _ ]konLap Lap inR koffLap inR Lap× × + + − × + +  
The individual rules, reactions and ODEs are then automatically enumerated.  A complete list of 
the rules can be found in Table 4.3.  
 - 133 - 
There are 24 kinetic parameters in the model, primarily equilibrium constants and off 
rates.  Equilibrium constants (keq) are defined as kon/off and have units 1/nM, koff values have 
units 1/min and kon have units 1/(nM x min).  It is important to keep in mind that dissociation 
constants (Kd), which are normally reported in the literature, are given by 1/keq.  For example, 
the Kd for lapatinib binding to ErbB1 has been measured to be 3nM (Karaman et al., 2008), so 
here the keq value is (1/3)nM.  Inhibitor concentrations are given in nM.  The following 
parameter values were obtained from the literature or estimated and were not fitted: keqGefitinib 
(1/nM) (Karaman et al., 2008), keqLapatinib (1/3nM), koff2Van (0.1/min).  We set these 
parameters to have equivalent values since we have no evidence that they are different: 
koffATP= koffATP2, koffAct=koffAct2=koffAct3, and koffGefitinib=koffGefitinib2.  17 unknown 
parameters remain and are estimated through fitting.  Descriptions of all parameters and their 
fitted values are detailed in Table 4.4. 
To normalize across many datasets collected at different times, we assume that 10% of 
the receptors are phosphorylated in serum starved cells and 40% after 10 minutes of 100ng/ml 
EGF stimulation.  All datasets were normalized to these values.  They were chosen so that the 
maximum phosphorylation we ever measured (in the presence of pervanadate) was ~95% and 
the minimum phosphorylation measured (in the presence of lapatinib) was ~5%. 
Since in this model we do not take into account an increase in ErbB1 phosphorylation 
caused by EGF binding and receptor dimerization, or a decrease in ErbB1 phosphorylation 
caused by internalization and degradation, the steady state of the model can be thought of as 
the pseudo-steady state of ErbB1 phosphorylation ~10-30 minutes after EGF addition to cells.  
We assume that 40% of ErbB1 receptors are phosphorylated after 10 minutes of EGF 
stimulation and force this steady state to be reached by adding artificial data points for fitting.  
An experimental time course of EGF treatment only was not used here.  We consider the effects 
of kinase and phosphatase inhibitors only after steady state is reached.   
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We performed parameter estimation in PottersWheel, where we simultaneously fit the 
model to a large dataset consisting of ErbB1 phosphorylation dynamics following treatment of 
H1666 cells with 100ng/ml EGF (at t=0) and then various gefitinib or lapatinib concentrations or 
the phosphatase inhibitor pervanadate (all single inhibitor treatments added at t=10 min).  The 
pervanadate experimental data was weighed more heavily since we used data of treatment with 
only one concentration as opposed to various concentrations of gefitinib and lapatinib.   
Error bars for model calibration were estimated using an error model.  We took the 
treatment condition where we had the most repeated measurements of ErbB1 phosphorylation 
(treatment with 10µM gefitinib on separate days; 4-6 independent measurements per time point 
after addition of drug) and calculated the average and standard deviation for each time point.  
We then plotted the average (x) vs. standard deviation (y) and performed linear regression to 
obtain the error model: y = 0.127x + 0.66, a 12.7% relative error with 0.66 offset. 
The Fortran integrator RADAU5 was used to numerically solve the system of ODEs.  We 
used a trust-region optimization approach in logarithmic parameter space and a chi-square 
tolerance and fit parameters tolerance of 1e-8.  We minimized the chi-square value, the sum of 
weighted and squared residuals between the model trajectories and our experimental time 
course measurements.  2000 fits were carried out, each time varying all parameters ( )p  before 
fitting with a disturbance strength s  of 0.3, corresponding to 10snew oldp p
ε×= × , with ε being 
normally distributed with mean 0 and variance 1 and oldp  being the initial guess for the 
parameter value. 
Simulations started at t = -60 min to allow for reaching basal steady state levels at t=0 
min and inhibitors were added to the system at t = 10 min.  Gefitinib and lapatinib were 
considered as step functions.  The sum of all species that were phosphorylated (including those 
that were phosphorylated and Shc bound) was compared to the experimental ErbB1 pY1173 
measurements.  ErbB1 phosphorylation was normalized to the total number of receptors so that 
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the percentage of receptors phosphorylated was plotted. 
To reveal the dependency of the different trends of ErbB1 dephosphorylation by 10µM 
gefitinib or lapatinib on the fitted ErbB1 phosphorylation and dephosphorylation rate constants, 
the rate constants from the best fit model (fit with the lowest chi-square value) were both 
decreased while keeping the ratio of the two parameters constant (Fig. 2.7D).  The model 
steady state level was rescaled to 40% to be able to compare the trends in dephosphorylation.  
Overall, kPhos was decreased from 209/min to 0.33/min and kDephos was decreased from 
37.5/min to 0.06/min. 
As already mentioned, this model is only applicable to analyze events occurring ~10-30 
min after EGF stimulation, since the model represents the steady state ErbB1 phosphorylation 
levels reached following EGF treatment and does not describe receptor degradation (which 
begins ~30 min).  Therefore, caution should be taken when comparing the model trajectories to 
experimental data after this time.  Furthermore, treatment of H1666 cells with pervanadate 
resulted in cell loss (likely detachment due to the effects of pervanadate on adhesion molecules) 
and therefore pervanadate data could only be plotted before 30 min. 
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Figure 4.1 - An illustration of the combinatorial complexity of binding events described in 
the 46 ODE model. 
This figure is complementary to Figure 2.7A since it does not show the difference between the active and 
inactive ErbB1 conformations but instead focuses on the combinatorial complexity of the basic binding 
events.  The reactions shown here describe gefitinib binding to the active ErbB1 conformation. 
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Table 4.2 – Species and initial protein concentrations in the 46 ODE model. 
If no initial concentration is specified it is given a value of zero.  Iressa = Gefitinib, Van = pervanadate. 
 
 
Species Initial 
Concentration 
Species Initial 
Concentration 
Phos 740nM inR_O _Phos _O  
PhosVan  inR_O _Phos _Shc  
acR_O _O _O  inR_O _Phos _P  
acR_O _O _Shc  inR_ATP _O _O  
acR_O _O _P  inR_ATP _O _Shc  
acR_O _Phos _O  inR_ATP _O _P  
acR_O _Phos _Shc  inR_ATP _Phos _O  
acR_O _Phos _P  inR_ATP _Phos _Shc  
acR_ATP _O _O  inR_ATP _Phos _P  
acR_ATP _O _Shc  inR_Iressa _O _O  
acR_ATP _O _P  inR_Iressa _O _Shc  
acR_ATP _Phos _O  inR_Iressa _O _P  
acR_ATP _Phos _Shc  inR_Iressa _Phos _O  
acR_ATP _Phos _P  inR_Iressa _Phos _Shc  
acR_Iressa _O _O  inR_Iressa _Phos _P  
acR_Iressa _O _Shc  inR_Lap _O _O  
acR_Iressa _O _P  inR_Lap _O _Shc  
acR_Iressa _Phos _O  inR_Lap _O _P  
acR_Iressa _Phos _Shc  inR_Lap _Phos _O 740nM 
acR_Iressa _Phos _P  inR_Lap _Phos _Shc  
inR_O _O _O 74nM inR_Lap _Phos _P  
inR_O _O _Shc  Shc  
inR_O _O _P  Van  
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Table 4.3 – Reaction rules describing the 46 ODE model. 
Reactions are in PottersWheel notation: reactants, products, modifiers, rateSignature, parameters. 
 
 
{'inR_O _<1:+>_<2:+>'},  {'inR_ATP _<1>_<2>'},  {},  'k1/k2*k3*k4*r1 - k3*p1', {'keqATP', 'aATP', 
'koffATP','ATP'} 
 
{'inR_O _<1:+>_<2:+>'},  {'inR_Iressa _<1>_<2>'}, {'Iressa'}, 'k1/k2*k3*m1*r1 - k3*p1', {'keqIressa', 
'aIressa', 'koffIressa'} 
 
{'inR_O _<1:+>_<2:+>'},  {'inR_Lap _<1>_<2>'},  {'Lap'},  'k1*k2*m1*r1 - k2*p1', {'keqLap', 
'koffLap'} 
  
{'acR_O _<1:+>_<2:+>'},  {'acR_ATP _<1>_<2>'},  {},  'k1*k2*k3*r1 - k2*p1', {'keqATP', 
'koffATP2','ATP'} 
 
{'acR_O _<1:+>_<2:+>'},  {'acR_Iressa _<1>_<2>'}, {'Iressa'}, 'k1*k2*m1*r1 - k2*p1', {'keqIressa', 
'koffIressa2'} 
  
{'inR_O _<1:+>_<2:+>'},  {'acR_O _<1>_<2>'},   {},   'k1*k2*r1 - k2*p1',    {'keqAct','koffAct'} 
 
{'inR_ATP _<1:+>_<2:+>'},  {'acR_ATP _<1>_<2>'},    {},   'k1*k2*k3*r1 - k2*p1', 
{'keqAct','koffAct2', 'aATP'} 
 
{'inR_Iressa _<1:+>_<2:+>'},  {'acR_Iressa _<1>_<2>'}, {},   'k1*k2*k3*r1 - k2*p1', 
{'keqAct','koffAct3', 'aIressa'} 
  
{'acR_<1:O|Iressa|ATP>_O _<2:+>',   'Phos'},   {'acR_<1>_Phos _<2>'}, {},  'k1*k2*r1*r2 - k2*p1', 
{'keqPhos','koffPhos'} 
 
{'inR_<1:+>_O _<2:+>', 'Phos'},   {'inR_<1>_Phos _<2>'}, {},  'k1*k2*r1*r2 - k2*p1', 
{'keqPhos','koffPhos'} 
  
{'<1:acR|inR>_ATP _<2:O|Phos>_O'},  {'<1>_O _<2>_P'},  {}, 'k1*r1', {'kPhos'} 
 
{'acR_<1:O|Iressa|ATP>_Phos _P'},  {'acR_<1>_Phos _O'},  {}, 'k1*r1', {'kDephos'} 
 
{'inR_<1:+>_Phos _P'},   {'inR_<1>_Phos _O'},  {}, 'k1*r1', {'kDephos'} 
  
{'acR_<1:O|Iressa|ATP>_<2:O|Phos>_P', 'Shc'},  {'acR_<1>_<2>_Shc'}, {}, 'k1*k2*r1*r2-k2*p1', 
{'keqShc', 'koffShc'} 
 
{'inR_<1:+>_<2:O|Phos>_P', 'Shc'},  {'inR_<1>_<2>_Shc'}, {}, 'k1*k2*r1*r2-k2*p1', {'keqShc', 
'koffShc'} 
  
{'Phos'}, {'PhosVan'}, {'Van'}, 'k1*k2*r1*m1 - k2*p1', {'keqVan','koffVan'} 
{'Van'}, {'inVan'}, {}, 'k1*k2*r1-k2*p1', {'keq2Van','koff2Van'} 
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Table 4.4 – Description of parameters in the 46 ODE model and their fitted values. 
Below are the parameter values from the parameter set that resulted in the best fit of the model to the 
experimental data.  Not every parameter was fitted but if the parameter was fitted it was given the 
indicated range (note: 1e3 = 103).  The reason for choosing those ranges is described.  keqAct is the 
equilibrium constant describing the switch between active and inactive conformations and has no units.  
“a” factors follow from thermodynamic considerations (principle of detailed balance).  Iressa = Gefitinib, 
Lap = lapatinib, Van = pervanadate.   
Dynamical  
Parameters 
Value Min Value Max Value Units Description 
ATP 2.5e6   nM ATP concentration 
aATP 49200 1e3 1e5  Factor by which the equilibrium constant of ATP 
binding is increased in the ErbB1 active 
conformation and activation of receptor is 
increased if ATP is bound. Has to be a strong 
effect otherwise the receptor would be active all 
the time 
aIressa 165 1.5e2 1e5  Factor by which Iressa binding is increased in 
active state, factor by which activation of 
receptor is increased if Iressa is bound. Should 
be in a similar range as for ATP 
kDephos 37.5 1 1e3 1/min From the smallest ODE model we estimated 
values somewhere between 1 and 10 and we 
know that in this model the values have to be 
higher 
kPhos 209 1 1e3 1/min Same argument as for kDephos 
 
keqATP 0.0004402 1e-7 1e-3 1/nM We assume that the binding affinity of ATP for 
the inactive ErbB1 conformation is low. The 
affinity for the active receptor is higher by the 
factor aATP 
keqAct 0.00109 1e-6 1  Activation if neither ATP nor Iressa are bound is 
very unlikely (therefore 1e-6), however very 
little is known about this process. Thus we 
assumed a quite large range. This equilibrium 
constant is increased by the factor aATP if ATP 
binds the receptor. Very low chance of switching 
to inactive if ATP is bound 
keqIressa 1   1/nM (Karaman et al., 2008) 
keqLap 1/3   1/nM (Karaman et al., 2008) 
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keqPhos 0.01006 1e-2 10 1/nM Allows phosphatase binding to be a little higher 
or lower compared to Iressa 
keqShc 0.00607 1/200 1/40 1/nM (Jones et al., 2006) 
keqVan 0.00188 1e-4 1e3 1/nM  
koffATP 65.3 1 1e4 1/min Assumed to be fast because Iressa can compete 
with ATP very rapidly 
koffATP2 Same as  
koffATP 
    
koffAct 0.0472 1e-2 1e4 1/min A conformational change should be very fast 
(monomolecular, no diffusion limit), thus a 
similar range as for ATP binding 
koffAct2 Same as  
koffAct 
    
koffAct3 Same as  
koffAct 
    
koffIressa 12.4 1 1e2 1/min Fast on rate so has to have fast off rate; would 
expect it to be slower than the dephosphorylation 
rate 
koffIressa2 Same as  
koffIressa 
   Same reasoning as for ATP 
koffLap 0.000458 1e-4 1e-1 1/min Much slower than Iressa 
koffPhos 0.497 1e-2 1e2 1/min  
koffShc 165 1 1e3 1/min Has to be fast too according to our Shc 
measurements, thus same parameters as for 
phosphorylation 
koffVan 0.367 1e-4 1 1/min Should be fast since pervanadate has a fast 
effect. However, the pervan concentration is 
enormous thus the reaction might be a bit slower 
than others 
keq2Van 8.14 1 9 1/nM This determines the new steady state (goes down 
to 20% after 7-10min) 
koff2Van 0.1   1/min This determines how fast it goes down; injection 
of vanadate with exponential decay 
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Model incorporating mechanisms for kinase activation and receptor trafficking 
To study ErbB1 dephosphorylation dynamics in a larger context and the effects of 
gefitinib (Iressa) in the presence of normal receptor trafficking, we constructed a more complete 
model that describes the relevant processes.  Ligand binding, ErbB dimerization and 
phosphorylation, adaptor protein and phosphatase binding, ubiquitination, internalization and 
degradation of the receptors are modeled here.  Lapatinib binding to an inactive ErbB1 
conformation is not described in this model since the size of the model would explode due to the 
combinatorial character of rule-based models. 
Specifically, our most detailed model of ErbB receptor signaling comprises the receptors 
ErbB1-3 which all can form homodimers as well as heterodimers; to simplify the model we do 
not include ErbB4 since many cell types including H1666 cells do not express detectable levels.  
The model also includes the two ErbB1 ligands EGF and amphiregulin (AR or Areg) as well as 
HRG, which is known to bind ErbB3.  Furthermore, we explicitly account for one ATP and one 
phosphatase binding domain at each of the three receptors.  We assume that the different 
receptors can recruit different phosphatases (“ErbB1/2/3 phosphatase” can be considered to be 
the family of phosphatases that can act on ErbB1/2/3 at that given time, with an average affinity, 
etc.), and that the small molecule inhibitor gefitinib competes with ATP for the mentioned ATP 
binding domain.  The ErbB1 receptor in our model provides three additional binding domains: 
(1) the phospho-domain Y1173, which can recruit Shc, (2) the phospho-domain Y1045, which, 
after phosphorylation and Cbl binding, plays an important role in internalization and degradation 
of the receptor, and (3) a domain at which ErbB1 can be labeled with ubiquitin for degradation.  
The model also comprises the Shc-recruiting phospho-domain Y1221/1222 on ErbB2 and the 
PI3K recruiting phospho-domain Y1289 on ErbB3.  These binding events can also be thought of 
as the binding of the family of adaptor proteins that can bind to these phospho-sites.  Finally, 
internalization as well as receptor synthesis and degradation are accounted for.  For sake of 
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simplicity, it is assumed that when the receptor is degraded, all proteins that are recruited to that 
receptor are released into the cytosol.   
A complete mechanistic description of all the mentioned processes would result in a 
model composed of more than 100,000 ordinary differential equations (ODEs).  Using the model 
reduction techniques of Conzelmann et al. (Conzelmann et al., 2008) and Koschorreck et al. 
(Koschorreck et al., 2007), which had to be partly extended, the model could be reduced to 648 
ODEs.  Details about the extension of the approximate reduction approach of Koschorreck et al. 
can be found below.  Since the model is still too complex for intensive simulation studies or 
automated parameter estimation, it has to be reduced further.  By focusing on the interplay of 
EGF and gefitinib, it is possible to further reduce the model eliminating all states required to 
describe signal propagation induced by Amphiregulin and HRG.  Due to the relatively low 
concentration of ErbB2 and ErbB3 in H1666 cells, another reasonable reduction step is the 
complete elimination of ErbB2 and ErbB3 from the model.  MCF-10A cells express low levels of 
ErbB1 and no detectable levels of ErbB2-4 by Western blotting (Neve et al., 2006).  The 
resulting model consists of 203 ODEs and allows us to study the phosphorylation dynamics of 
ErbB1 after EGF stimulation and drug inhibition in greater detail. 
We use a rule-based approach to formulate the model equations.  Tools that support 
rule-based modeling are, for instance, BioNetGen, ALC, PottersWheel and little b (Blinov et al., 
2004; Koschorreck and Gilles, 2008; Maiwald and Timmer, 2008; Mallavarapu et al., 2009).  
However, considerable model reduction is necessary in order to get a model of manageable 
size.  Unfortunately, neither the application of the exact reduction approach by Conzelmann et 
al. (Conzelmann et al., 2008) nor the usage of Koschorreck’s layer based reduction approach 
(Koschorreck et al., 2007) are very helpful in this case.  The structure of the highly complex 
ErbB receptor system would not allow us to eliminate more than a few states using these 
approaches.  Therefore, we had to develop a new reduction technique, which can be 
considered a generalization of Koschorreck’s layer-based approach.  The layer-based approach 
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uses the special properties of so-called all-or-none interactions as they usually occur between 
the phosphorylation of a domain and its subsequent adaptor recruitment.  Usually, it is assumed 
that an adaptor protein such as Shc can only bind to a domain if this domain is phosphorylated.  
The other way around, the same domain will only get dephosphorylated if the adaptor 
dissociates first.  The same assumptions are made in our model for Shc, Cbl and PI3K binding.  
However, since we do not consider further adaptor recruitment, the benefits from solely using 
the layer-based approach would have been negligible.   
Interestingly, it is possible to show that the same method can easily be extended and 
applied to a set of consecutive, unidirectional interactions.  One of the simplest examples is 
shown in Figure 4.2.  The receptor R possesses three binding domains.  If domain 1 gets 
occupied by a ligand, the binding affinity of domain 2 towards its ligand changes.  However, 
binding of ligand 2 has no effect on the recruitment of ligand 1, but changes the binding affinity 
of domain 3.  If one accounts for mass conversation relations, a complete mechanistic model of 
this system will consist of seven ordinary differential equations.  To generate a reduced model 
version, the system is split up into two modules.  The first module only describes the domains 1 
and 2, while the second module describes the domains 2 and 3.  Since ligand binding to domain 
3 has no effect on the other two domains, the first module accurately describes the dynamics of 
domains 1 and 2.  A problem occurs when we model the second module.  Domain 1 is not part 
of this module and therefore will in a first step not be accounted for.  As a result domain 2 
appears to be completely uninfluenced in this module, and therefore all reactions describing 
ligand recruitment to domain 2 have to be parameterized by the same kinetic parameters.  It is 
not obvious which parameters can be used to describe this seemingly independent process, 
since we know that domain 2 does not always have the same affinity for its ligand, and that a 
switch in affinity is caused by domain 1.  This problem can be solved by assuming that the 
unknown kinetic parameters kY and k-Y correspond to the weighted mean value of the true 
parameter values k2, k4 and k-2, k-4: 
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2 4 2 4
[0,0, ] [1,0, ] [0,1, ] [1,1, ]
[ ,0, ] [ ,0, ] [ ,1, ] [ ,1, ]Y Y
R X R X R X R Xk k k k k k
R X X R X X R X X R X X− − −
= + = +  
The used weights correspond to the fractions of receptors that can undergo the 
respective reaction step.  For instance, the binding process of ligand to the second receptor 
domain requires that this domain is unoccupied (R[X,0,X]).  The ‘X’s here represent 
placeholders and indicate that the state of that domain is irrelevant.  Now, one fraction of all 
these species recruit the ligand with k2, namely all species with an unoccupied first domain 
(R[0,0,X]), while the remaining fraction (R[1,0,X]) binds the ligand with k3.  The same reasoning 
is used to formulate the expression for k-Y.  The new parameters are concentration dependent 
and therefore vary over time.   
The described modeling approach yields two small models both consisting of three 
ordinary differential equations, if we again account for all mass conservation relations.  One 
more state can be eliminated due to the redundant information about process two in both 
models when these are integrated into one model.  One can mathematically prove that the 
reduced model provides the same convergence properties as the ones introduced by 
Koschorreck et al. (Koschorreck et al., 2007).   
Analogously, the large ErbB receptor network is split into modules that are modeled 
separately.  The model consists of five modules describing: 1) ligand binding (EGF, AR, HRG) 
to ErbB1 and ErbB3, dimerization (homo and heterodimerization of ErbB1-3), ubiquitination, 
internalization and degradation of the receptors, 2) phosphorylation of ErbB1-3, 3) Shc binding, 
4) Cbl binding, and 5) PI3K binding.  Some of the resulting modules can be further reduced by 
using the exact model reduction approach as it has been introduced in Conzelmann et al. 
(Conzelmann et al., 2008).  The connections between the different modules are established by 
using the same kind of concentration dependent kinetic parameters as shown in the example 
above.   
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The ALC (Automated Layer Construction) computer program written in Perl supports 
rules, macrostates and modularity (Koschorreck and Gilles, 2008).  ALC was used to convert 
model definitions given in a rule-based syntax into computational model files in different formats, 
including Mathematica and MATLAB. 
We provide an example of how the reaction rules are translated into reaction rates and 
ODEs for the very small Cbl-binding module that contains three species: free Cbl (Cbl), ErbB1 
phosphorylated at the Cbl-binding site and not bound by Cbl (ErbB1[X,X,X,X,X,X,p]) and ErbB1 
phosphorylated and bound by Cbl at that site (ErbB1[X,X,X,X,X,X,Cbl]).  While these species 
are represented as monomers here, they are taken to be all ErbB1 species phosphorylated at 
the Cbl-binding site (monomers and dimers).  The X’s mean that it is irrelevant what happens at 
those sites for the reaction being described, so all possibilities are allowed.  There are three 
reaction rules in this module:  
 
(1) Cbl binds to ErbB1 that is phosphorylated at the Cbl-binding site with the equilibrium 
constant (always defined as on rate/off rate) kCbleq and the off rate kCbloff: 
ErbB1[X,X,X,X,X,X,p]+Cbl↔ErbB1[X,X,X,X,X,X,Cbl]. 
 
(2)-(3) ErbB1 degradation reactions depend on whether or not Cbl is bound.  We assume that 
when ErbB1 is degraded, all other proteins bound are released into the cytosol.  These 
degradation reactions are irreversible.  Recall that the full model was developed and then 
reduced to the 203 ODE version, which is why there are ErbB12 and ErbB13 terms here that 
indicate ErbB1:ErbB2 and ErbB1:ErbB3 heterodimers, respectively: 
ErbB1[X,X,X,X,X,X,p]→0    
ErbB1[X,X,X,X,X,X,Cbl]→Cbl  
The same rate constant describes both of these reactions, where the “fac” variables correspond 
to the earlier mentioned weights and the information to calculate the weights comes from the 
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other modules not discussed here: 
kdegErbB1*fac1degInttot1+kdegErbB1ub*fac1degIntubtot1+kdegErbB11*fac11degInttot1+kdegErbB11ub1*fa
c11degIntub1tot1+kdegErbB11ub2*fac11degIntub2tot1+kdegErbB12*fac12degInttot1+kdegErbB12ub*fac12de
gIntubtot1+kdegErbB13*fac13degInttot1+kdegErbB13ub*fac13degIntubtot1  
 
The reaction rates are given by: 
r1=kCbleq*kCbloff*ErbB1[X,X,X,X,X,X,p]*Cbl-kCbloff*ErbB1[X,X,X,X,X,X,Cbl] 
r2=(kdegErbB1*fac1degInttot1+kdegErbB1ub*fac1degIntubtot1+kdegErbB11*fac11degInttot1+kdegErb
B11ub1*fac11degIntub1tot1+kdegErbB11ub2*fac11degIntub2tot1+kdegErbB12*fac12degInttot1+kdegEr
bB12ub*fac12degIntubtot1+kdegErbB13*fac13degInttot1+kdegErbB13ub*fac13degIntubtot1)*ErbB1[X,X
,X,X,X,X,p] 
r3=(kdegErbB1*fac1degInttot1+kdegErbB1ub*fac1degIntubtot1+kdegErbB11*fac11degInttot1+kdegErb
B11ub1*fac11degIntub1tot1+kdegErbB11ub2*fac11degIntub2tot1+kdegErbB12*fac12degInttot1+kdegEr
bB12ub*fac12degIntubtot1+kdegErbB13*fac13degInttot1+kdegErbB13ub*fac13degIntubtot1)*ErbB1[X,X
,X,X,X,X,Cbl] 
 
The three ODEs are therefore: 
Cbl' = -r1+r3 
ErbB1[X,X,X,X,X,X,Cbl]' = r1-r3 
ErbB1[X,X,X,X,X,X,p]' = -r1-r2 
 
The following modification factor (weights described above) for the Cbl module describes the 
fraction of receptors that are not Cbl bound: 
facCbl=ErbB1[X, X, X, X, X, X, p]/(ErbB1[X, X, X, X, X, X, p]+ErbB1[X, X, X, X, X, X, Cbl]) 
This modification factor is used, for example, when defining the phosphorylation reaction of the 
Cbl-binding site on ErbB1 in the module describing ErbB1 phosphorylation events.  Only 
receptors that are phosphorylated at that site and not Cbl bound can be dephosphorylated. 
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The macrostates in this modification factor are: 
ErbB1[X, X, X, X, X, X, Cbl], ErbB1[X, X, X, X, X, X, p] 
 
Macrostates are then generated by the transformation of the individual species 
concentrations (microstates), and all species discussed from here on out will refer to the 
macrostates.  The notation ErbB1[ ].X or ErbB1_X (MATLAB notation) means that the 
macrostate comprises both monomers and dimers.  Phosphorylated species include those that 
are adaptor bound.  For example, the variable ErbB1[X,X,X,X,X,p,X].X comprises all receptors 
that are phosphorylated at the Shc binding site, including those that are bound by Shc, 
regardless of the states of the other sites.  Calculating ErbB1[X,X,X,X,X,p,X].X - 
ErbB1[X,X,X,X,X,Shc,X].X will produce the number of receptors that are phosphorylated at that 
site but not Shc bound. 
A list of species comprising the 203 ODE model can be found in Tables 4.5 and 4.6.  
The complete set of ODEs is enormous since each ODE has hundreds of algebraic 
expressions, and even the rules used to generate the ODEs (following model reduction) are too 
long to report here.  The 203 ODE model was imported into PottersWheel for parameter 
estimation and analysis.  Initial protein concentrations are given in molecules per cell, gefitinib 
concentrations are in nM, and EGF is given in ng/ml.  Off rates are in 1/min.  Rate parameters 
were assigned to the reaction classes (rules) rather than specific reactions. There are 55 
parameters including scaling parameters for both phosphorylated and total ErbB1. A complete 
list of all parameters as well as their fitted values is shown in Table 4.7. 
The data was normalized for fitting in the following way: we assumed that MCF-10A cells 
express 100,000 ErbB1 receptors per cell and that 50% of receptors are degraded after 4 hours 
of EGF treatment.  Although it is unclear how much signal can be attributed to background 
staining using methods such as microscopy, Western blotting and ELISAs, our results suggest 
that a significant fraction of receptors is not degraded over this time (data not shown).  We 
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normalized data of pY1173-ErbB1 such that 1% of the receptors were phosphorylated before 
EGF stimulation and a maximum of ~50% were phosphorylated after EGF stimulation. 
Scaling parameters were fit since the experimental measurements were in arbitrary units 
(relative, not absolute amounts).  A default error model of 10% error plus 5% of the maximum 
signal was used (yStd(i) 0.1*y(i) + 0.05*max(y), for data point i with max(y) denoting the 
maximum over all data points). 
The following non-zero initial conditions were used: ErbB1 (“ErbB1XXXXXXX_X”) = 105 
molecules per cell (as measured for H1666 cells, also reasonable for MCF-10A cells (Neve 
Cancer Cell 2006)), Shc = 3.5x106 molecules per cell, Cbl = 106 molecules per cell and ErbB1 
phosphatases (“Phos1”) = 106 molecules per cell.  Shc, Cbl and the phosphatases were 
assumed to be in excess of the receptor.  To get a reasonable estimate for a steady state 
without EGF, which corresponds to the start scenario of the model, the model was run to steady 
state with no EGF or drug using these initial protein concentrations and values of 10-12 for the 
other species.  The steady state values for the protein concentrations were then used as the 
initial conditions to simulate the effects of ligand stimulation. 
Due to the large number of parameters we expected the model to be non-identifiable 
and the landscape of the objective function to contain multiple local minima.  We therefore used 
simulated annealing for broad searches through parameter space, spanning 10-fold above and 
below a priori parameter values.  We performed two rounds of simulated annealing followed by 
trust region optimization.  The model state describing ErbB1 phosphorylated at the Shc-binding 
site (ErbB1XXXXXpX_X) was compared to measurements of ErbB1 pY1173 and the model 
state describing the overall level of ErbB1 (ErbB1XXXXXXX_X) to total ErbB1 measurements.   
Sensitivity analysis was performed by making the following calculations: sens = 
(x(k=1.01) - x(k=1))/x(k=1)/0.1, where the individual parameter values (k) were increased by 1% 
and the effects on the model species concentrations were determined.  We asked how the 
various parameter values influence ErbB1 Y1173 phosphorylation and total receptor levels after 
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20 and 240 minutes of EGF stimulation or EGF stimulation for one minute followed by 1µM 
gefitinib treatment. 
 
 
 
 
 
Figure 4.2 – Simple example of how the model reduction approach was applied by 
separation into modules. 
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Table 4.5 – Macrospecies in the 203 ODE model. 
Key for the different possibilities for the binding sites on ErbB1 monomers and homodimers: 
ErbB1{0,Int}{0,EGF}{0,ATP,Inh}{0,ub}{0,Phos1}{0,p,Shc}{0,p,Cbl} 
ErbB11{0,Int}{0,EGF}{0,ATP,Inh}{0,ub}{0,Phos1}{0,p}{0,p,Cbl}{0,EGF}{0,ATP,Inh} 
{0,ub}{0,Phos1}{0,p,Shc}{0,p,Cbl} 
 
Species Species Species 
ErbB1XXXXXXp_X ErbB1XEGFXXXXX_X ErbB11symIntEGFXubXXCblEGFXubXXX 
ErbB1XXXXXpX_X ErbB1XEGFXXXXCbl_X ErbB11symIntEGFXubXXCblEGFXXXXCbl 
ErbB1XXXXXpp_X             ErbB1XEGFXXXXp_X ErbB11symIntEGFXubXXCblEGFXXXXp 
ErbB1XXXXPhos1XX_X ErbB1XEGFXubXXX_X ErbB11symIntEGFXubXXCblEGFXXXXX 
ErbB1XXXXPhos1Xp_X ErbB1XEGFXubXXCbl_X ErbB11symIntEGFXubXXCblXXubXXCbl 
ErbB1XXXXPhos1pX_X ErbB1XEGFXubXXp_X             ErbB11symIntEGFXubXXCblXXubXXp 
ErbB1XXXXPhos1pp_X               ErbB1IntXXXXXX_X ErbB11symIntEGFXubXXCblXXubXXX 
ErbB1XXATPXXXX_X ErbB1IntXXubXXX_X ErbB11symIntEGFXubXXCblXXXXXCbl 
ErbB1XXInhXXXX_X ErbB1IntXXubXXCbl_X            ErbB11symIntEGFXubXXCblXXXXXp 
ErbB11symXXATPXXXXXXXPhos1pp ErbB1IntXXubXXp_X              ErbB11symIntEGFXubXXCblXXXXXX 
ErbB11symXXATPXXXXXXXPhos1pX ErbB1IntEGFXXXXX_X              ErbB11symIntEGFXubXXpEGFXubXXX 
ErbB11symXXATPXXXXXXXPhos1Xp ErbB1IntEGFXXXXCbl_X ErbB11symIntEGFXubXXpEGFXXXXCbl 
ErbB11symXXATPXXXXXXXPhos1XX ErbB1IntEGFXXXXp_X ErbB11symIntEGFXubXXpEGFXXXXp 
ErbB11symXXATPXXXXXXXXpp ErbB1IntEGFXubXXX_X           ErbB11symIntEGFXubXXpEGFXXXXX 
ErbB11symXXATPXXXXXXXXpX ErbB1IntEGFXubXXCbl_X         ErbB11symIntEGFXubXXpXXubXXCbl 
ErbB11symXXATPXXXXXXXXXp ErbB1IntEGFXubXXp_X            ErbB11symIntEGFXubXXpXXubXXp 
ErbB11symXXATPXXXXXXXXXX ErbB11IntEGFXubXXCblEGFXubXXCbl   ErbB11symIntEGFXubXXpXXubXXX 
ErbB11symXXInhXXXXXXXPhos1pp ErbB11IntEGFXubXXpEGFXubXXp ErbB11symIntEGFXubXXpXXXXXCbl 
ErbB11symXXInhXXXXXXXPhos1pX ErbB11IntEGFXubXXXEGFXubXXX ErbB11symIntEGFXubXXpXXXXXp 
ErbB11symXXInhXXXXXXXPhos1Xp ErbB11IntEGFXXXXCblEGFXXXXCbl ErbB11symIntEGFXubXXpXXXXXX 
ErbB11symXXInhXXXXXXXPhos1XX     ErbB11IntEGFXXXXpEGFXXXXp ErbB11symIntEGFXubXXXEGFXXXXCbl 
ErbB11symXXInhXXXXXXXXpp ErbB11IntEGFXXXXXEGFXXXXX ErbB11symIntEGFXubXXXEGFXXXXp 
ErbB11symXXInhXXXXXXXXpX ErbB11IntXXubXXCblXXubXXCbl ErbB11symIntEGFXubXXXEGFXXXXX 
ErbB11symXXInhXXXXXXXXXp ErbB11IntXXubXXpXXubXXp ErbB11symIntEGFXubXXXXXubXXCbl 
ErbB11symXXInhXXXXXXXXXX       ErbB11IntXXubXXXXXubXXX ErbB11symIntEGFXubXXXXXubXXp 
ErbB11symXXXXPhos1ppXXXXXX ErbB11IntXXXXXXXXXXXX ErbB11symIntEGFXubXXXXXubXXX 
ErbB11symXXXXPhos1pXXXXXXX ErbB11XEGFXubXXCblEGFXubXXCbl ErbB11symIntEGFXubXXXXXXXXCbl 
ErbB11symXXXXPhos1XpXXXXXX ErbB11XEGFXubXXpEGFXubXXp ErbB11symIntEGFXubXXXXXXXXp 
ErbB11symXXXXPhos1XXXXXXXX ErbB11XEGFXubXXXEGFXubXXX ErbB11symIntEGFXubXXXXXXXXX 
ErbB11symXXXXXppXXXXXX ErbB11XEGFXXXXCblEGFXXXXCbl ErbB11symIntEGFXXXXCblEGFXXXXp 
ErbB11symXXXXXpXXXXXXX ErbB11XEGFXXXXpEGFXXXXp ErbB11symIntEGFXXXXCblEGFXXXXX 
ErbB11symXXXXXXpXXXXXX ErbB11XEGFXXXXXEGFXXXXX ErbB11symIntEGFXXXXCblXXubXXCbl 
Phos1 ErbB11XXXubXXCblXXubXXCbl ErbB11symIntEGFXXXXCblXXubXXp 
ErbB1XXXXXXX_X ErbB11XXXubXXpXXubXXp ErbB11symIntEGFXXXXCblXXubXXX 
ErbB1XXXubXXX_X ErbB11XXXubXXXXXubXXX ErbB11symIntEGFXXXXCblXXXXXCbl 
ErbB1XXXubXXCbl_X ErbB11XXXXXXXXXXXXX ErbB11symIntEGFXXXXCblXXXXXp 
ErbB1XXXubXXp_X ErbB11symIntEGFXubXXCblEGFXubXXp ErbB11symIntEGFXXXXCblXXXXXX 
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Table 4.6 – Macrospecies in the 203 ODE model (continued). 
 
Species Species Species 
ErbB11symIntEGFXXXXpEGFXXXXX ErbB11symXEGFXubXXCblXXubXXp ErbB11symXEGFXXXXCblXXXXXX 
ErbB11symIntEGFXXXXpXXubXXCbl ErbB11symXEGFXubXXCblXXubXXX ErbB11symXEGFXXXXpEGFXXXXX 
ErbB11symIntEGFXXXXpXXubXXp ErbB11symXEGFXubXXCblXXXXXCbl ErbB11symXEGFXXXXpXXubXXCbl 
ErbB11symIntEGFXXXXpXXubXXX ErbB11symXEGFXubXXCblXXXXXp ErbB11symXEGFXXXXpXXubXXp 
ErbB11symIntEGFXXXXpXXXXXCbl ErbB11symXEGFXubXXCblXXXXXX ErbB11symXEGFXXXXpXXubXXX 
ErbB11symIntEGFXXXXpXXXXXp ErbB11symXEGFXubXXpEGFXubXXX ErbB11symXEGFXXXXpXXXXXCbl 
ErbB11symIntEGFXXXXpXXXXXX ErbB11symXEGFXubXXpEGFXXXXCbl ErbB11symXEGFXXXXpXXXXXp 
ErbB11symIntEGFXXXXXXXubXXCbl ErbB11symXEGFXubXXpEGFXXXXp ErbB11symXEGFXXXXpXXXXXX 
ErbB11symIntEGFXXXXXXXubXXp ErbB11symXEGFXubXXpEGFXXXXX ErbB11symXEGFXXXXXXXubXXCbl 
ErbB11symIntEGFXXXXXXXubXXX ErbB11symXEGFXubXXpXXubXXCbl ErbB11symXEGFXXXXXXXubXXp 
ErbB11symIntEGFXXXXXXXXXXCbl ErbB11symXEGFXubXXpXXubXXp ErbB11symXEGFXXXXXXXubXXX 
ErbB11symIntEGFXXXXXXXXXXp ErbB11symXEGFXubXXpXXubXXX ErbB11symXEGFXXXXXXXXXXCbl 
ErbB11symIntEGFXXXXXXXXXXX ErbB11symXEGFXubXXpXXXXXCbl ErbB11symXEGFXXXXXXXXXXp 
ErbB11symIntXXubXXCblXXubXXp ErbB11symXEGFXubXXpXXXXXp ErbB11symXEGFXXXXXXXXXXX 
ErbB11symIntXXubXXCblXXubXXX ErbB11symXEGFXubXXpXXXXXX ErbB11symXXXubXXCblXXubXXp 
ErbB11symIntXXubXXCblXXXXXCbl ErbB11symXEGFXubXXXEGFXXXXCbl ErbB11symXXXubXXCblXXubXXX 
ErbB11symIntXXubXXCblXXXXXp ErbB11symXEGFXubXXXEGFXXXXp ErbB11symXXXubXXCblXXXXXCbl 
ErbB11symIntXXubXXCblXXXXXX ErbB11symXEGFXubXXXEGFXXXXX ErbB11symXXXubXXCblXXXXXp 
ErbB11symIntXXubXXpXXubXXX ErbB11symXEGFXubXXXXXubXXCbl ErbB11symXXXubXXCblXXXXXX 
ErbB11symIntXXubXXpXXXXXCbl ErbB11symXEGFXubXXXXXubXXp ErbB11symXXXubXXpXXubXXX 
ErbB11symIntXXubXXpXXXXXp ErbB11symXEGFXubXXXXXubXXX ErbB11symXXXubXXpXXXXXCbl 
ErbB11symIntXXubXXpXXXXXX ErbB11symXEGFXubXXXXXXXXCbl ErbB11symXXXubXXpXXXXXp 
ErbB11symIntXXubXXXXXXXXCbl ErbB11symXEGFXubXXXXXXXXp ErbB11symXXXubXXpXXXXXX 
ErbB11symIntXXubXXXXXXXXp ErbB11symXEGFXubXXXXXXXXX ErbB11symXXXubXXXXXXXXCbl 
ErbB11symIntXXubXXXXXXXXX ErbB11symXEGFXXXXCblEGFXXXXp ErbB11symXXXubXXXXXXXXp 
ErbB11symXEGFXubXXCblEGFXubXXp ErbB11symXEGFXXXXCblEGFXXXXX ErbB11symXXXubXXXXXXXXX 
ErbB11symXEGFXubXXCblEGFXubXXX ErbB11symXEGFXXXXCblXXubXXCbl ErbB1XXXXXShcX_X 
ErbB11symXEGFXubXXCblEGFXXXXCbl ErbB11symXEGFXXXXCblXXubXXp Shc 
ErbB11symXEGFXubXXCblEGFXXXXp ErbB11symXEGFXXXXCblXXubXXX ErbB1XXXXXXCbl_X 
ErbB11symXEGFXubXXCblEGFXXXXX ErbB11symXEGFXXXXCblXXXXXCbl Cbl 
ErbB11symXEGFXubXXCblXXubXXCbl ErbB11symXEGFXXXXCblXXXXXp  
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Table 4.7 – Parameters in the 203 ODE model and their fitted values. 
Below are the parameter values from the parameter set that resulted in the best fit of the model to the 
experimental data after two rounds of simulated annealing (in log space) and one round of trust region 
optimization.  Parameters were given the indicated range (note: 1e3 = 103).  koff values are given in units 
1/min. 
Dynamical  
Parameters 
Value Min Value Max Value Units Description 
kDim11eq 1.6e-7 5.24e-9 4.71e-6   
aEGFDim11 15.7 0.511 460  how much the affinity changes for 
EGF when ErbB1 is dimerized –  
thermodynamic constraint, 
dimerized because conformation is 
such that ligand can bind more 
easily 
k1Dim11off 0.0367 0.00124 1.12   
k2Dim11off 0.03604 0.00119 1.07   
k3Dim11off 0.0645 0.00217 1.96   
k1EGFeq 6.04 0.12 180   
k2EGFeq 7.21e-7 2.38e-8 2.14e-5   
k1EGFoff 1.4 0.0467 42   
k2EGFoff 0.01805 0.000612 0.551   
k5EGFoff 0.436 0.0146 13.2   
k6EGFoff 0.367 0.0121 10.9   
k1ATPeq 0.814 0.0273 24.5   
k1ATPoff 1.68 0.0563 50.6   
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k1Inheq 3.98 0.133 119   
k1Inhoff 4.05 0.133 119   
k1Phos1eq 0.0239 0.000775 0.697   
k1Phos1off 5.38 0.18 162   
k1PShceq 0.000909 3.04e-5 0.0274  phosphatase driven not ATP 
k1ATPShceq 86.9 3.004 2700  phosphorylation reaction driven by 
ATP, Shc binding site 
k1Poff 0.00196 6.63e-5 0.0597   
k2Poff 2.54 0.0854 76.9   
k3Poff 20.03 0.670 602   
k1PCbleq 0.0428 0.0014005 1.26   
k1ATPCbleq 46.8 1.57 1420   
k4Poff 2.93e-5 9.43e-7 0.000849   
k5Poff 72.6 2.31 2080   
k6Poff 4.92 0.162 146   
k1ErbB1IntOn 0.002006 7.23e-5 0.06503   
k1ErbB1IntOff 0.0674 0.00225 2.022   
k2ErbB1IntOn 0.0317 0.00105 0.942   
k2ErbB1IntOff 0.00427 0.000139 0.125   
k1ErbB11IntOn 0.00282 9.4e-5 0.0846   
 - 154 - 
k1ErbB11IntOff 0.0839 0.00281 2.53   
k2ErbB11IntOn 0.12 0.004011 3.61   
k2ErbB11IntOff 0.00735 0.000241 0.217   
k3ErbB11IntOn 0.0498 0.00165 1.48   
k3ErbB11IntOff 0.0112 0.000369 0.332   
kCbleq 2.98e-7 1.077e-8 9.69e-6   
kCbloff 0.245 0.008068 7.26   
k1ubeq 0.0219 0.000753 0.678   
k1uboff 6.74 0.224 202   
k2ubeq 7.32 0.245 220   
k2uboff 68.9 2.34 2107   
kdegErbB1 0.115 0.00372 3.35   
kdegErbB1ub 0.198 0.00667 6.004   
kdegErbB11 0.00785 0.000263 0.237   
kdegErbB11ub1 2.12 0.0706 63.6   
kdegErbB11ub2 0.116 0.00391 3.52   
kShc1eq 6.006e-5 2.03e-6 0.00183   
kShc1off 0.755 0.0258 23.2   
ksyn1 288 8.95 8056   
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ATP 7831 266 240000   
EGFInt 0.00146 4.84e-5 0.0435  internalized free ligand in 
endosomes 
 
scale_pR_C1 0.776 0.0287 25.8   
scale_tR_C1 0.929 0.0317 28.5   
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